{
  "0": {
    "score": 4.0,
    "explanation": "4: 模型答案内容非常全面，涵盖了分期、治疗建议及后续免疫治疗，且无明显错误，但分期为IIIC而非参考答案中的IIIB，存在分期细微不符的情况。"
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive and covers all key points from the reference answer, including the need for brain MRI, detailed molecular testing, PD-L1 assessment, and consideration of tissue adequacy and liquid biopsy, with no major omissions or errors."
  },
  "2": {
    "score": 4.0,
    "explanation": "4: The model answer provides a thorough discussion of the differential between multiple primary lung cancers and intrathoracic metastasis, and outlines staging and treatment options. However, it does not clearly state the guideline-based default of M1a (IVA) staging for contralateral solitary nodules, and the initial treatment recommendation is incomplete due to truncation. Minor omissions prevent a perfect score."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and recommended treatment strategy without omissions or errors."
  },
  "4": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and treatment recommendations, with no significant omissions or errors."
  },
  "5": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it differs from the reference answer in TNM分期（IA3 vs IB），并且对脑MRI的必要性表述略有不同，未完全体现“可选”而是更倾向于建议补充，属于细微分歧。整体内容详实，无重大遗漏。"
  },
  "6": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up management, imaging modalities, and frequency, with appropriate detail. However, it provides more detail than required and slightly deviates from the reference answer's specific follow-up intervals (e.g., recommends every 3 months CT in the first 2 years, while the reference allows 3–6 months for 3 years), and includes additional considerations (e.g., immunotherapy) not explicitly mentioned in the reference. Minor omissions include not specifying the transition to low-dose non-contrast CT after 5 years."
  },
  "7": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough approach, but it assigns the clinical stage as IA3 (T1cN0M0) instead of IB (T2aN0M0), which is a minor but important staging discrepancy. Otherwise, the treatment recommendations and rationale are appropriate and comprehensive."
  },
  "8": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points addressed, including the rationale for omitting chemotherapy, the recommendation for endocrine therapy, and the addition of post-BCS radiotherapy, which is standard care. No major omissions or errors are present."
  },
  "9": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects: postoperative radiotherapy, HER2-targeted therapy with chemotherapy, endocrine therapy, and individualized treatment considerations. No major omissions or errors are present."
  },
  "10": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up timing, risk assessment, management rationale, and additional recommendations such as smoking cessation. No major omissions or errors are present."
  },
  "11": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, histology, mutation status, PD-L1 expression, ECOG, and the rationale for platinum-based chemotherapy plus immunotherapy as first-line, with KRAS G12C inhibitors reserved for subsequent lines. No major omissions or errors."
  },
  "12": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage (cT1cN2M0, IIIA) and outlines appropriate treatment options, including MDT discussion, chemoradiotherapy, and consolidation immunotherapy. However, it places more emphasis on不可手术切除的N2（unresectable N2）为主，未充分强调术前评估和新辅助治疗后手术的可能性，略有细节遗漏。"
  },
  "13": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细说明了NTRK抑制剂为首选，列举了具体药物，并补充了指南依据和后续治疗选择，无明显遗漏或错误。"
  },
  "14": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed reasoning for staging and appropriate management recommendations. However, it differs from the reference answer in T分期（T1c vs T2a）和分期（IA3 vs IB），主要因对胸膜牵拉的解读不同，属于细微分歧，但整体内容无重大遗漏。"
  },
  "15": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy and follow-up, including chemotherapy, targeted therapy, immunotherapy, and detailed follow-up schedules. However, it introduces additional details (e.g., targeted and immunotherapy) not explicitly required by the reference answer and suggests some optional investigations (e.g., brain MRI, tumor markers) that are not routinely recommended, which could be considered minor deviations."
  },
  "16": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of standard chemotherapy and immunotherapy options, but it omits the recent guideline recommendation of amivantamab for EGFR exon 20 insertion mutations in squamous NSCLC, which is the key point in the reference answer. It also overstates the lack of data for targeted therapy in squamous histology, leading to a partial but not complete or fully accurate response."
  },
  "17": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage as cT2aN0M0 (IIA) and outlining appropriate treatment strategies. However, it omits the possibility of IIB staging (T2b) and does not mention the need for close follow-up or management of potential nodal upstaging or recurrence, which are included in the reference answer."
  },
  "18": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering所有关键点，包括指南依据、辅助化疗适应证、高危因素、个体化决策和随访建议，无明显遗漏或错误。"
  },
  "19": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为完整，涵盖了大部分必要的术前检查、分期和治疗建议，但未提及腋窝可疑淋巴结的穿刺活检及标记夹放置这一关键细节，且对影像学检查的顺序和必要性描述略有不同。整体为小的遗漏，临床内容基本准确。"
  },
  "20": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explains the rationale, cites guidelines, and makes no major omissions or errors."
  },
  "21": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes appropriate details on follow-up, indications for adjuvant therapy, and lifestyle advice, with no significant omissions or errors."
  },
  "22": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including PD-L1 and major driver gene testing, as well as detailed pathology assessment. However, it underemphasizes the need for broad molecular profiling (e.g., KRAS, METex14, NTRK, BRAF, RET, ERBB2) in all cases, and is more conservative about recommending these tests in squamous cell carcinoma, which is a minor omission compared to the reference answer."
  },
  "23": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including patient summary, rationale for chemotherapy, and endocrine therapy. However, it omits the option of considering gene expression profiling in borderline cases and does not explicitly mention that endocrine therapy is the mainstay, with chemotherapy considered based on risk assessment and gene profiling, as in the reference answer."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM and stage, and providing appropriate, guideline-based recommendations for follow-up and management without omissions or errors."
  },
  "25": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indication and rationale for neoadjuvant therapy, recommended regimens, and comprehensive preoperative assessments, with no major omissions or errors."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, multidisciplinary evaluation, neoadjuvant therapy, surgical considerations, and alternative strategies, with no major omissions or errors."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of ROS1 inhibitors, rationale, guideline support, and additional considerations. No major omissions or errors are present."
  },
  "28": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of staging and treatment, but it incorrectly assigns stage IIIC instead of IIIB for cT2N3M0 according to the AJCC 8th edition. All other clinical content is accurate and detailed, with appropriate recommendations for concurrent chemoradiotherapy and consolidation immunotherapy."
  },
  "29": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommendation to switch to RET inhibitors, the timing of switching, the role of PD-L1, and the handling of bevacizumab, with no major omissions or errors."
  },
  "30": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including preoperative assessment, surgical treatment, and alternatives if surgery is not feasible. However, it omits the specific mention of brain MRI to rule out brain metastasis and does not emphasize the need for mediastinal lymph node pathological evaluation before surgery, which are important details in the reference answer."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including endocrine therapy with CDK4/6 inhibitors, bone-modifying agents, calcium/vitamin D supplementation, pain management, and monitoring, with no major omissions or errors."
  },
  "32": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the need for salvage local therapy (preferably radiotherapy), consideration of adjuvant chemotherapy, and detailed follow-up measures. However, it omits the option of repeat surgical resection as the first-line recommendation for R1 resection, which is emphasized in the reference answer."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (cT3N0M0, Stage IIB), rationale, and appropriate next steps in management, with no significant omissions or errors."
  },
  "34": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends considering endocrine therapy after total mastectomy for DCIS, which is not standard practice per guidelines; it also overstates indications and does not emphasize that endocrine therapy is not routinely recommended in this scenario, representing a notable error in clinical content."
  },
  "35": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, recommending appropriate second- or third-generation ALK-TKIs and providing rationale and guideline references. However, it omits mention of塞瑞替尼（ceritinib） and 克唑替尼（crizotinib） as alternative options if the preferred agents are not tolerated, which is present in the reference answer."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上基本一致，详细阐述了辅助化疗的适应证、方案及分子分型的进一步处理，内容更为全面，无重大遗漏或错误。"
  },
  "37": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including prioritizing RET抑制剂、免疫治疗的次要地位、化疗的选择，并引用指南依据。唯一小的遗漏是未明确提及胸腔积液的局部处理和姑息/戒烟指导。"
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing MET抑制剂, addressing the role of PD-L1, and mentioning alternatives if targeted therapy is unavailable. No major omissions or errors are present."
  },
  "39": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and adds appropriate detail regarding molecular testing and individualized therapy selection, with no major omissions or errors."
  },
  "40": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, correctly emphasizes the need for routine brain MRI to rule out asymptomatic brain metastases, and even adds relevant guideline references and further practical assessments, with no major omissions or errors."
  },
  "41": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging and standard treatment, including neoadjuvant chemoradiotherapy, surgery, and consolidation immunotherapy. However, it slightly overemphasizes neoadjuvant therapy and underplays the option of definitive chemoradiation for unresectable cases, which is more directly addressed in the reference answer. Minor details about radiotherapy dose and the sequence of durvalumab are also less explicit."
  },
  "42": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including优先再次手术、不能手术时放疗±化疗、不推荐单纯随访，并提及多学科讨论和指南依据，无重大遗漏或错误。"
  },
  "43": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, but it incorrectly assigns the stage as IIA instead of IB (according to the AJCC 8th edition, cT2aN0M0 for peripheral adenocarcinoma is IB), which is a minor but important detail. Other content is accurate and thorough."
  },
  "44": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging, clinical assessment, and special considerations for R2 resection. However, it suggests a slightly more frequent follow-up schedule than the reference and includes tumor markers (which are not standard), and does not explicitly mention the avoidance of routine PET/CT or brain MRI unless symptomatic, which are minor omissions."
  },
  "45": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key investigations (chest enhanced CT, PET-CT, brain MRI, tissue biopsy), and includes additional relevant details without any major omissions or errors."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including diagnosis为双原发肺癌,分期原则,手术为首选,术前评估,辅助治疗及不可手术时的替代方案,无明显遗漏或错误。"
  },
  "47": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers staging, necessary further assessments, and provides guideline-based first-line treatment recommendations for RET-positive NSCLC, with no major omissions or errors."
  },
  "48": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical content, including pathology, imaging, systemic evaluation, and patient counseling, with some additional details (e.g., fertility and genetic counseling) not in the reference. However, it omits the specific mention of placing a marker in the tumor and axillary nodes, which is a minor but relevant omission."
  },
  "49": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including frequency, content, and additional considerations such as smoking cessation and management of complications. However, it introduces some minor variations in follow-up intervals and includes optional tumor marker testing, which are not emphasized in the reference answer. The core clinical content is accurate and comprehensive."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including guideline recommendations, drug choices, timing of therapy switch, and patient context, with no major omissions or errors."
  },
  "51": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for brain MRI, and correctly addressing why the other options are inappropriate, with no major omissions or errors."
  },
  "52": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including MRI评估、腋窝超声及穿刺、实验室检查、肿块标记等，但对标记物植入的具体流程、实验室检查细节（如碱性磷酸酶）、以及影像学补充检查的适应证描述略有简化或未完全展开。"
  },
  "53": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the rationale for not using KRAS G12C inhibitors first-line, the recommendation for platinum-based chemotherapy plus immunotherapy, and the approach to maintenance therapy. There are no major omissions or errors."
  },
  "54": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the clinical scenario, including the limitations of immunotherapy and standard EGFR-TKIs, and the consideration of platinum-based chemotherapy. However, it underemphasizes the prioritization of EGFR exon 20-specific inhibitors as first-line if available, and does not mention early palliative care or smoking cessation advice, which are included in the reference answer."
  },
  "55": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging, necessary preoperative assessments, and treatment recommendations. However, it omits some specific details such as the need to mark suspicious axillary lymph nodes, the explicit mention of PET/CT as an alternative for systemic evaluation, and the recommendation for 1 year of anti-HER2 therapy postoperatively."
  },
  "56": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, content, and additional management. However, it slightly deviates in the recommended frequency and duration of chest CT scans and includes some extra details not emphasized in the reference, such as laboratory tests and MDT, which are not core to the reference answer."
  },
  "57": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides accurate staging, appropriate surgical recommendations, and discusses alternatives and nuances, even adding detail about the AJCC 8th edition and SBRT as an option."
  },
  "58": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including orthopedic evaluation/intervention, prioritization of EGFR exon 20-specific targeted therapy, chemotherapy and immunotherapy considerations, bone protection, and supportive care, with no major omissions or errors."
  },
  "59": {
    "score": 3.0,
    "explanation": "3: The model answer provides a generally correct approach to staging and management, but it incorrectly assigns the clinical stage as IIA instead of IB, which is a significant inaccuracy. The rest of the management plan is appropriate, but this staging error affects the overall score."
  },
  "60": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including frequency, content, and additional considerations. However, it provides a broader follow-up interval (3–6 months vs. fixed 6 months), and omits the specific mention of low-dose non-contrast CT after 3 years and the explicit recommendation for FDG-PET/CT for suspected recurrence, which are present in the reference answer."
  },
  "61": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of staging and treatment, but it incorrectly assigns the stage as IIIC instead of IIIB for T2N3M0 NSCLC per the 8th AJCC edition. Otherwise, the treatment recommendations are accurate and comprehensive."
  },
  "62": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, including accurate staging, rationale for adjuvant chemoradiotherapy, and consideration of targeted/immune therapy, with no major omissions or errors."
  },
  "63": {
    "score": 3.0,
    "explanation": "3: The model answer provides a standard approach for advanced squamous cell lung cancer with immunotherapy and chemotherapy, but it omits the guideline-recommended first-line use of HER2-targeted therapy (fam-trastuzumab deruxtecan) for HER2-mutant cases, which is a major omission. It also incorrectly downplays the role of HER2-targeted agents in this setting."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes appropriate follow-up intervals, imaging recommendations, lifestyle advice, and management steps, with no major omissions or errors."
  },
  "65": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it suggests a slightly more frequent follow-up interval (every 3–6 months vs. every 6 months) and includes more detail on follow-up duration. Minor differences in interval recommendations and additional references are present, but no major omissions or errors."
  },
  "66": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the priority of re-resection, the role of adjuvant radiotherapy if reoperation is not feasible, and the limited role of adjuvant chemotherapy. There are no major omissions or errors."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key points from the reference answer, including follow-up frequency, recommended imaging, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors. It also references relevant guidelines and provides a clear summary."
  },
  "68": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and adds relevant details such as lifestyle advice and optional laboratory tests, without introducing errors or omitting major content."
  },
  "69": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including re-resection as first choice, adjuvant radiotherapy if re-resection is not feasible, and consideration of adjuvant chemotherapy, with appropriate guideline references and rationale. No major omissions or errors."
  },
  "70": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (cT2N3M0, IIIC), rationale, and stepwise treatment principles, including MDT evaluation, chemoradiotherapy, and consolidation immunotherapy, with no major omissions or errors."
  },
  "71": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, clearly recommending MET抑制剂（如卡马替尼或替沃替尼）为首选，并说明理由。唯一的轻微遗漏是未提及crizotinib作为可选项及姑息治疗的重要性。"
  },
  "72": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key investigations, including imaging, laboratory, and cardiac assessments, with some additional relevant details. However, it omits the specific mention of axillary lymph node biopsy and marker placement, which are important steps highlighted in the reference answer."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并且对支持治疗、系统抗肿瘤治疗不推荐的原因及姑息性局部治疗进行了详细阐述。"
  },
  "74": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including indications, rationale, and specific radiotherapy fields. However, it introduces more nuance regarding internal mammary irradiation and omits a clear statement that comprehensive regional nodal irradiation (RNI) is generally recommended per guidelines, which is present in the reference answer."
  },
  "75": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately recommending osimertinib as first-line therapy for EGFR 19del NSCLC with brain metastases, and provides rationale and guideline references. However, it omits mention of the alternative option (amivantamab-vmjw plus lazertinib) and does not address supportive care or smoking cessation, which are minor but relevant omissions."
  },
  "76": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, correctly identifying trastuzumab deruxtecan (DS-8201) as the first-line therapy and providing appropriate alternatives. However, it introduces the option of combining HER2-targeted therapy with chemotherapy, which is not standard per current guidelines, and gives more detail than required, leading to minor deviations."
  },
  "77": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including the recommended follow-up intervals and key examinations. However, it slightly deviates from the reference by not specifying the exact transition at 3 years and 5 years, and it suggests some flexibility in CT intervals and additional tests, which are not routinely recommended per the reference. Minor omissions and slight over-inclusiveness prevent a perfect score."
  },
  "78": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, and the indications for brain MRI and PET/CT, with no major omissions or errors."
  },
  "79": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and supportive care. However, it slightly differs in the timing of follow-up intervals (first 2 years vs. first 3 years) and omits the specific recommendation for non-contrast low-dose CT after 5 years, which are minor omissions."
  },
  "80": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of the reference answer, including the use of RET抑制剂、无需重复基因检测、以及免疫治疗的补充，但对PD-L1检测和姑息治疗等细节提及不够完整。"
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points, including staging, lack of high-risk features, guideline recommendations, and follow-up advice, with no significant omissions or errors."
  },
  "82": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the indication for adjuvant chemotherapy, recommended regimen, and rationale. It adds extra detail about targeted and immunotherapy, but slightly overemphasizes these options for IB stage, which are not standard per current guidelines, leading to a minor omission in clarity."
  },
  "83": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for EGFR-TKI selection, the limited role of immunotherapy, and the need for individualized management, with no major omissions or errors."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在分期和治疗建议上内容完全一致，涵盖了所有关键点，无明显遗漏或错误。"
  },
  "85": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of indication for adjuvant chemotherapy in IB stage without high-risk factors and providing a detailed, guideline-consistent follow-up plan."
  },
  "86": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and appropriate recommendations for postoperative management, but it incorrectly stages the patient as IIA (T2aN0M0) instead of the correct Stage IB per the AJCC 8th edition. This is a significant inaccuracy, though the rest of the content is largely complete."
  },
  "87": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points: correct staging (I期), appropriate discussion of chemotherapy indications (including multigene testing), and recommendation of endocrine therapy. However, it omits specific mention of ovarian suppression as an option for premenopausal women and does not detail the nuanced use of Oncotype DX scores (e.g., the 16–25 range), which are present in the reference answer."
  },
  "88": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key elements of follow-up frequency, content, and health education, referencing relevant guidelines. However, it slightly overemphasizes laboratory tests (which are not routinely recommended) and suggests a more frequent follow-up interval (every 3–6 months) than the reference answer (every 6 months), and does not explicitly mention the avoidance of routine PET/CT or brain MRI unless indicated."
  },
  "89": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including systemic therapy as the mainstay, individualized treatment based on molecular profiling, specific gene targets for testing, and the role of palliative care. There are no major omissions or errors."
  },
  "90": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including the recommendation for CDK4/6抑制剂联合芳香化酶抑制剂或氟维司群。However, it omits the explicit mention of卵巢功能抑制（如GnRH激动剂）或卵巢切除 for premenopausal women, which is a critical step in this age group, and does not address genetic counseling for high-risk family history."
  },
  "91": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM staging, correct stage grouping (IIIB), and a detailed, guideline-based treatment plan including chemoradiotherapy and consolidation immunotherapy, with no major omissions or errors."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、分期分级、手术与辅助化疗建议，并补充了具体化疗方案和术中进展的处理，无重大遗漏或错误。"
  },
  "93": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including axillary assessment, systemic and metastatic workup, cardiac function evaluation, and additional relevant considerations, with no major omissions or errors."
  },
  "94": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, including分期、进一步检查、治疗方案和分子检测等要点，但对新辅助治疗的具体方案（如免疫联合化疗）和分子检测的详细内容略有简化，且对多学科管理和早期姑息支持未作详细说明。"
  },
  "95": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including preoperative assessments (lung and heart function, brain MRI, lab tests) and the necessity of molecular and PD-L1 testing. However, it omits the specific mention of纵隔淋巴结评估（如EBUS或纵隔镜活检） to clarify N staging, which is a minor but important detail."
  },
  "96": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main management options and follow-up strategy, but it omits specific recommendations against routine use of FDG-PET/CT and brain MRI in the absence of symptoms, and the follow-up CT protocol is less precise than the reference. Minor differences in follow-up intervals and additional mention of tumor markers are present."
  },
  "97": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for EGFR-TKI monotherapy (osimertinib), the non-recommendation of immunotherapy despite PD-L1 positivity, and appropriate guideline references, with no major omissions or errors."
  },
  "98": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging, rationale, and treatment options, but incorrectly assigns stage IIIA instead of IIIB, which is a minor but important detail. Otherwise, the clinical content and recommendations are accurate and comprehensive."
  },
  "99": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期判断准确，治疗建议全面，且对辅助化疗的适应证补充说明，无重大遗漏或错误。"
  },
  "100": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it incorrectly assigns the stage as IIA (T2aN0M0) instead of IB (T2aN0M0) according to the AJCC 8th edition for non-small cell lung cancer. Otherwise, the treatment recommendations and reasoning are appropriate."
  },
  "101": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and structured approach but incorrectly分期s the tumor as IA2期 (T2aN0M0) instead of IIB期 (T2bN0M0), which is a significant inaccuracy. However, the recommended treatment (肺叶切除+系统性淋巴结清扫) and postoperative considerations are otherwise appropriate."
  },
  "102": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including分期、辅助治疗的适应证、个体化决策和随访建议，但分期误写为IIA期（应为IB期），且部分内容略显冗长。整体临床内容与参考答案基本一致，仅有小的分期错误和细节差异。"
  },
  "103": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, correctly prioritizing ALK-TKI as first-line therapy, listing appropriate agents, and accurately noting that immunotherapy and chemotherapy are not first-line choices despite PD-L1 positivity. There are no major omissions or errors."
  },
  "104": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points regarding staging and treatment, including the use of KRAS G12C抑制剂和免疫治疗的考量。它略微扩展了局部治疗的可能性，但未明确强调KRAS G12C抑制剂为首选及支持/姑息治疗的重要性，且对分期表述略有冗余。"
  },
  "105": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including re-resection as first choice, PORT as an alternative, rationale against adjuvant chemotherapy, MDT discussion, and detailed follow-up recommendations. No major omissions or errors."
  },
  "106": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of postoperative follow-up for stage I (pT1aN0M0) NSCLC after R0 resection, including surveillance intervals, imaging modality, lifestyle advice, and the lack of need for adjuvant therapy, with no major omissions or errors."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the diagnosis, mutation, recommended first-line MET inhibitor therapy, and the rationale for not using chemotherapy or immunotherapy first. No major omissions or errors."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes appropriate rationale for omitting further invasive staging, surgical recommendations, and perioperative considerations, with no major omissions or errors."
  },
  "109": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, including the rationale for EGFR-TKI use, specific drug recommendations, and relevant guidelines, with no major omissions or errors."
  },
  "110": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, surgical options, and adjuvant therapy. However, it omits some minor but relevant details such as recommending preoperative MRI and laboratory evaluation, and the mention of localization clip placement if not already done."
  },
  "111": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including follow-up intervals, imaging modality, and lifestyle advice. However, it slightly overextends the follow-up period (suggesting at least 5 years and beyond) and does not specify that contrast-enhanced CT can be considered, as in the reference answer. Minor differences in the timing and frequency of imaging are present."
  },
  "112": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期、MPLC诊断、手术为首选、淋巴结清扫、术后辅助治疗及不适合手术时的替代方案，无明显遗漏或错误。"
  },
  "113": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough approach, but it incorrectly分期为IIA期（应为IB期），且对纵隔淋巴结评估的讨论略显冗余。其余内容与参考答案基本一致，仅有细微分歧。"
  },
  "114": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and includes appropriate details on follow-up intervals, recommended examinations, and smoking cessation advice, with no major omissions or errors."
  },
  "115": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive and guideline-based approach but incorrectly states that HER2靶向药物（如trastuzumab deruxtecan）仅用于二线及以后，未将其作为一线推荐，遗漏了最新NCCN指南将Enhertu作为一线首选的关键信息。"
  },
  "116": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up frequency, content, and additional recommendations. However, it omits the specific recommendation against routine FDG-PET/CT or brain MRI, and the cancer survivorship management aspect is less emphasized."
  },
  "117": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，涵盖了再次手术、放疗、化疗的适应证及证据，并补充了免疫治疗的现状，无重大遗漏或错误。"
  },
  "118": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of third-generation EGFR-TKI (osimertinib) as first-line therapy, alternatives, and the non-recommendation of immunotherapy or chemotherapy. No major omissions or errors."
  },
  "119": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and the consideration of multiple primary lung cancers, but it omits the explicit mention of the AJCC第8版TNM分期和多学科讨论、分子病理及基因检测等进一步鉴别建议，内容略有简化。"
  },
  "120": {
    "score": 5.0,
    "explanation": "5: 临床分期和诊疗建议与参考答案完全一致，内容全面，无明显遗漏或错误。"
  },
  "121": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it differs from the reference answer inT分期（T1c vs T2a）和分期（IA3 vs IB），且未强调MDT讨论和术前评估细节。其余治疗建议和管理基本一致，仅有轻微分歧。"
  },
  "122": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床分期和治疗推荐方面内容一致，涵盖了分期依据、分子分型、治疗原则、术前新辅助治疗、手术方式及后续辅助治疗等要点，无明显遗漏或错误。"
  },
  "123": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured approach but incorrectly stages the tumor as IIA (T2bN0M0) instead of the correct IIB (T3N0M0), given the tumor size (>5cm). This is a significant staging error, though the treatment recommendations are otherwise appropriate."
  },
  "124": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it assigns the stage as IIA (cT2aN0M0) rather than IIB (T3N0M0) as in the reference answer, due to a different interpretation of pleural invasion. This is a minor but important discrepancy in clinical staging, though the treatment recommendations are otherwise appropriate."
  },
  "125": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering手术切除为首选、再次放疗的适应证与风险、全身治疗建议及指南依据，无重大遗漏或错误。"
  },
  "126": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including SRS as first choice, surgical options if indicated, and the rationale for not choosing WBRT, with no major omissions or errors."
  },
  "127": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including staging, receptor status, rationale for neoadjuvant therapy, specific chemotherapy regimens, surgical planning, and subsequent adjuvant therapy, with no major omissions or errors."
  },
  "128": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including the recommended frequency and type of imaging, clinical follow-up, and lifestyle advice. However, it adds some details (e.g., lab tests, more frequent clinical visits) and omits the specific mention of low-dose non-contrast CT after 2–3 years, which is a minor omission."
  },
  "129": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including comprehensive preoperative assessment, the necessity and scope of molecular testing, multidisciplinary discussion, and individualized treatment strategies for stage IIIA NSCLC. There are no major omissions or errors."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and even provides additional guideline references and practical details. There are no major omissions or errors."
  },
  "131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key points from the reference answer, including the recommendation for adjuvant platinum-based chemotherapy, detailed follow-up intervals and modalities, and additional considerations such as targeted/immune therapy, smoking cessation, and management of complications, with no major omissions or errors."
  },
  "132": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为完整，涵盖了分期、辅助治疗和随访方案，但将分期定为IIA而非IB，且对辅助化疗的推荐略偏积极，未强调“可考虑”而非“必须”，与参考答案有细微差异。"
  },
  "133": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of preoperative assessment and treatment decision, including functional evaluation, MDT discussion, surgical approach, and adjuvant/neoadjuvant therapy, with no major omissions or errors."
  },
  "134": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly identifying the stage, necessary additional tests, and treatment recommendations. However, it omits the need for纵隔淋巴结的病理学评估 (e.g., EBUS or mediastinoscopy), which is a key step before surgery, and does not mention the possible need for spine or thoracic inlet MRI if the tumor is close to those structures."
  },
  "135": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it differs from the reference answer by assigning stage IA3 (cT1cN0M0) instead of IB, which may reflect a difference in staging criteria interpretation, and it includes more detail on alternative surgical options and SBRT, which, while not incorrect, slightly diverges from the reference's focus."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the recommended first-line systemic therapy (HER2-targeted agents, specific drug names, and alternatives), rationale for not using immunotherapy, and detailed management considerations, fully aligning with the reference answer with no major omissions or errors."
  },
  "137": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, but it omits specific mention that routine FDG-PET/CT or brain MRI are not recommended unless clinically indicated, and does not explicitly mention ongoing smoking cessation counseling. Otherwise, the clinical content and follow-up schedule are accurate."
  },
  "138": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps including re-operation, PORT, adjuvant chemotherapy, MDT discussion, and follow-up considerations, with no major omissions or errors."
  },
  "139": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects current guidelines, and covers all key points from the reference answer, including surgical indication, preoperative assessment, the role of neoadjuvant therapy, and postoperative management, with no major omissions or errors."
  },
  "140": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential steps of molecular testing and subsequent treatment planning, but it omits the recommendation for brain MRI with contrast to assess for intracranial metastases, which is a key detail in the reference answer."
  },
  "141": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the staging (IIIB/IIIC, TanyN3M0) and the recommended initial treatment (concurrent chemoradiotherapy followed by durvalumab consolidation), with no major omissions or errors."
  },
  "142": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it uses the AJCC第8版分期（ⅢC期），而参考答案采用ⅢB期（T2N3M0），且对T2a/b分期有些许不确定性。其余治疗方案描述详细，内容与参考答案基本一致，仅有分期细节上的小差异。"
  },
  "143": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides appropriate rationale and guideline-based recommendations without major omissions or errors."
  },
  "144": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant chemotherapy, consideration of radiotherapy, and a detailed follow-up plan. However, it introduces additional options (immunotherapy, targeted therapy) not specified in the reference answer and slightly differs in the follow-up intervals, which are minor deviations but do not constitute major omissions or errors."
  },
  "145": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (pT1bN0M0, IA2), rationale, and appropriate follow-up recommendations, with no major omissions or errors."
  },
  "147": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects—chemotherapy, anti-HER2 therapy, endocrine therapy, and also appropriately adds radiotherapy, which is guideline-recommended in this context. No major omissions or errors."
  },
  "148": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key aspects of the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "149": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including the use of pemetrexed maintenance and the rationale for maintenance therapy. However, it introduces immunotherapy options (e.g., pembrolizumab, atezolizumab) despite PD-L1 <1%, which is not standard per NCCN guidelines in this context, and does not emphasize close follow-up as clearly as the reference answer. Minor omissions and slight overextension lower the score."
  },
  "150": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it stages the tumor as T1c (2–3 cm, IA3) instead of T1b (2–2.9 cm, IA2) as in the reference answer, which is a minor discrepancy. The treatment recommendations are otherwise appropriate and comprehensive."
  },
  "151": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the rationale for adjuvant chemoradiotherapy, specific regimens, follow-up, and additional considerations such as molecular testing, with no major omissions or errors."
  },
  "152": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage and outlining appropriate initial treatment options, including chemoradiotherapy and neoadjuvant approaches. However, it places more emphasis on concurrent chemoradiotherapy as the first choice, whereas the reference answer prioritizes neoadjuvant therapy followed by surgery if feasible, which is a minor difference in emphasis but not a major omission."
  },
  "153": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, including local management of pleural effusion, systemic therapy recommendations, and the role of KRAS G12C inhibitors. However, it omits explicit mention of smoking cessation and palliative care integration, which are present in the reference answer."
  },
  "154": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including staging, rationale, and treatment options. However, it assigns stage IIIC (T任何N3M0) instead of IIIB (T1-2N3M0) as in the reference, and is slightly more detailed than required, but these are minor discrepancies."
  },
  "155": {
    "score": 4.0,
    "explanation": "4: The model answer covers almost all key clinical content, including staging, the rationale for neoadjuvant therapy, recommended regimens, and post-operative management. However, it omits specific mention of tumor and lymph node marker placement, and does not detail the use of T-DM1 for non-pCR cases, which are important minor details."
  },
  "156": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately covering clinical staging, indications for neoadjuvant therapy, and next-step assessments. It adds some extra details (e.g., Ki-67, BRCA testing) and minor staging nuance (IIIA vs. II), but omits explicit mention of evaluating surgical tolerance and repeats some points, making it slightly more detailed but with minor omissions compared to the reference."
  },
  "157": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including guideline recommendations, PS score implications, and the rationale for best supportive care. However, it introduces additional discussion about possible exceptions (e.g., if PS 3 is tumor-related), which, while accurate, is not emphasized in the reference answer and could be seen as a minor deviation."
  },
  "158": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately prioritizes ROS1靶向治疗（尤其恩曲替尼）为首选，详细阐述了理由和不推荐方案，但未明确提及脑转移的姑息性放疗和吸烟戒断指导等综合管理措施。"
  },
  "159": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including accurate TNM staging, appropriate surgical recommendations, and consideration of alternative therapies, with no major omissions or errors."
  },
  "160": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging (IV期M1a) and the rationale for EGFR-TKI therapy, including drug options. However, it omits specific mention of local management of the pleural effusion (如胸腔穿刺引流、化学性胸膜固定) and smoking cessation/palliative care recommendations, which are present in the reference answer."
  },
  "161": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of standard concurrent chemoradiotherapy for unresectable superior sulcus NSCLC, and discusses the role of EGFR mutation. However, it introduces durvalumab as consolidation, which is standard for stage III NSCLC but not specifically for EGFR-mutant cases, where osimertinib is now supported by evidence. The answer also does not explicitly mention osimertinib as consolidation after chemoradiation in EGFR-mutant patients, which is a minor but important omission."
  },
  "162": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期,术前评估,分子检测,MDT,和治疗建议，但未明确提及纵隔淋巴结的病理性评估（如EBUS-TBNA），这是参考答案中的一个重要细节。"
  },
  "163": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes re-resection, includes appropriate alternatives (PORT, consideration of adjuvant chemotherapy in high-risk cases), and aligns with current guidelines. No major omissions or errors."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, surgical management, lack of need for adjuvant therapy, consideration of high-risk features, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "165": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers the indications and considerations for adjuvant chemotherapy, details the follow-up schedule, and includes relevant guideline references. There are no major omissions or errors compared to the reference answer."
  },
  "166": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately discusses the significance of the EGFR G719X mutation, correctly prioritizes second-generation EGFR-TKIs, and references relevant guidelines. There are no major omissions or errors compared to the reference answer."
  },
  "167": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including reoperation as first choice, radiotherapy as an alternative, and the rationale for not recommending chemotherapy. It also correctly addresses follow-up and MDT discussion, with no major omissions or errors."
  },
  "168": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，涵盖了再次手术、放疗的选择及其适应证，并明确指出不推荐单独化疗，无重大遗漏或错误。"
  },
  "169": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately details the T, N, and M staging, as well as appropriate treatment recommendations. However, it incorrectly states the stage as IIA (T2bN1M0) instead of IIB, which is a minor but important omission. Otherwise, the clinical content closely matches the reference answer."
  },
  "170": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but diverges from the reference answer by prioritizing neoadjuvant therapy before surgery, whereas the reference answer recommends upfront surgery as the first choice. The model also introduces options (e.g., chemoradiotherapy) not indicated as first-line in the reference, leading to partial coverage with some inaccuracies."
  },
  "171": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, covering MDT评估、手术为主的综合治疗、辅助化疗及靶向/免疫治疗、以及不能手术时的同步放化疗。唯一小的遗漏是未明确提及分子检测的具体内容和患者支持（如戒烟、姑息治疗），但整体内容规范且无重大错误。"
  },
  "172": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion of treatment options, including local and systemic therapies, and emphasizes multidisciplinary evaluation. However, it does not mention that observation is also an option per NCCN 2B recommendations, which is a minor omission."
  },
  "173": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, targeted therapy options, management of brain metastases, and additional considerations without major omissions or errors."
  },
  "174": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the clinical content in the reference answer, including HER2-targeted therapy as first-line, alternatives if unavailable, consideration of immunotherapy/chemotherapy, and symptom management. No major omissions or errors are present."
  },
  "175": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访时间表、内容、影像学检查、并发症监测及生活方式指导，但对随访5年后的影像学（低剂量非增强CT）及FDG-PET/CT、脑MRI并非常规随访项目的说明略有不足。"
  },
  "176": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough analysis and appropriate treatment recommendations, but it incorrectly assigns the stage as IIA instead of IB according to the AJCC 8th edition, which is a significant inaccuracy. Otherwise, the clinical reasoning and management plan are largely correct."
  },
  "177": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical approach, adjuvant chemotherapy, alternative options if surgery is not feasible, and considerations for lymph node involvement, with no major omissions or errors."
  },
  "178": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical and pathological staging, as well as appropriate next-step treatment recommendations. However, it incorrectly assigns the clinical stage as IIIA instead of IIA (cT2N1M0 per AJCC 8th edition is IIA), which is a minor but notable error. Otherwise, the answer is thorough and accurate."
  },
  "179": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including preoperative laboratory tests, cardiac function assessment (which is particularly relevant for HER2+ patients), and the need for axillary lymph node biopsy. However, it omits mention of breast MRI or PET/CT as optional imaging for further staging, which are included in the reference answer."
  },
  "180": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, includes all key clinical content from the reference answer, and adds relevant, guideline-supported alternatives without introducing errors or omissions."
  },
  "181": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging and preoperative workup in detail, but it includes some additional tests (e.g., routine head MRI, bone scan) that are not strictly necessary in asymptomatic early-stage patients, and does not emphasize that PET/CT is preferred for occult metastasis screening. Minor over-investigation is present, but no major omissions."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including随访频率, 推荐影像学检查, 不推荐的检查, 以及戒烟和生存管理，无明显遗漏或错误。"
  },
  "183": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访影像学检查的时间表和内容，但未明确提及“切缘阴性”对随访的影响，且未强调常规无需脑MRI或PET/CT，仅在有症状时考虑。此外，前3年与2年分段略有不同，属于细微差别。整体内容与参考答案高度一致，仅有轻微遗漏。"
  },
  "184": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides accurate staging and appropriate treatment recommendations. However, it uses the 8th edition AJCC staging (T1cN0M0, IA3) instead of T2aN0 (IIA) as in the reference, which may reflect a difference in staging criteria or interpretation, but otherwise covers all key points."
  },
  "185": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of indication for adjuvant chemotherapy, the rationale, and a detailed, guideline-based follow-up plan. No major omissions or errors are present."
  },
  "186": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of postoperative follow-up, including timing, content, and lifestyle advice, with reference to guidelines. However, it slightly overcomplicates the follow-up intervals and includes some additional but non-essential details not specified in the reference answer, such as extended follow-up beyond 3 years and more emphasis on symptom-driven imaging."
  },
  "187": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing MET抑制剂单药治疗, addressing the role of免疫治疗 and化疗, and providing appropriate context for treatment sequencing without any major omissions or errors."
  },
  "188": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including detailed TNM staging, rationale for unresectability, and standard treatment strategies. However, it incorrectly assigns stage IIIC instead of IIIB for cT1cN3M0 (per AJCC 8th edition), which is a minor but notable staging error."
  },
  "189": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including the need for bronchoscopy and additional preoperative assessments. However, it does not explicitly mention that mediastinal lymph node pathological evaluation (e.g., mediastinoscopy) is not routinely required for clinical N0 patients, which is a minor omission."
  },
  "190": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for immunotherapy plus chemotherapy as first-line, the role of KRAS G12C inhibitors in later lines, and the lack of other actionable mutations. No major omissions or errors."
  },
  "191": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访时间表、内容、戒烟指导等要点，但对3年后随访频率描述略有不清（未明确3年后每年随访，而是写第3-5年每年一次，5年后可延长），且未强调低剂量非增强CT优先，略有细节出入。"
  },
  "192": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，涵盖了手术方式、淋巴结清扫及特殊情况说明，无明显遗漏或错误。"
  },
  "193": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of EGFR 20插入突变靶向治疗（amivantamab或mobocertinib），化疗和免疫治疗的次要地位，并引用了权威指南，无重大遗漏或错误。"
  },
  "194": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including staging, rationale, and treatment recommendations. However, it incorrectly assigns the stage as IIIC (cT2N3M0), whereas according to the AJCC 8th edition, T2N3M0 is stage IIIB, not IIIC. This is a minor but important error."
  },
  "195": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the limited efficacy of traditional EGFR TKIs, the recommendation of amivantamab or mobocertinib as first-line if available, alternatives if not available, and the role of immunotherapy and chemotherapy, with no major omissions or errors."
  },
  "196": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good understanding of staging and management, but it omits the recommendation for脑MRI to rule out occult metastasis and does not mention the need for pathological mediastinal lymph node assessment prior to surgery, which are important steps in the reference answer."
  },
  "197": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including二次手术优先、辅助放疗/化疗的适应证、时机、以及不建议立即放化疗，并有指南依据，无明显遗漏或错误。"
  },
  "198": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including re-resection as first choice, radiotherapy if surgery is not feasible, individualized consideration of adjuvant therapy, and detailed follow-up recommendations. It also adds appropriate detail on assessment and MDT discussion, with no major omissions or errors."
  },
  "199": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers术前评估和腋窝处理的主要内容，包括分期、实验室检查、MDT讨论、新辅助治疗建议及前哨淋巴结活检策略，但未提及乳腺病灶标记物植入和骨扫描（可选），且部分表述略有冗余。"
  },
  "200": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the indication for neoadjuvant therapy and necessary pre-treatment assessments. However, it adds some extra details (e.g., fertility preservation, PD-L1, BRCA testing) not emphasized in the reference and omits the specific mention of tumor marker placement for localization, which is a minor but relevant omission."
  },
  "201": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the choice of osimertinib, rationale, the limited role of PD-L1, and guideline references, with no major omissions or errors."
  },
  "202": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including follow-up intervals, recommended imaging, lifestyle interventions, and indications for further testing, with no major omissions or errors."
  },
  "203": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred first-line regimen, rationale, the role of KRAS G12C inhibitors, and relevant guidelines, with no major omissions or errors."
  },
  "204": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including concurrent chemoradiotherapy as the standard, durvalumab maintenance, and consideration of targeted therapy for driver mutations, with additional detail and no major omissions or errors."
  },
  "205": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, treatment principles, specific regimens, and the role of consolidation immunotherapy, with no major omissions or errors."
  },
  "206": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访影像学内容和频率，但前3年未提及每3-6个月随访的可选性，且未明确提及体格检查（H&P）作为随访的一部分，略有简化。其他细节如吸烟干预和癌症幸存者评估未提及。"
  },
  "207": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including systemic evaluation, local and metastatic assessment, and additional considerations like fertility and genetic counseling. However, it omits the specific mention of placing localization markers in the primary tumor and biopsied lymph node, which is an important detail in the reference answer."
  },
  "208": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the rationale for neoadjuvant therapy, multidisciplinary evaluation, and alternative strategies for unresectable cases, with no major omissions or errors."
  },
  "209": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of need for adjuvant therapy, rationale, and detailed follow-up recommendations, with no significant omissions or errors."
  },
  "210": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for RET inhibitor monotherapy as first-line treatment, referencing guidelines, and appropriately discussing alternatives and their relative priorities. No major omissions or errors are present."
  },
  "211": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, including risk assessment, guideline references, and the role of endocrine therapy. However, it is slightly verbose and does not explicitly mention routine follow-up as in the reference answer, and the section on radiotherapy is cut off."
  },
  "212": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical points, including staging, standard first-line treatment, the significance of HER2 mutation, and the limited evidence for HER2-targeted therapy in squamous cell carcinoma. However, it omits explicit mention of multidisciplinary management, smoking cessation, and palliative care, which are present in the reference answer."
  },
  "213": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including re-resection as first choice, PORT if re-resection is not feasible, the limited role of adjuvant chemotherapy, MDT discussion, and appropriate follow-up. No major omissions or errors."
  },
  "214": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and includes appropriate rationale for RET抑制剂首选、脑转移处理、PD-L1表达意义及姑息措施，无重大遗漏或错误。"
  },
  "215": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, correctly prioritizes EGFR-TKI therapy (especially osimertinib), addresses CNS involvement, and appropriately discusses alternatives and non-recommended options, matching the reference answer with no major omissions or errors."
  },
  "216": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and lifestyle advice. However, it slightly deviates from the reference answer regarding the exact duration and frequency of CT scans, and does not explicitly mention the recommendation against routine PET/CT or brain MRI in asymptomatic patients."
  },
  "217": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key points from the reference answer, including mediastinal lymph node biopsy, advanced imaging for tumor invasion, and pulmonary function testing, and even adds reasonable details (e.g., cardiac assessment) without introducing errors or omissions."
  },
  "218": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (IIIB/IIIC, N3M0), standard concurrent chemoradiotherapy, and durvalumab consolidation, with no major omissions or errors."
  },
  "219": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of indication for adjuvant systemic therapy, the rationale, follow-up recommendations, and relevant guideline references, with no major omissions or errors."
  },
  "220": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it introduces the option of a 12-month follow-up CT, which is more conservative than the reference answer that states no routine follow-up is needed. This is a minor deviation, as some guidelines allow for optional follow-up, but the main recommendation should be no routine imaging."
  },
  "221": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but incorrectly assumes the tumor is resectable and prioritizes neoadjuvant therapy and surgery, whereas the reference answer clearly states the standard is concurrent chemoradiotherapy with consolidation (immunotherapy or EGFR-TKI), reflecting current guidelines for unresectable stage IIIA NSCLC with N2 involvement. There are notable omissions and inaccuracies regarding the standard of care."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，分期判断准确，治疗建议全面，涵盖了系统治疗、分子检测和MDT讨论，无重大遗漏或错误。"
  },
  "223": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of ALK-TKI (with specific drug examples), rationale, and guideline references, with no major omissions or errors."
  },
  "224": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and even additional relevant details without any major omissions or errors."
  },
  "225": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including comprehensive preoperative assessment, marking of lesions, detailed systemic evaluation, and the recommendation for neoadjuvant chemotherapy with dual anti-HER2 therapy. There are no major omissions or errors."
  },
  "226": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional detail and no major omissions or errors."
  },
  "227": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy and follow-up, including chemotherapy, radiotherapy, targeted and immunotherapy, and MDT discussion. However, it omits some details on imaging modalities (e.g., specific mention of chest CT, PET-CT, brain MRI in follow-up) and does not explicitly mention smoking cessation and survivorship care."
  },
  "228": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed staging rationale and outlines appropriate treatment options, but incorrectly assigns the stage as IIIA instead of IIIB, which is a significant inaccuracy. The rest of the content is largely correct, but this staging error affects the overall score."
  },
  "229": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including surgical resection, adjuvant chemotherapy, possible adjuvant immunotherapy, and MDT discussion. However, it omits the option of neoadjuvant (preoperative) therapy, which is the current preferred approach for resectable stage IIIA NSCLC, and does not mention the alternative of chemoradiotherapy for unresectable cases."
  },
  "230": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommendation for re-resection, alternative radiotherapy if unfit for surgery, and the rationale for not recommending observation or adjuvant chemotherapy. No major omissions or errors are present."
  },
  "231": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, providing detailed follow-up intervals and appropriate recommendations regarding imaging. However, it introduces some minor additional details (e.g., laboratory tests) and slight variations in CT frequency, but these do not significantly detract from the core clinical content."
  },
  "232": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, including the lack of indication for routine adjuvant therapy in Stage IB NSCLC without high-risk features, the importance of follow-up, and consideration of molecular testing, with no major omissions or errors."
  },
  "233": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general indications and rationale for 21-gene RT-PCR testing and correctly identifies that the patient fits the criteria, but it omits the key guideline nuance that testing is not routinely required if endocrine therapy alone is planned and there is no uncertainty about chemotherapy benefit. This leads to a partial but not fully accurate recommendation."
  },
  "234": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including recommended imaging (chest CT), follow-up frequency, and additional considerations. However, it slightly overemphasizes optional imaging (abdominal CT/ultrasound) and does not specify the transition to annual low-dose CT after 5 years, which is a minor omission."
  },
  "235": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive recommendations for platinum-based doublet chemotherapy combined with immunotherapy, and includes rationale and specific regimens without any major omissions or errors."
  },
  "236": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key steps (systemic staging with PET-CT and brain MRI, pathological confirmation of mediastinal nodes, MDT discussion), and even adds appropriate details (molecular testing) without omitting any major points from the reference answer."
  },
  "237": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and even provides additional relevant details without introducing errors or omissions."
  },
  "238": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach for advanced squamous NSCLC but incorrectly prioritizes immunotherapy plus chemotherapy over BRAF/MEK inhibitor therapy, which is the guideline-recommended first-line treatment for BRAF V600E-mutant NSCLC regardless of histology or PD-L1 status. There are also some inaccuracies regarding the use of BRAF inhibitors in squamous cell carcinoma."
  },
  "239": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗建议及术后处理均无遗漏或错误，且补充了合理的细节。"
  },
  "240": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, further diagnostic steps, and treatment options, with no major omissions or errors."
  },
  "241": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points on staging and treatment, with no major omissions or errors."
  },
  "242": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including correct N3 staging, inoperability, and standard treatment with concurrent chemoradiotherapy and consolidation immunotherapy. However, it incorrectly assigns stage IIIC instead of IIIB (N3 with T1–2 is IIIB per AJCC 8th edition), which is a minor but notable staging inaccuracy."
  },
  "243": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up intervals, imaging modality, and the fact that follow-up frequency does not change if adjuvant chemotherapy is not given. However, it introduces a 3–6 month interval (rather than strictly 6 months) in the first 2 years and extends 6-monthly follow-up to 5 years instead of 3, which is a minor deviation from the reference answer."
  },
  "244": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the need for adjuvant radiotherapy and chemotherapy, and mentions the possibility of re-operation. However, it places more emphasis on adjuvant therapy as the first choice rather than re-operation, which is the guideline-recommended first-line approach for R1 resection if feasible. Minor omission of prioritizing re-resection accounts for the point deduction."
  },
  "245": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了再次手术、放疗、辅助化疗及详细随访计划，无重大遗漏或错误，仅在随访频率细节上略有扩展，整体内容完整。"
  },
  "246": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating the stage (IA2/pT1bN0M0), the lack of need for adjuvant therapy, and the recommendation for regular follow-up, with no major omissions or errors."
  },
  "247": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, MDT discussion, assessment of patient status, preferred concurrent chemoradiotherapy, alternatives for poor performance status, and supportive care, with the addition of current standard durvalumab consolidation. No major omissions or errors."
  },
  "248": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, methods, and imaging recommendations. However, it suggests a slightly more frequent follow-up schedule than the reference and does not explicitly mention the avoidance of routine FDG-PET/CT or brain MRI in asymptomatic patients, which is a minor omission."
  },
  "249": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, structured approach, but it incorrectly classifies the T stage as T3 instead of T4 (since the reference answer uses >7cm for T4, but the actual tumor is 6.2cm, which is T3 per AJCC 8th edition). It also omits the explicit recommendation for brain MRI and biomarker testing, which are important next steps."
  },
  "250": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, rationale, and detailed treatment recommendations without major omissions or errors."
  },
  "251": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key recommendations, including再手术、放疗、辅助化疗、分子检测及随访，但对随访方案的具体时间安排（如每6个月复查H&P和胸部CT，2-3年后每年低剂量CT）描述不够详细，且对辅助化疗和靶向/免疫治疗的适用性略有扩展，属于次要遗漏。"
  },
  "252": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the TNM staging, and provides appropriate management recommendations, including MDT discussion, chemoradiotherapy, and consideration of immunotherapy, with no major omissions or errors."
  },
  "253": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including standard chemo-immunotherapy, the limited evidence for HER2-targeted therapy in squamous cell carcinoma, and the importance of clinical trials. However, it omits mention of antibody-drug conjugates like trastuzumab deruxtecan (T-DXd) as a specific HER2-targeted option and does not explicitly state that single-agent immunotherapy is less effective with PD-L1<1%."
  },
  "254": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, multidisciplinary evaluation, pathological confirmation, detailed treatment pathways (including neoadjuvant therapy, surgery, and alternatives for unresectable cases), and necessary assessments, with no major omissions or errors."
  },
  "255": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, specific drug examples, and supporting evidence, with no major omissions or errors."
  },
  "256": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the recommendation for best supportive care and the rationale against standard anti-tumor therapy. It adds some nuance about possible exceptions (e.g., if PS 3 is tumor-related), which is acceptable, but slightly overemphasizes the option of reduced-dose therapy, which is not routinely recommended. Minor differences in emphasis prevent a perfect score."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including breast-conserving surgery, sentinel lymph node biopsy, postoperative radiotherapy, and consideration of neoadjuvant therapy if breast conservation is not feasible initially. No major omissions or errors."
  },
  "258": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗原则及具体流程均无遗漏或错误，表述更为详细，无重大遗漏或错误。"
  },
  "259": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, including the standard treatment (lobectomy with systematic lymph node dissection) and a comprehensive list of appropriate preoperative evaluations, with no major omissions or errors."
  },
  "260": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and even expands on rationale and details without introducing errors or omissions. It fully aligns with current guidelines and clinical practice."
  },
  "261": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guideline basis, and stepwise management of the axilla, with no major omissions or errors."
  },
  "262": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the stage as IA2 (T1bN0M0) and listing appropriate preoperative assessments. However, it includes some additional tests (e.g., tumor markers, head imaging) not emphasized in the reference answer and does not specifically mention the need for mediastinal lymph node pathological evaluation in suspicious cases, which is a minor omission."
  },
  "263": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate staging, detailed rationale, and comprehensive discussion of standard and alternative treatment strategies, including MDT evaluation and consolidation immunotherapy. No major omissions or errors are present."
  },
  "264": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, further preoperative assessment, and appropriate neoadjuvant therapy. However, it omits the recommendation for axillary lymph node marker placement and does not mention the use of T-DM1 for residual disease postoperatively, which are important details in the reference answer."
  },
  "265": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including imaging, pathology, systemic staging, laboratory tests, fertility, and genetic counseling. However, it omits some minor details such as psychological assessment, social support evaluation, and the explicit need to complete the immunohistochemistry report (e.g., lymphovascular invasion)."
  },
  "266": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based recommendations, including the use of capmatinib and tepotinib as first-line options, which are also approved MET inhibitors. However, it omits crizotinib, which is specifically mentioned in the reference answer, and does not emphasize multidisciplinary and palliative care considerations as much as the reference."
  },
  "267": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including病理复核、分期评估、实验室检查、影像学完善、治疗方案制定（分子分型指导下的系统治疗）、支持治疗及MDT讨论，无明显遗漏或错误。"
  },
  "268": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including immunotherapy plus platinum-based chemotherapy, bone-modifying agents, and supportive care, with no major omissions or errors."
  },
  "269": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of staging and management, but it questions the T分期（T2a vs T1c）基于肿瘤大小，指出分期应为IA3（cT1cN0M0），而参考答案为IB（T2aN0M0）。此外，模型答案对辅助治疗的适应证和术前支气管镜检查等细节略有遗漏。"
  },
  "270": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately describes the staging, emphasizes the need for pathological confirmation of N3 nodes, and outlines appropriate next steps and treatment, with no major omissions or errors."
  },
  "271": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based recommendations, but it overemphasizes辅助化疗 as the standard and underrepresents“可考虑单纯观察”的合理性，未充分体现与患者沟通和权衡决策的过程，且随访方案略有细节差异。"
  },
  "272": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing correct staging (IA2, T1bN0M0) and appropriate treatment recommendations. However, it omits mention of anatomical segmentectomy as an alternative to lobectomy and does not explicitly state the need for intraoperative or preoperative pathological mediastinal lymph node assessment, which are minor but relevant details."
  },
  "273": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding maintenance immunotherapy, the role of KRAS G12C inhibitors upon progression, and additional considerations. There are no major omissions or errors."
  },
  "274": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including urgent symptom control (steroids, antiepileptics), whole-brain radiotherapy, and subsequent ROS1-targeted therapy, with appropriate prioritization and rationale. There are no major omissions or errors."
  },
  "275": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了辅助治疗的适应证、随访频率、影像学检查建议及戒烟指导，无重大遗漏或错误。"
  },
  "276": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the preferred use of amivantamab or mobocertinib, the limited efficacy of first/second-generation EGFR-TKIs, chemotherapy options, and local management of pleural effusion. However, it introduces immunotherapy as a possible option, which is not recommended in the reference answer for EGFR-mutant patients, and the discussion of palliative care and smoking cessation is less explicit."
  },
  "277": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, the need to clarify the nature of the left lung nodule, and outlines appropriate treatment strategies for both scenarios (second primary vs. metastasis). However, it is slightly less definitive in stating that, per guidelines, these are most likely two primary tumors, and it does not explicitly mention the need for preoperative pulmonary function assessment or the recommendation for systematic lymph node dissection during surgery, which are present in the reference answer."
  },
  "278": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need to switch to ALK-TKI therapy, rationale, drug choices, and supportive management considerations, with no major omissions or errors."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including maintenance immunotherapy, the timing and rationale for KRAS G12C inhibitor use, and guideline-based recommendations, with no major omissions or errors."
  },
  "280": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the rationale, drug options, and guideline references, but it overstates the recommendation for endocrine therapy after mastectomy (应“可考虑”而非“建议”)，且未强调全乳切除后内分泌治疗并非常规，属于可选项，略有倾向性表述。"
  },
  "281": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical resection as first-line treatment, the need for systematic lymph node dissection, and the role of adjuvant chemotherapy. It also adds relevant details about molecular testing, which is appropriate and up-to-date. No major omissions or errors."
  },
  "282": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear understanding of the staging and management principles, but it omits the explicit reference to NCCN guidelines and multidisciplinary discussion, and does not mention the need for comprehensive lung function assessment before surgery."
  },
  "283": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including分期、病理学确诊、全面分期评估、治疗原则、以及多学科讨论, with no major omissions or errors."
  },
  "284": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including pathology, imaging, laboratory tests, and marking procedures. However, it adds some extra content (e.g., fertility and genetic counseling) and slightly underemphasizes the need to confirm that both the primary tumor and suspicious lymph node have been marked if not already done, which are minor omissions."
  },
  "285": {
    "score": 3.0,
    "explanation": "3: The model answer provides a structured and partially accurate approach but incorrectly classifies the second nodule as T3 rather than T4, which is a significant error per AJCC 8th edition. It also underestimates the clinical stage (IIb instead of at least IIIA), though it does discuss the need for further pathological clarification and the clinical implications."
  },
  "286": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of KRAS G12C inhibitors, specific drug names, guideline recommendations, and alternative options if targeted therapy is unavailable, with no major omissions or errors."
  },
  "287": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including maintenance therapy with immunotherapy (± pemetrexed), the role of KRAS G12C inhibitors upon progression, and referencing relevant guidelines. No major omissions or errors."
  },
  "288": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it incorrectly assigns stage IIIC instead of IIIB for T2N3M0 (per AJCC 8th edition), and omits explicit mention of smoking cessation and early palliative care integration, which are present in the reference answer."
  },
  "289": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including staging, rationale for platinum-based doublet chemotherapy plus immunotherapy, consideration of PD-L1 status, ECOG score, and supportive care measures. There are no major omissions or errors."
  },
  "290": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of platinum-based chemotherapy plus immunotherapy as first-line treatment, the role of KRAS G12C inhibitors in later lines, and considerations for brain metastases. No major omissions or errors are present."
  },
  "291": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency and the indications for PET-CT and brain MRI, with no major omissions or errors."
  },
  "292": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, logical approach, but it differs from the reference answer in T分期（T1c vs T3）和临床分期（IA3 vs IIB），因对“邻近胸膜”是否等同于“侵犯胸壁”理解不同，且未强调脑MRI/骨扫描的适应证，存在轻微分歧和小遗漏。"
  },
  "293": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key management steps, including re-resection as first choice and radiotherapy if surgery is not feasible. However, it omits details about postoperative surveillance (regular follow-up with history, physical exam, and CT scans) and smoking cessation advice, which are present in the reference answer."
  },
  "294": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient risk stratification, guideline recommendations, the role and limitations of gene expression profiling, and the rationale for recommending adjuvant chemotherapy. No major omissions or errors are present."
  },
  "295": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including CDK4/6抑制剂联合内分泌治疗为首选、化疗作为后续选择、骨改良药物的应用，并补充了指南依据和具体药物方案，无重大遗漏或错误。"
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering HER2靶向治疗（trastuzumab deruxtecan为首选）、免疫治疗的次选地位、以及患者体力状况的考量，无明显遗漏或错误。"
  },
  "297": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including accurate TNM staging, surgical management, and alternative options. However, it incorrectly assigns the stage as IA2 instead of IB (per the reference answer and AJCC 8th edition for T2aN0M0), which is a minor but important omission."
  },
  "298": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including no need for adjuvant therapy, detailed follow-up intervals, and adds appropriate lifestyle advice without introducing errors or omissions."
  },
  "299": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, content, and additional considerations. However, it slightly differs in the timing of follow-up intervals (front-loading the first 2 years as every 3 months rather than 3–6 months for the first 3 years), and it suggests PET-CT more liberally than guidelines recommend. Minor omissions include not explicitly stating that PET/CT or brain MRI are not routinely recommended in asymptomatic patients."
  },
  "300": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including follow-up intervals, main examinations, and lifestyle advice. However, it provides slightly more detail than required (e.g., lab tests, functional assessment) and minor differences in interval recommendations (e.g., 3–6 months vs. 6 months), but these do not constitute major omissions or errors."
  },
  "301": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, symptom monitoring, lifestyle advice, and survivor care. However, it slightly overstates the frequency of follow-up CT scans (every visit vs. every 6 months per reference) and adds some details (e.g., vaccines) not specified in the reference, while omitting the explicit recommendation against routine PET/CT or brain MRI in asymptomatic patients."
  },
  "302": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为全面，涵盖了KRAS G12C抑制剂、免疫治疗、化疗和支持治疗等选项，并对PS 2患者的特殊性进行了说明，但对KRAS G12C抑制剂在鳞癌中的适用性和指南推荐的强调略有保留，且未明确指出应与姑息治疗密切结合，略有细节遗漏。"
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the rationale for adjuvant chemotherapy, patient selection, chemotherapy regimens, and detailed follow-up recommendations. There are no major omissions or errors."
  },
  "304": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the stage (IA2/T1bN0M0), preferred surgical approach, and alternatives for high-risk patients, with no significant omissions or errors."
  },
  "305": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of the reference answer, and provides detailed rationale for each step, including the necessity of brain MRI and the specifics of preoperative assessment and treatment planning, with no major omissions or errors."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and adds relevant details about molecular testing and possible targeted/immune therapies, without any major omissions or errors."
  },
  "307": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including the rationale for ALK-TKI monotherapy, specific drug recommendations (with preference for newer generation inhibitors), and the reasoning for not choosing chemotherapy or immunotherapy, matching the reference answer without major omissions or errors."
  },
  "308": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need for bronchoscopic palliative intervention, systemic therapy, rationale, and guideline references, with no major omissions or errors."
  },
  "309": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, recommended regimen (platinum doublet chemotherapy plus immunotherapy), specific drug options, treatment duration, and rationale, with no major omissions or errors."
  },
  "310": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, but it incorrectly classifies the tumor as T1c (should be T1b for 2.2 cm per AJCC 8th edition), leading to an incorrect stage (IA3 instead of IA2). Otherwise, the treatment recommendations and rationale are appropriate."
  },
  "311": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key points regarding the limited efficacy of standard EGFR-TKIs, the role of platinum-based chemotherapy, and the limited benefit of immunotherapy, but it omits amivantamab as the current preferred first-line therapy for EGFR exon 20 insertion mutations, which is a major omission."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need for multidisciplinary evaluation, assessment of resectability, perioperative and chemoradiotherapy options, comprehensive molecular testing (including PD-L1), and the rationale for these steps. There are no major omissions or errors."
  },
  "313": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers the recommended follow-up intervals, imaging modalities, and the indications for brain MRI and PET-CT, with no major omissions or errors compared to the reference answer."
  },
  "314": {
    "score": 4.0,
    "explanation": "4: The model answer covers most key points, including emergency management, supportive care, and specific interventions (radiotherapy and stenting). However, it omits the importance of comprehensive staging (e.g., brain MRI, PET/CT), does not mention the role of concurrent chemoradiotherapy as standard if not previously given, and lacks advice on smoking cessation and palliative care integration."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "316": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides accurate staging, emphasizes the need for pathological confirmation of N2 disease, and outlines appropriate multidisciplinary and treatment strategies."
  },
  "317": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes additional relevant details such as bone-modifying agents and supportive care, with no major omissions or errors."
  },
  "318": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including detailed TNM staging, rationale, and standard treatment recommendations, with no major omissions or errors."
  },
  "319": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects of staging, further evaluation, and management, with no major omissions or errors."
  },
  "320": {
    "score": 5.0,
    "explanation": "5: The model answer provides a thorough and accurate clinical staging (cT1bN0M0, IA2) and details the recommended next steps, including surgical options, alternative treatments, and considerations for adjuvant therapy, matching the reference answer in clinical content without major omissions or errors."
  },
  "321": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the staging rationale, and outlines the next steps and treatment options, including necessary further assessments and multidisciplinary discussion, with no major omissions or errors."
  },
  "322": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, appropriate treatment recommendations, and even includes additional details about surgical options and postoperative considerations without any major omissions or errors."
  },
  "323": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and supportive care. However, it suggests a slightly more frequent follow-up schedule in the first two years and includes optional laboratory tests, which are not emphasized in the reference answer. Minor differences in imaging modality details and timing prevent a perfect score."
  },
  "324": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, rationale, and appropriate next steps, with no significant omissions or errors."
  },
  "325": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "326": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the ineffectiveness of conventional EGFR-TKIs, the recommendation for platinum-based chemotherapy ± immunotherapy, and the consideration of exon 20-specific targeted agents. However, it slightly underemphasizes multidisciplinary and palliative care, and the discussion of targeted therapy as a later-line option for squamous histology is more cautious than the reference, which is a minor omission."
  },
  "327": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately covering staging and treatment planning, including neoadjuvant therapy, surgery, and adjuvant therapy. However, it omits some minor but important details such as baseline organ function assessment, the placement of marker clips, and the specific recommendation of T-DM1 for non-pCR cases."
  },
  "328": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging and treatment included and no significant omissions or errors."
  },
  "329": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the recommendation for salvage radiotherapy, MDT discussion, and a detailed follow-up plan. However, it places more emphasis on radiotherapy as the first choice rather than reoperation, which is the reference's primary recommendation, and omits explicit mention of smoking cessation advice."
  },
  "330": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including tumor characteristics, surgical options, the role of radiotherapy, endocrine therapy, and the lack of indication for chemotherapy or HER2-targeted therapy, with no major omissions or errors."
  },
  "331": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, providing detailed rationale for adjuvant chemotherapy and referencing guidelines. However, it omits the option of close observation as an acceptable alternative for patients who decline or cannot tolerate chemotherapy, which is included in the reference answer."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for concurrent chemoradiotherapy, the role of durvalumab consolidation, and the inoperability due to N3 disease, with no major omissions or errors."
  },
  "333": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of staging and management, including MDT evaluation, further pathological assessment, and treatment options. However, it introduces additional details (e.g., molecular testing, durvalumab) not specified in the reference and slightly overemphasizes concurrent chemoradiotherapy as the first choice, whereas the reference prioritizes surgical evaluation for resectable N2. Minor omissions and differences prevent a perfect score."
  },
  "334": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访频率、内容和高危因素，但对3-5年随访频率描述略有不清（未明确2-3年与3-5年间的频率变化），且未强调“胸部增强CT”而是提及低剂量CT，此外对FDG-PET/CT和脑MRI的常规不推荐未明确指出。"
  },
  "335": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage (cT2aN0M1a, IVa) and the rationale for systemic therapy, including molecular testing. However, it underemphasizes the possibility of treating as synchronous double primary lung cancers with curative intent, which the reference answer highlights as a potential option after MDT discussion."
  },
  "336": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, including prioritization of MET抑制剂（capmatinib或tepotinib）为一线治疗, alternative options if MET inhibitors are unavailable, and appropriate exclusion of irrelevant targeted therapies. There are no major omissions or errors."
  },
  "337": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for EGFR-TKI (afatinib) as first-line therapy, the management of brain metastases, the limited role of immunotherapy, and supportive care. There are no major omissions or errors."
  },
  "338": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications for adjuvant chemotherapy and trastuzumab, rationale, guideline support, and even elaborates on regimen options without introducing errors or omissions."
  },
  "339": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the indication for adjuvant chemotherapy, rationale, guideline support, and appropriate regimen suggestions, with no major omissions or errors."
  },
  "340": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it omits that免疫单药治疗（如帕博利珠单抗单药）也是指南推荐的可选一线方案，尤其在PD-L1≥1%时。强调联合化疗为主流推荐略有偏颇，未充分体现单药免疫的适应证。"
  },
  "341": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for CDK4/6 inhibitor plus aromatase inhibitor, rationale, alternative options, and bone-modifying agents, with no major omissions or errors."
  },
  "342": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, clinical stage, and necessary preoperative assessments, with no major omissions or errors."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of EGFR-TKIs (osimertinib or afatinib), rationale for drug choice, non-recommendation of immunotherapy/chemotherapy, and consideration of brain metastases. No major omissions or errors."
  },
  "344": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential elements of the reference answer, including follow-up intervals, imaging modality, and lifestyle counseling. However, it slightly overstates the frequency of follow-up in years 3–5 and includes optional imaging not routinely recommended, which are minor deviations."
  },
  "345": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including molecular testing, imaging, functional assessment, and treatment options. However, it omits the explicit mention of FDG-PET/CT as the preferred modality for systemic staging and does not clearly state the role of pleurodesis for malignant effusion, which are present in the reference answer."
  },
  "346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, including patient characteristics, rationale for endocrine therapy, radiotherapy, the role of chemotherapy, and the use of 21-gene expression profiling with reference to the RxPONDER study. There are no major omissions or errors."
  },
  "347": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, including adjuvant chemotherapy, postoperative radiotherapy, rationale, and follow-up considerations, with no major omissions or errors. It even adds relevant details about immunotherapy and treatment sequencing, which are accurate and guideline-based."
  },
  "348": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，涵盖了检测适应证、治疗推荐及具体方案，无重大遗漏或错误。"
  },
  "349": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM staging, rationale, and appropriate management recommendations without omissions or errors."
  },
  "350": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points regarding the lack of need for adjuvant therapy and provides a detailed, guideline-consistent follow-up plan, even adding relevant details about high-risk factors and unnecessary tests."
  },
  "351": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of EGFR-TKIs (with preference for osimertinib), rationale, alternative options, and integration with palliative care and radiotherapy. No major omissions or errors."
  },
  "352": {
    "score": 3.0,
    "explanation": "3: The model answer misclassifies the T stage as T3 instead of T4 (since chest wall invasion defines T4 regardless of size), leading to an incorrect overall stage (IIIB instead of IIIA). The treatment recommendations are generally appropriate, but the staging error is a significant omission."
  },
  "353": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it differs from the reference answer in分期 (IA3 vs IB) due to interpretation of T分期（T1c vs T2a），并未提及术后高危因素时可考虑辅助化疗，属于细微分歧和小遗漏。"
  },
  "354": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细说明了EGFR G719X突变后首选EGFR-TKI（如阿法替尼），并补充了剂量、指南依据及免疫治疗不优先的理由，无重大遗漏或错误。"
  },
  "355": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed reasoning and appropriate recommendations. However, it differs from the reference answer in TNM分期（T1cN0M0, IA3期 vs T2aN0M0, IB期）—this is due to a difference in interpreting the tumor size cutoff, which is a minor but relevant detail. Otherwise, the management plan is appropriate and comprehensive."
  },
  "356": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, clinical and imaging assessments, and supportive care. However, it slightly deviates from the reference answer regarding the exact timing and frequency of chest CT, and does not explicitly state that routine PET-CT or brain MRI are not recommended unless clinically indicated."
  },
  "357": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for adjuvant chemotherapy in TNBC >1cm, guideline recommendations, and rationale, with no major omissions or errors."
  },
  "358": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects of treatment and molecular testing, with no major omissions or errors. It even provides additional detail and rationale consistent with current guidelines."
  },
  "359": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects current guidelines, and covers all key points from the reference answer without major omissions or errors."
  },
  "360": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for concurrent chemoradiotherapy as the initial treatment and addressing the specifics of N2 disease, with no major omissions or errors."
  },
  "361": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of recommending reoperation for R0 resection and considering radiotherapy if surgery is not feasible. However, it omits the recommendation for regular follow-up and smoking cessation guidance, which are present in the reference answer."
  },
  "362": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly describing the T, N, and M status, and recommending concurrent chemoradiotherapy with durvalumab maintenance. However, it assigns stage IIIC (AJCC 8th), while the reference uses IIIB; both are reasonable depending on the staging system, but this could cause minor confusion. Otherwise, there are no major omissions."
  },
  "363": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, including staging, recommended concurrent chemoradiotherapy, and consolidation with durvalumab. However, it omits the specific mention of osimertinib as a consolidation option for EGFR-mutant cases, which is present in the reference answer."
  },
  "364": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality choices, and the non-recommendation of routine PET/CT or brain MRI, with no major omissions or errors."
  },
  "365": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately describes the need for pathological mediastinal lymph node assessment, details the staging process, and outlines appropriate treatment strategies based on staging, matching the reference answer with no major omissions or errors."
  },
  "366": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and stepwise management, with no major omissions or errors."
  },
  "367": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for EGFR-TKI as first-line therapy, the limited role of immunotherapy, and specific drug recommendations, with no major omissions or errors."
  },
  "368": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，涵盖了风险评估、随访CT、PET-CT及活检等处理措施，无重大遗漏或错误。"
  },
  "369": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including HER2靶向治疗至1年、放疗指征、无需补充化疗和内分泌治疗，无重大遗漏或错误。"
  },
  "370": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including correct TNM staging, recommended further assessments, and multidisciplinary evaluation. However, it incorrectly classifies T4N0M0 as stage IIIB instead of IIIA, which is a minor but notable error."
  },
  "371": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommended first-line regimen, rationale, guideline support, and dosing, with no major omissions or errors."
  },
  "372": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of next-generation ALK-TKIs (especially Alectinib), their superiority over chemotherapy, and specific mention of CNS efficacy in brain metastases, with no major omissions or errors."
  },
  "373": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps of pathology confirmation, reassessment of receptor status, systemic evaluation, and appropriate HER2-targeted and endocrine therapy options. However, it omits some minor details such as specific laboratory tests (e.g., alkaline phosphatase), the explicit mention of broad molecular/genetic testing, and regular imaging follow-up."
  },
  "374": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps (re-operation, PORT, adjuvant chemotherapy), and even references relevant guidelines. There are no major omissions or errors."
  },
  "375": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately describes the staging (with updated AJCC terminology), and provides a guideline-based, detailed rationale for first-line therapy, including drug choices and the role of immunotherapy. No major omissions or errors."
  },
  "376": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy and follow-up, with additional details on targeted and immunotherapy. However, it slightly overreaches beyond the reference answer by including newer adjuvant options and more detailed regimens, and omits explicit mention of not routinely recommending PET-CT or brain MRI in follow-up."
  },
  "377": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, rationale for direct surgery, details of surgical options, and postoperative adjuvant therapy considerations, with no major omissions or errors."
  },
  "378": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the indications for adjuvant chemotherapy, details high-risk factors, and provides a thorough, guideline-based follow-up plan. There are no major omissions or errors compared to the reference answer."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期 (T1cN2M0, IIIA期) and detailing the recommended multidisciplinary approach, neoadjuvant therapy options, surgical considerations, and postoperative/adjuvant strategies, with no major omissions or errors."
  },
  "380": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covering all key points from the reference answer, including pulmonary function testing, PET-CT, mediastinal lymph node assessment, and surgical planning, with only minor expansions (e.g., MDT discussion) and no major omissions or errors."
  },
  "381": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and lifestyle advice. However, it suggests a slightly more frequent follow-up schedule in the first two years and includes optional tumor markers, which are not emphasized in the reference. Minor differences in imaging modality recommendations and omission of the explicit statement against routine PET/CT or brain MRI prevent a perfect score."
  },
  "382": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up content, frequency, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "383": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including adjuvant chemotherapy, postoperative radiotherapy for R1 resection, MDT discussion, and guideline references, with no major omissions or errors."
  },
  "384": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (IIIB, T any, N3, M0) and providing comprehensive, guideline-based treatment recommendations, including the option of consolidation immunotherapy, with no major omissions or errors."
  },
  "385": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the TNM staging, rationale for T4N0M0 (IIIB), and providing appropriate, guideline-based treatment recommendations with no major omissions or errors."
  },
  "386": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, treatment recommendations, and rationale. However, it incorrectly assigns the stage as IIIC instead of IIIB (T2N3M0 is IIIB per AJCC 8th edition), which is a minor but important omission. Otherwise, the clinical content is accurate and thorough."
  },
  "387": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indication for ROS1靶向抑制剂（如克唑替尼、恩曲替尼）一线治疗，并补充了剂量、注意事项和指南依据，无重大遗漏或错误。"
  },
  "388": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, content, and imaging recommendations. However, it omits the specific recommendation for contrast-enhanced CT in the first 5 years, the use of low-dose non-contrast CT after 5 years, and the explicit statement that routine PET/CT or brain MRI is not recommended unless symptomatic."
  },
  "389": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including comprehensive molecular testing, PD-L1 assessment, testing methods, and individualized treatment strategies based on results, as well as smoking cessation advice. There are no major omissions or errors."
  },
  "390": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including diagnosis, staging, molecular subtype, recommended chemotherapy and anti-HER2 therapy, duration, and the rationale for omitting endocrine therapy. It also appropriately discusses the consideration of radiotherapy, which is a reasonable addition. No major omissions or errors."
  },
  "391": {
    "score": 4.0,
    "explanation": "4: 模型答案内容基本完整，详细说明了辅助化疗的推荐理由和具体药物选择，随访方案也较为详细，但随访时间间隔与参考答案略有不同，且未强调可选择观察、需结合患者意愿和健康指导等细节。"
  },
  "392": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and includes appropriate rationale, treatment options, and decision-making considerations without major omissions or errors."
  },
  "393": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it incorrectly stages the tumor as T2a (IA2/IB) instead of T2b (IIA) for a 3.2cm lesion, which is a minor but important detail. Otherwise, the treatment recommendations and rationale are appropriate and comprehensive."
  },
  "394": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the key points, and provides detailed rationale for each treatment option, fully aligning with the reference answer without major omissions or errors."
  },
  "395": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，分期和首选治疗方案均准确，未有重大遗漏或错误，仅对辅助化疗的适应证略简化，但不影响核心内容。"
  },
  "396": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including risk assessment, PET/CT evaluation, indications for biopsy or surgery, and follow-up strategy, with no significant omissions or errors."
  },
  "397": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including accurate staging (IVB, M1b), comprehensive molecular and PD-L1 testing recommendations, and additional relevant assessments. There are no major omissions or errors."
  },
  "398": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including laboratory tests, cardiac assessment, MRI indications, and additional considerations like genetic testing and anesthesia evaluation. However, it omits the specific mention of在穿刺点置入影像可见标记物 for手术定位 and does not emphasize腋窝可疑淋巴结穿刺及标志夹放置, which are important for surgical planning."
  },
  "399": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred approach (re-operation if feasible), the alternative of salvage radiotherapy, and the reasons for not recommending surveillance alone. It also references relevant guidelines, with no major omissions or errors."
  },
  "400": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访频率、检查项目及指南依据，但未明确强调首2-3年内胸部CT建议含对比增强、2年后为低剂量无增强CT，以及未提及戒烟建议，存在细节性小遗漏。"
  },
  "401": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer and adds up-to-date, guideline-based options such as adjuvant immunotherapy and targeted therapy, with no major omissions or errors. It is comprehensive and clinically accurate."
  },
  "402": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points regarding adjuvant chemotherapy and follow-up, including staging, treatment recommendations, and follow-up intervals. However, it omits explicit mention of smoking cessation advice and is slightly more detailed than required, with minor deviations in follow-up interval specifics."
  },
  "403": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers clinical staging, rationale for neoadjuvant therapy, and axillary evaluation, but omits some key details such as the importance of pre-treatment tumor bed marking and the use of metal markers for suspicious nodes if biopsied. Minor inaccuracies exist in the description of HR阴性为“三阴性”，但整体内容与参考答案高度一致。"
  },
  "404": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, structured approach, but it assigns the stage as IIA (cT2aN0M0) rather than IB, which is a minor discrepancy according to the latest AJCC 8th edition. The rest of the management plan is appropriate and matches the reference answer."
  },
  "405": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately covering staging, HER2-targeted therapy, and the need for further molecular and PD-L1 testing. However, it omits discussion of brain metastasis management (e.g., WBRT/SRS) and supportive care, which are important aspects in the reference answer."
  },
  "406": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key steps including病理性纵隔淋巴结评估、脑转移排查、MDT讨论、治疗分层、分子标志物检测等，与参考答案内容一致，无重大遗漏或错误。"
  },
  "407": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modalities, and the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "408": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of treatment and follow-up, with additional detail on radiotherapy, chemotherapy, and possible immunotherapy/targeted therapy. However, it slightly overextends beyond standard recommendations (e.g., routine consideration of immunotherapy/targeted therapy postoperatively in this context) and the follow-up intervals are somewhat more detailed than the reference, but the core clinical content is accurate."
  },
  "409": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points: endocrine therapy with CDK4/6 inhibitor as first-line, indications for chemotherapy, the importance of gene testing, and specific genes to test. However, it omits explicit mention of bone-protective therapy, which is a key aspect in the reference answer."
  },
  "410": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for EGFR-TKI as first-line therapy, addressing the role of PD-L1, and discussing subsequent management, with no major omissions or errors."
  },
  "411": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, and the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "412": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and standard treatment recommendations, but it omits the suggestion to perform a brain MRI to rule out intracranial metastasis and does not explicitly mention multidisciplinary team evaluation or neoadjuvant therapy as a preferred initial approach."
  },
  "413": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of ALK-TKI therapy, the irrelevance of high PD-L1 expression in the presence of ALK rearrangement, and the lack of impact of squamous histology on treatment choice. No major omissions or errors are present."
  },
  "414": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline-based recommendations, and specific regimen details without any major omissions or errors."
  },
  "415": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and all recommended treatment options without omissions or errors."
  },
  "416": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, treatment recommendations, and the rationale for each step. However, it assigns stage IIIA (T?N2M0) instead of the more appropriate stage IIIB (T4N2M0) given the \"左肺上叶占位\" with \"左侧纵隔淋巴结肿大,\" which may suggest T4 disease. This is a minor but relevant staging omission. Otherwise, the treatment plan aligns well with the reference answer."
  },
  "417": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of need for adjuvant therapy and providing a detailed, guideline-consistent follow-up plan with no major omissions or errors."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive details on the preferred first-line therapy, rationale, alternatives, and guideline support, with no major omissions or errors."
  },
  "419": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of the reference answer, including the need for neoadjuvant therapy, further cardiac and laboratory evaluation, and rationale for treatment. However, it omits the specific recommendation for image-guided core needle biopsy with marker placement and does not mention axillary lymph node biopsy if suspicious nodes are found, which are important minor details."
  },
  "420": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good understanding, but it introduces some ambiguity regarding the inclusion of the supraclavicular region, which is not routinely recommended for all such cases per the reference answer. Otherwise, it covers the key clinical content and rationale."
  },
  "421": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the TNM staging, and thoroughly covers postoperative adjuvant therapy options, including chemotherapy, targeted, and immunotherapy, as well as the nuanced role of radiotherapy and the need for molecular testing. There are no major omissions or errors compared to the reference answer."
  },
  "422": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the likelihood of multiple primary lung cancers, separate staging, and the need for preoperative assessment and surgical consideration. However, it omits explicit mention of the overall stage IVA (M1a) classification and the importance of multidisciplinary discussion and mediastinal lymph node pathological evaluation, which are present in the reference answer."
  },
  "423": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including再手术、放疗、化疗和详细随访策略，但对随访时间节点略有扩展，且未特别强调戒烟干预和肿瘤生存管理，属于轻微遗漏。"
  },
  "424": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、手术方案、术前评估、替代治疗及术后处理均有详细阐述，无明显遗漏或错误。"
  },
  "425": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for MET TKI therapy, specific drug recommendations (capmatinib, tepotinib), rationale, and guideline references, with no major omissions or errors."
  },
  "426": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps of axillary assessment and subsequent management, including clinical, imaging, and pathological evaluation, as well as the rationale for neoadjuvant therapy. However, it omits the specific recommendation for percutaneous biopsy and marking of suspicious nodes if found on ultrasound, and does not mention pre-treatment clip placement in the primary tumor, which are present in the reference answer."
  },
  "427": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the staging, diagnostic steps, and treatment plan, and includes all key points from the reference answer without major omissions or errors."
  },
  "428": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis but incorrectly classifies the staging as M1a (IVa) based on the assumption that the second nodule is in a different lobe, whereas the reference answer correctly identifies it as T3 (same lobe) or possibly N1, without evidence of distant metastasis. This leads to a significant difference in staging and treatment recommendations, though the rest of the answer is thorough."
  },
  "429": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly recommends SLNB over routine axillary dissection, with appropriate rationale. However, it omits the important detail that if only 1–2 sentinel nodes are positive and whole-breast radiotherapy is planned, further axillary dissection may not be necessary, which is a key nuance in current guidelines."
  },
  "430": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, content, and rationale. However, it omits specific recommendations against routine PET/CT or brain MRI in asymptomatic patients and does not mention smoking cessation counseling, which are present in the reference answer."
  },
  "431": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of MET抑制剂（capmatinib或tepotinib）为一线治疗, rationale, and appropriate exclusion of immunotherapy/chemotherapy as first-line options. No major omissions or errors."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate staging, rationale, and detailed standard treatment recommendations, including consolidation immunotherapy. No major omissions or errors."
  },
  "433": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need for postoperative radiotherapy, adjuvant chemotherapy, and consideration of immunotherapy, with no major omissions or errors."
  },
  "434": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points covered, including分期依据、PFT、PET/CT、纵隔淋巴结评估，并补充了脑MRI和基础评估，无重大遗漏或错误。"
  },
  "435": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it slightly differs in the recommended follow-up intervals (e.g., 2–5年每6–12个月 vs. 3年后每6个月) and includes上腹部CT作为常规内容，未强调低剂量CT。其余内容准确，未有重大遗漏。"
  },
  "436": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points: correct clinical staging (cT2N0M0), rationale for neoadjuvant therapy, and appropriate next steps. However, it omits some minor but relevant details such as the recommendation for marker clip placement, specific preoperative workup, and axillary ultrasound/biopsy considerations."
  },
  "437": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, treatment recommendations, and rationale, with no significant omissions or errors."
  },
  "438": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (IIIB, T2bN3M0), rationale, and appropriate next steps including MDT discussion, non-surgical management, concurrent chemoradiation, and consolidation immunotherapy, with no major omissions or errors."
  },
  "439": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, MDT evaluation, standard treatment (concurrent chemoradiotherapy), and consideration of consolidation immunotherapy. However, it incorrectly stages the tumor as IIIA instead of IIIB (the reference answer uses T4, not T3), and the molecular testing section is incomplete. These are minor but notable omissions."
  },
  "440": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred use of trastuzumab deruxtecan, alternative HER2-targeted agents, the limited role of immunotherapy, and maintenance options, with no major omissions or errors."
  },
  "441": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately covering the key points of endocrine therapy as the mainstay and generally not recommending chemotherapy unless high-risk features are present. It adds detail about radiotherapy and multigene testing, which is reasonable, but the answer is slightly verbose and could be more concise; minor omissions include not explicitly stating that chemotherapy is not recommended in the absence of high-risk features."
  },
  "442": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and recommended treatment, including HER2-targeted therapy and chemotherapy. However, it omits mention of bone-protective agents and supportive/palliative care, which are included in the reference answer."
  },
  "443": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need for systemic therapy and/or postoperative radiotherapy, the role of adjuvant chemotherapy, multidisciplinary discussion, and follow-up. It adds the option of re-operation for R0 resection, which is a valid and guideline-supported consideration, and does not omit any major content."
  },
  "444": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations of adjuvant chemoradiation for R1 resection in Stage IIIA NSCLC, as per guidelines. However, it introduces additional details about molecular testing and immunotherapy, which, while relevant in some contexts, are not the primary standard for this scenario and may slightly distract from the main guideline-based recommendation."
  },
  "445": {
    "score": 5.0,
    "explanation": "5: The model answer is nearly identical in clinical content to the reference answer, covering all key points including the prioritization of EGFR-TKI (especially afatinib) for G719X mutation, the limited role of immunotherapy, and the rationale based on guidelines. There are no major omissions or errors."
  },
  "446": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the correct staging (M1b, IVB) and appropriate molecular/immunological tests, but it omits KRAS and ERBB2 (HER2) from the recommended gene panel, which are included in the reference answer."
  },
  "447": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including neoadjuvant therapy, specific drug recommendations, rationale, and necessary preoperative assessments. No major omissions or errors are present."
  },
  "448": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of actionable mutations, low PD-L1, the recommendation for platinum-based doublet chemotherapy plus immunotherapy, and the rationale. No major omissions or errors are present."
  },
  "449": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the N3 status, unresectability, and recommending concurrent chemoradiotherapy. However, it assigns stage IIIC (AJCC 8th), while the reference uses IIIB, and includes consolidation immunotherapy, which, though current, is not mentioned in the reference. Minor staging discrepancy and extra detail account for the slight deduction."
  },
  "450": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up strategy, lack of indication for routine brain MRI or PET/CT, and no routine adjuvant therapy unless high-risk features are present. There are no major omissions or errors."
  },
  "451": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including staging, need for biomarker testing, and systemic therapy. However, it incorrectly states the stage as IVB instead of IVA (M1b), which is a minor but notable error; otherwise, the clinical reasoning and recommendations are appropriate."
  },
  "452": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and treatment options, but it places more emphasis on同步放化疗 as the standard, whereas the reference answer prioritizes新辅助治疗后手术为首选，且未明确强调术后辅助治疗和随访，存在轻微取向差异和小的细节遗漏。"
  },
  "453": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including TNM分期、IIIa期判断、进一步病理确认、分子检测及治疗策略，但在治疗建议部分略显冗长，且未明确强调“不可一期手术切除”这一要点，存在轻微表述差异。"
  },
  "454": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the recommended postoperative management, including adjuvant chemotherapy, molecular testing for targeted/immune therapy, and follow-up, with no major omissions or errors. It also correctly notes that postoperative radiotherapy is not routinely recommended, fully aligning with current guidelines and the reference answer."
  },
  "455": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, detailed rationale, and appropriate treatment recommendations without omissions or errors."
  },
  "456": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of EGFR-TKI (especially afatinib), guideline recommendations, and the context of rare EGFR mutations in squamous cell carcinoma, with no major omissions or errors."
  },
  "457": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key aspects, including systemic staging, cardiac assessment, lab tests, imaging, molecular review, and genetic counseling. However, it omits the specific recommendation for tumor and lymph node marker placement during biopsy, which is important for surgical planning, and does not mention targeted axillary lymph node biopsy."
  },
  "458": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including staging, molecular testing, and treatment strategy. However, it incorrectly assigns stage IIIC instead of IIIB, which is a minor but important staging detail. Otherwise, the clinical reasoning and recommendations are appropriate."
  },
  "459": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，分期分析详细，治疗方案包括同步放化疗及巩固免疫治疗，未有重大遗漏或错误。"
  },
  "460": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "461": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and covers the relevant mutations and treatment options, but it incorrectly prioritizes afatinib over osimertinib, which is the guideline-recommended agent for these rare EGFR mutations after progression. This is a significant omission, though the rest of the answer is accurate and thorough."
  },
  "462": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendation, and adjuvant therapy, with no major omissions or errors."
  },
  "463": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, the need to distinguish between multiple primary lung cancers and metastasis, and outlines the initial treatment strategy, including further lymph node assessment and surgical options. However, it omits the specific T staging for the right upper lobe nodule (should be T1c, not T2a for 3cm), and does not mention SBRT as an alternative to surgery, which is a minor omission."
  },
  "464": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately confirms the staging, and details appropriate next steps including brain MRI, MDT discussion, standard chemoradiotherapy, immunotherapy, and molecular testing, with no major omissions or errors."
  },
  "465": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "466": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prioritizing re-resection, considering radiotherapy if surgery is not feasible, and not recommending observation alone, with no major omissions or errors."
  },
  "467": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale for endocrine therapy with CDK4/6 inhibitor, specific drug options, bone-modifying agents, and the reasoning against chemotherapy. No major omissions or errors."
  },
  "468": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommendation of EGFR-TKI (especially osimertinib) as first-line therapy, the rationale for not using immunotherapy, and the consideration of brain metastases. No major omissions or errors are present."
  },
  "469": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers随访频率、内容、影像学检查、特殊考虑等要点，但未明确强调戒烟干预和肿瘤生存管理，也未具体指出常规无需脑MRI或PET/CT，仅在有症状时考虑，存在轻微细节遗漏。"
  },
  "470": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately addresses the lack of need for adjuvant therapy and provides a detailed, guideline-consistent follow-up plan."
  },
  "471": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and recommended adjuvant chemotherapy, with no significant omissions or errors."
  },
  "472": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including prompt initiation of ALK抑制剂、停用化疗/放化疗、脑转移管理、随访评估，并补充了药物选择和具体管理细节，无明显遗漏或错误。"
  },
  "473": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical content, including staging principles, surgical recommendations, and adjuvant therapy. However, it introduces uncertainty about the T stage due to lack of tumor size, whereas the reference answer assumes T2a based on typical presentation, and the model answer does not explicitly state a final stage. Minor details about high-risk factors and adjuvant therapy indications are also less emphasized."
  },
  "474": {
    "score": 4.0,
    "explanation": "4: The model answer is comprehensive and well-structured, accurately reflecting current guidelines and the clinical scenario. However, it slightly underemphasizes the consideration for chest wall radiotherapy in cases of very close margins (<1mm), which the reference answer highlights as a point for possible discussion."
  },
  "475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including分期, further assessment, and detailed, guideline-based treatment recommendations, with no major omissions or errors. It is essentially identical in clinical substance to the reference answer."
  },
  "476": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the rarity of ALK重排 in squamous cell carcinoma, the prioritization of ALK-TKI, the limited role of immunotherapy, and the importance of symptom management. However, it omits explicit mention of smoking cessation advice and palliative care integration, which are present in the reference answer."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately details the clinical staging, and covers all key aspects of further preoperative assessment and treatment, including additional relevant considerations such as cardiac evaluation and genetic testing, with no major omissions or errors."
  },
  "478": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of TNM分期和治疗原则，但分期为ⅢA期而非参考答案中的ⅢB期，且对手术可能性的讨论略多于参考答案，存在轻微分歧。整体内容准确，细节丰富，仅有小的分期分歧。"
  },
  "479": {
    "score": 4.0,
    "explanation": "4: The model answer is very thorough and covers almost all key points, including detailed TNM staging, rationale, and standard treatment recommendations. However, it uses the ⅢC stage (AJCC 8th edition), while the reference answer uses IIIB, and it does not explicitly mention the need for molecular testing and PD-L1 assessment before immunotherapy, which are minor but relevant omissions."
  },
  "480": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of ALK-TKI as first-line therapy, rationale for not using immunotherapy despite PD-L1 positivity, and specific drug recommendations, with no major omissions or errors."
  },
  "481": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough staging rationale and appropriate treatment recommendations, but incorrectly assigns the stage as IA2 instead of IB for a 2.5 cm tumor (T2aN0M0), which is a significant inaccuracy. Otherwise, the management plan is largely correct and covers key points."
  },
  "482": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the stage, rationale, and follow-up recommendations, with no significant omissions or errors."
  },
  "483": {
    "score": 5.0,
    "explanation": "5: The model answer covers all required biomarker tests (including those in the reference and more), and provides a detailed, accurate discussion of both local and systemic treatment options, matching the reference answer in clinical content without major omissions or errors."
  },
  "484": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including MDT assessment, neoadjuvant therapy with possible surgery, and chemoradiotherapy for unresectable cases, with no major omissions or errors."
  },
  "485": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期和治疗方案均准确，且补充了部分细节，无重大遗漏或错误。"
  },
  "486": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides detailed rationale for adjuvant chemotherapy, gene testing, and immunotherapy, with no major omissions or errors."
  },
  "487": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects current guidelines, addresses maintenance therapy, the role and limitations of KRAS G12C inhibitors in squamous cell carcinoma, and provides appropriate follow-up and second-line options, with no major omissions or errors."
  },
  "488": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately details the TNM and clinical staging, and provides appropriate initial treatment recommendations with relevant considerations, matching the reference answer without major omissions or errors."
  },
  "489": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, recommended imaging, and the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "490": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer and adds further clinically relevant details, with no major omissions or errors. It demonstrates comprehensive and accurate preoperative assessment for Stage IIB NSCLC."
  },
  "491": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly identical to the reference answer, but it incorrectly labels the stage as \"IA2期\" instead of \"IB期\" for a 3.5 cm tumor (which should be Stage IB per AJCC 8th edition). Otherwise, the clinical content and recommended management are accurate and complete."
  },
  "492": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage and primary treatment strategy, but it omits the mention of pre-treatment cardiopulmonary assessment and the general recommendation against surgery, which are included in the reference answer."
  },
  "493": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing dabrafenib plus trametinib as first-line therapy for BRAF V600E-mutant squamous NSCLC, and appropriately mentioning alternatives only if targeted therapy is unavailable or intolerable. No major omissions or errors are present."
  },
  "494": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points from the reference answer, including imaging, pathology, axillary assessment, systemic evaluation, and additional considerations like genetic testing. However, it omits the explicit mention of placing a marker in the primary tumor during core needle biopsy and is less specific about the imaging modalities for distant metastasis screening."
  },
  "495": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers随访频率, 内容, 影像学检查, 戒烟指导等要点，但未明确强调前2-3年每6个月随访（而是写前2年），且未区分增强CT与低剂量无增强CT的具体使用时机，略有细节出入。"
  },
  "496": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up intervals, content, and smoking cessation. However, it recommends chest CT at every follow-up (including after 2 years), whereas the reference answer specifies annual low-dose CT after 2–3 years and does not mention extending follow-up beyond 5 years. There is also mention of additional imaging (brain MRI, bone scan) if symptomatic, which is appropriate but not explicitly stated in the reference. Minor differences in detail prevent a perfect score."
  },
  "497": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale for changing endocrine therapy, use of CDK4/6 inhibitors, and deferral of chemotherapy in the absence of visceral crisis. No major omissions or errors."
  },
  "498": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main recommendations, including re-resection as first choice and radiotherapy as an alternative. However, it omits the specifics of follow-up (定期体检和胸部CT) and survivorship care (戒烟干预等), which are present in the reference answer."
  },
  "499": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including staging, molecular typing, preoperative assessment, neoadjuvant therapy, HER2-targeted treatment, surgical planning, and postoperative management, with no major omissions or errors."
  },
  "500": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging and treatment included and no significant omissions or errors."
  },
  "501": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points from the reference answer, including local and distant staging, pathology review, laboratory tests, and additional relevant assessments. However, it adds some extra details (e.g., fertility and psychosocial evaluation) and slightly underemphasizes the specific recommendation for axillary lymph node biopsy if suspicious nodes are found, which is a minor omission."
  },
  "502": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points from the reference answer, including肿瘤及腋窝标记、实验室检查、乳腺MRI的适应证等。它还补充了基因检测和生育力保护等内容，但部分内容（如胸腹盆MRI的选择、碱性磷酸酶、PET/CT的补充指征）略有遗漏或未强调。整体内容详实，只有少量细节未完全覆盖。"
  },
  "503": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of current guidelines, but it omits that BRAF抑制剂可作为一线治疗的可能性（如NCCN指南所述），并将其仅推荐为后线选择，存在轻微偏差。"
  },
  "504": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including bronchoscopy, mediastinal lymph node assessment, brain MRI, and additional preoperative evaluations. However, it adds some details (e.g., cardiac and laboratory assessment, molecular testing) not explicitly required by the reference answer, and the emphasis on individualized mediastinal sampling could be clearer regarding standard recommendations. Minor omissions and slight over-expansion prevent a perfect score."
  },
  "505": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, but it incorrectly assigns the stage as IIb instead of IIIB for T3N0M0, which is a significant but single error. The treatment strategy is otherwise appropriate and detailed."
  },
  "506": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including follow-up intervals, imaging recommendations, and the non-routine use of PET-CT/brain MRI. However, it introduces some additional details (e.g., lab tests, more granular follow-up intervals) and slightly deviates from the reference in the frequency and duration of follow-up, which are minor omissions rather than major errors."
  },
  "507": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, recommending surgical resection as first-line and considering radiotherapy if surgery is not feasible. However, it omits the recommendation for comprehensive imaging (胸部增强CT、脑部增强MRI及FDG-PET/CT) to rule out other metastases before proceeding, which is a minor but important detail."
  },
  "508": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points regarding the low incidence of driver mutations in squamous cell carcinoma, the guideline recommendations for molecular and PD-L1 testing, and the preferred treatment strategies. However, it slightly overstates the recommendation against routine molecular testing (the reference answer allows for broader testing in some cases) and could be clearer about the nuances for when to consider molecular testing."
  },
  "509": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major local control options, including bronchoscopic interventions, radiotherapy, and the possibility of systemic therapy. However, it omits mention of photodynamic therapy and smoking cessation counseling, which are present in the reference answer."
  },
  "510": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and initial treatment plan, but it omits some important details such as recommending preoperative brain MRI, mediastinal lymph node assessment (e.g., EBUS or mediastinoscopy), and molecular testing for driver mutations and PD-L1, which are present in the reference answer."
  },
  "511": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of systemic therapy (chemotherapy, immunotherapy, targeted therapy) and palliative local treatment, but it introduces additional details (e.g., molecular testing, immunotherapy) not explicitly mentioned in the reference answer and could be seen as slightly overreaching for the scenario described. Minor omissions include not emphasizing the option of close observation as in the reference."
  },
  "512": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it omits the explicit mention of concurrent病史/体格检查（H&P）随访，并未强调3年内的分段（2年 vs 3年），且未提及对残余或新发异常时可缩短间隔的建议。"
  },
  "513": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including preoperative assessments and the recommendation against neoadjuvant therapy. However, it omits the specific mention of bronchoscopy to assess airway involvement and synchronous lesions, which is a notable but minor omission."
  },
  "514": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the lack of indication for routine PET/CT or brain MRI, with no major omissions or errors."
  },
  "515": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and recommended treatment options, including nuances regarding surgery and the role of immunotherapy, with no major omissions or errors."
  },
  "516": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including systemic therapy, molecular testing, and supportive care, but it slightly overstates the clinical stage (IV vs. advanced N1) and omits explicit mention of multidisciplinary evaluation and smoking cessation counseling."
  },
  "517": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing TNM分期、分期分级、手术建议、术前评估、术后处理及随访，无重大遗漏或错误。"
  },
  "518": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, treatment recommendations, and rationale, with no significant omissions or errors."
  },
  "519": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main management steps, including reoperation, postoperative radiotherapy, and consideration of adjuvant chemotherapy in high-risk cases. However, it omits specific follow-up recommendations and does not explicitly mention the need for regular imaging and physical examination as outlined in the reference answer."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the standard of care (synchronous chemoradiotherapy), addresses the role of molecular and PD-L1 testing, and provides appropriate rationale and references, with no major omissions or errors."
  },
  "521": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the lack of recommendation for adjuvant therapy, follow-up intervals, and imaging. However, it omits specific mention of smoking cessation counseling and the explicit recommendation against routine brain MRI or PET-CT, which are present in the reference answer."
  },
  "522": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, correctly prioritizing re-resection and considering radiotherapy if surgery is not feasible. However, it omits specific follow-up intervals and imaging recommendations, and introduces a discussion on adjuvant chemotherapy, which is not emphasized in the reference answer."
  },
  "523": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and treatment, but it does not specifically mention“preoperative concurrent chemoradiation”as the standard (仅提及新辅助化疗±放疗), nor does it mention durvalumab consolidation for unresectable cases, which are minor but relevant omissions."
  },
  "524": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、IIIB期、治疗原则（同步放化疗、巩固免疫治疗），并无重要遗漏或错误。"
  },
  "525": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemotherapy and follow-up, but it slightly overstates the recommendation for adjuvant chemotherapy (guidelines allow observation or adjuvant therapy for T2bN0) and adds some details (e.g., molecular testing) not emphasized in the reference. Minor differences in follow-up intervals and additional tests are present, but overall clinical content is very similar."
  },
  "526": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, recommended surgical approach, and considerations for further management, with no significant omissions or errors."
  },
  "527": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, and postoperative considerations, with no major omissions or errors."
  },
  "528": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prior treatments, negative molecular markers, PD-L1 status, and the rationale for immunotherapy as the preferred next step, with appropriate alternatives and guideline references. No major omissions or errors are present."
  },
  "529": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides appropriate rationale for 21-gene expression profiling and adjuvant therapy choices, with no significant omissions or errors."
  },
  "530": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including guideline recommendations, indications for MRI, and patient-specific factors, with no major omissions or errors."
  },
  "531": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major clinical points, including indications for neoadjuvant therapy and key pre-treatment assessments. However, it omits explicit mention of multidisciplinary discussion and does not clearly state the need for chest/abdominal/pelvic CT or bone scan to rule out distant metastasis, which are present in the reference answer."
  },
  "532": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it introduces the possibility of further anatomical resection (肺段或肺叶切除) if the wedge resection is not deemed oncologically adequate, which is not explicitly discussed in the reference answer. Otherwise, it covers all key points and guideline recommendations."
  },
  "533": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of RET-targeted therapy, specific drug recommendations, rationale for not choosing immunotherapy or chemotherapy as first-line, and the need for ongoing assessment and supportive care. No major omissions or errors are present."
  },
  "534": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of clinical staging and management, including TNM classification, preoperative assessment, surgical and adjuvant therapy, and molecular testing. However, it slightly overstates the stage as IIIA (should be IIB per AJCC 8th edition for T3N0M0) and does not specifically mention the need for invasive mediastinal staging (e.g., EBUS-TBNA), which is a minor omission."
  },
  "535": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points including ROS1靶向抑制剂为首选、具体药物（克唑替尼、恩曲替尼）、指南依据、患者全身状况评估及不良反应监测，无重大遗漏或错误。"
  },
  "536": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modality, and indications for PET-CT/brain MRI, with no major omissions or errors."
  },
  "537": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including endocrine resistance, the need for chemotherapy due to visceral crisis, ovarian suppression if considering endocrine therapy, bone-modifying agents, and supportive care, with no major omissions or errors."
  },
  "538": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including further staging, molecular pathology testing, and treatment options. However, it omits some minor details such as the recommendation for early palliative care integration, smoking cessation advice, and the specific mention of tissue adequacy and possible re-biopsy or ctDNA testing if tissue is insufficient."
  },
  "539": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it incorrectly将pT2aN0M0分期为IIA期（实际上为IB期），并未明确强调“无高危因素”这一前提，存在分期和高危因素表述上的小瑕疵。"
  },
  "540": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it provides a slightly more detailed follow-up schedule and mentions some flexibility in imaging intervals, which could be seen as minor deviations. The core recommendations regarding follow-up frequency and the non-routine use of FDG-PET/CT or brain MRI are consistent with the reference."
  },
  "541": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including chemoradiotherapy, individualized planning, and follow-up, and adds appropriate detail on molecular testing and targeted/immune therapy, which are current standard considerations. No major omissions or errors."
  },
  "542": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including MET抑制剂为首选、免疫治疗和化疗为后线，但增加了局部治疗评估的内容，虽合理但非参考答案的核心要点，略有扩展，未造成实质性遗漏或错误。"
  },
  "543": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including precise clinical staging (cT4dN1M0), rationale for diagnosis, and a detailed, guideline-concordant treatment plan with no major omissions or errors."
  },
  "544": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key aspects, including pathology confirmation, genetic testing, baseline labs, cardiac assessment, MDT discussion, and patient education. However, it omits the specific mention of placing imaging-visible markers in the breast tumor and biopsied lymph node, and does not explicitly recommend breast MRI, which are important steps highlighted in the reference answer."
  },
  "545": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, rationale for concurrent chemoradiotherapy, use of durvalumab as consolidation, and relevant guidelines, with no major omissions or errors."
  },
  "546": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including patient risk factors, guideline recommendations, and the role/limitations of gene expression profiling in premenopausal women. However, it slightly overemphasizes the limited value of gene profiling in premenopausal patients and could more clearly state that gene testing can still aid decision-making, as in the reference answer."
  },
  "547": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including concurrent chemoradiotherapy as standard, durvalumab consolidation, and additional considerations. There are no major omissions or errors."
  },
  "548": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps, including staging, surgical approach, and adjuvant therapy, with appropriate references. However, it contains a minor inaccuracy in staging (T3N0M0为IIb期, 实为IIIA期) and does not explicitly mention management of切缘阳性（R1/R2）或术后放疗的指征。"
  },
  "549": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covering all key aspects of the reference answer and adding relevant clinical details such as genetic testing, cardiac assessment, and multidisciplinary discussion, with no major omissions or errors."
  },
  "550": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and mirrors the reference answer in all key aspects, including accurate staging, a complete list of recommended molecular and immunological tests, and appropriate recommendations for bone protection therapy, with relevant precautions. No major omissions or errors are present."
  },
  "551": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM and stage, surgical recommendations, perioperative considerations, and alternative treatments, with no major omissions or errors."
  },
  "552": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for EGFR-TKI selection, specific drug recommendations, reasons for not choosing immunotherapy or chemotherapy, and alternative options if osimertinib is unavailable. No major omissions or errors are present."
  },
  "553": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the recommended follow-up schedule, imaging modalities, and the indications for FDG-PET/CT and brain MRI. It also adds relevant details about R1 resection and MDT discussion, with no major omissions or errors."
  },
  "554": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including adjuvant radiotherapy, chemotherapy, and follow-up. However, it omits the preferred option of re-resection to achieve negative margins (R0), which is the first-line recommendation in the reference answer. It also adds details about molecular testing and targeted/immune therapy, which, while relevant, are not emphasized in the reference."
  },
  "555": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It accurately describes the staging, management, and follow-up recommendations, and even provides supporting guideline references."
  },
  "556": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期、分子检测、全身治疗、骨转移处理和支持治疗等要点，但未明确强调“多学科会诊”以及骨科固定和姑息性放疗应优先于全身治疗的顺序，且对局部姑息治疗的适应证描述略显不足。"
  },
  "557": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage and recommending appropriate surgical management. However, it omits the mention of preoperative bronchoscopy to exclude endobronchial lesions and does not explicitly state that lobectomy with systematic lymph node dissection is also a standard option, as in the reference answer."
  },
  "558": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough analysis and rationale but ultimately recommends chemo-immunotherapy as first-line, omitting the current guideline-supported use of amivantamab for EGFR exon 20 insertion mutations, which is the key point in the reference answer. It also overemphasizes the lack of evidence in squamous histology, leading to a partial but not complete answer."
  },
  "559": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, need for pathological confirmation, exclusion of brain metastasis, standard chemoradiotherapy, and follow-up, with additional appropriate details on molecular testing and MDT discussion. No major omissions or errors."
  },
  "560": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, the rationale for neoadjuvant therapy, and treatment options. However, it omits some details such as the placement of localization markers, the specific recommendation for dual anti-HER2 therapy (trastuzumab + pertuzumab), and the post-neoadjuvant use of T-DM1 if indicated."
  },
  "561": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including chemotherapy, anti-HER2 therapy, and radiotherapy, with appropriate rationale and references. However, it introduces pertuzumab as a standard recommendation, which is not universally required per the reference answer, and slightly overemphasizes the chemotherapy regimen details, making minor deviations from the reference."
  },
  "562": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps (neoadjuvant chemoradiotherapy, re-evaluation, surgery, and postoperative management), and even provides additional detail without introducing errors or omissions."
  },
  "563": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of BRAF/MEK inhibitor therapy, the role of PD-L1 expression, and alternative options if targeted therapy is not feasible. No major omissions or errors are present."
  },
  "564": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗方案及替代方案均有详细阐述，无明显遗漏或错误。"
  },
  "565": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key elements of the reference answer, including follow-up intervals, content, and escalation for suspicious findings. However, it omits the specific recommendation for low-dose CT after 5 years and does not explicitly mention shortening intervals if new abnormalities are found, though it does suggest further workup."
  },
  "566": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up and management, including frequency, content, and additional supportive measures. However, it slightly deviates from the reference by recommending more frequent imaging in the first 2–3 years (rather than 1–3 years), and does not explicitly state that PET/CT和脑MRI are not for routine use but only when recurrence is suspected. Minor omissions prevent a perfect score."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了随访频率、内容及不推荐常规脑MRI/PET-CT等要点，无重大遗漏或错误，并补充了健康管理建议。"
  },
  "568": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key steps including手术耐受性评估, 纵隔淋巴结评估, 手术为主的治疗, 术后辅助化疗, 以及不能手术时的替代方案，与参考答案内容一致，无重大遗漏或错误。"
  },
  "569": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为完整，涵盖了辅助放疗、化疗、分子检测、随访及综合管理，但对“再次手术切除”这一首选方案未提及，且随访频率略有不同，存在轻微偏差。"
  },
  "570": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including分期、鉴别多原发与转移、分子检测、功能评估及治疗策略，但内容较为详细，部分细节如术后辅助治疗的决策未明确强调，且结尾略有不全。"
  },
  "571": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate management steps. However, it incorrectly classifies the stage as IA2 instead of IB (for a 3.5 cm tumor per AJCC 8th edition), and does not mention the possibility of adjuvant therapy for high-risk IB patients, which are minor but relevant omissions."
  },
  "572": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including accurate TNM staging, rationale for surgery, and the need for MDT discussion. However, it omits the recommendation for preoperative molecular testing and PD-L1 assessment, and does not explicitly mention the need to further evaluate for occult mediastinal lymph node metastasis, which are minor but relevant omissions."
  },
  "573": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and appropriate treatment options for synchronous early-stage primary lung cancers, but it incorrectly stages the disease as two separate early-stage tumors rather than Stage IVA (M1a) per current guidelines, and omits the emphasis on systemic therapy as standard for this stage."
  },
  "574": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale, specific drug regimens, and supporting evidence, with no major omissions or errors."
  },
  "575": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在随访策略、影像学检查选择及随访间隔等核心内容上完全一致，且无重大遗漏或错误，内容详实且符合指南推荐。"
  },
  "576": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including first-line TRK inhibitor therapy, bone metastasis management, and alternative options if TRK inhibitors are unavailable, with no major omissions or errors."
  },
  "577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including accurate staging, detailed multidisciplinary treatment strategies, and comprehensive molecular testing recommendations, with no major omissions or errors."
  },
  "578": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the clinical scenario, but it introduces new concepts such as neoadjuvant chemoradiotherapy and surgery, which are not the standard of care for T2N2M0 (stage IIIA) NSCLC per current guidelines. The reference answer correctly prioritizes concurrent chemoradiotherapy followed by consolidation osimertinib, while the model answer suggests surgery as an option, which is not routinely recommended for N2 disease. Minor deviations from guideline-based recommendations prevent a perfect score."
  },
  "579": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately covers staging, standard treatment, MDT evaluation, and the role of immunotherapy, providing comprehensive and precise recommendations."
  },
  "580": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical resection, preoperative assessment, adjuvant chemotherapy, and management of chest wall invasion, with no major omissions or errors."
  },
  "581": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including targeted therapy, chemotherapy, immunotherapy, local brain treatment, and supportive care. However, it is more detailed than the reference and introduces some discussion about drug accessibility and specific drug activity, which, while accurate, slightly diverges from the concise focus of the reference answer. Minor omissions include not explicitly mentioning early palliative care and multidisciplinary management."
  },
  "582": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and treatment, including the nuances of cytology-negative pleural effusion and the need for clinical judgment. However, it is slightly more verbose and does not explicitly mention multidisciplinary team evaluation or the recommendation for regular efficacy follow-up, which are present in the reference answer."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and includes additional relevant details such as cardiac function assessment and general condition evaluation, with no major omissions or errors."
  },
  "584": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up frequency, imaging modality, and the lack of routine PET-CT or brain MRI in asymptomatic patients. However, it omits specific mention of regular smoking cessation counseling and survivorship management, and the follow-up intervals are slightly more detailed than the reference, but not incorrect."
  },
  "585": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the non-routine use of FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "586": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, surgical treatment, and consideration of adjuvant therapy based on high-risk features. However, it overemphasizes纵隔淋巴结病理学评估（如EBUS-TBNA或纵隔镜检查） despite PET-CT and imaging not showing suspicious nodes, and it does not mention脑MRI（可选） to rule out brain metastasis, which is a minor omission."
  },
  "587": {
    "score": 4.0,
    "explanation": "4: 模型答案内容基本完整，详细说明了EGFR-TKI为首选，并补充了奥希替尼的优势，但遗漏了联合抗血管生成药物（如贝伐珠单抗、雷莫芦单抗）的可选方案及姑息治疗和吸烟干预的建议。"
  },
  "588": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, and the non-routine use of FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "589": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly identical to the reference answer, clearly recommending ROS1 TKI monotherapy (crizotinib or entrectinib) and correctly excluding chemotherapy/immunotherapy as first-line. However, it omits mention of local symptomatic management (e.g., pleural drainage) and smoking cessation/palliative care, which are minor but relevant details."
  },
  "590": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential clinical content, including staging and treatment recommendations. However, it introduces some ambiguity regarding M1b/M1c (the reference answer specifies M1b), and does not mention palliative thoracic radiotherapy for local symptoms, which is a minor omission."
  },
  "591": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of actionable mutations, PD-L1 status, first-line platinum-based chemotherapy with or without immunotherapy, and supportive care. It even adds appropriate detail on dosing and bone metastasis management, with no major omissions or errors."
  },
  "592": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including systemic therapy (adjuvant chemotherapy), radiotherapy for local control, and even adds appropriate considerations for re-resection and molecular testing, with no major omissions or errors."
  },
  "593": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for RET抑制剂（Selpercatinib或Pralsetinib） as first-line therapy, rationale, supporting guidelines, and the exclusion of other therapies unless RET inhibitors are unavailable or intolerable. No major omissions or errors."
  },
  "594": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, risk assessment, and lifestyle advice. However, it suggests more frequent follow-up than the reference and adds recommendations for MDT讨论 and补救性治疗, which, while reasonable, go beyond the reference answer's scope and omit the explicit advice against routinePET/CT or脑MRI."
  },
  "595": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the TNM staging, rationale for T4 assignment, stage grouping, and stepwise treatment recommendations including MDT discussion, surgical considerations, and adjuvant therapy. No major omissions or errors are present."
  },
  "596": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the clinical staging, main treatment process, and postoperative adjuvant therapy, with good detail and accuracy. However, it omits the explicit mention of multidisciplinary team (MDT) involvement and postoperative follow-up management, which are included in the reference answer."
  },
  "597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including staging, surgical and adjuvant treatment recommendations, indications for radiotherapy and endocrine therapy, lymph node management, and genetic counseling, with no major omissions or errors."
  },
  "598": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including tumor biology, systemic staging, cardiac assessment, labs, and imaging. However, it omits the specific mention of tumor marker placement for localization, and does not explicitly state the need for axillary node biopsy marking, which are minor but relevant omissions."
  },
  "599": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering staging, rationale, and specific RET靶向药物推荐, with no major omissions or errors."
  },
  "600": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rarity of ALK rearrangement in squamous cell carcinoma, the recommendation for ALK-TKI as first-line therapy, specific drug options, and the rationale for not prioritizing chemotherapy or immunotherapy. No major omissions or errors are present."
  },
  "601": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, with detailed rationale for afatinib as the preferred EGFR-TKI and appropriate mention of additional molecular and PD-L1 testing. However, it includes some extra workup (e.g., brain MRI, PET-CT) not specified in the reference and slightly overemphasizes T790M testing, which is more relevant after EGFR-TKI exposure, leading to minor deviations from the reference answer."
  },
  "602": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of treatment and molecular testing, but it underemphasizes the need for broad molecular testing (beyond PD-L1) as recommended in the reference answer, and is more conservative regarding routine gene testing in squamous cell carcinoma. Minor omissions exist regarding the full list of genes to be tested."
  },
  "603": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering HER2靶向治疗（DS-8201为首选），并补充了可选方案和相关指南依据，无重大遗漏或错误。"
  },
  "604": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps, including consideration of brain MRI, MDT discussion, pathological confirmation, and treatment options. However, it places more emphasis on brain MRI than the reference answer (which considers it optional), and adds molecular profiling, which, while useful, is not strictly required at this stage for early-stage NSCLC. Minor differences in emphasis and additional details account for the slight deduction."
  },
  "605": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including schedule, imaging, symptom monitoring, and supportive care. However, it slightly overemphasizes additional tests (e.g., lab, functional studies) and introduces immunotherapy considerations not specified in the reference, while not explicitly stating that routine brain MRI and PET/CT are unnecessary without symptoms."
  },
  "606": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including symptomatic brain metastasis management with whole-brain radiotherapy, BRAF/MEK inhibitor targeted therapy, chemotherapy as an alternative, and supportive care. Minor additions (e.g., steroid use) enhance rather than detract from accuracy."
  },
  "607": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, covering all key aspects of the reference answer, including adjuvant chemoradiotherapy, follow-up, and additional considerations, with no major omissions or errors."
  },
  "608": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of post-operative management for stage IIB NSCLC with R1 resection, including the option of re-resection, adjuvant chemoradiotherapy, and consideration of targeted/immune therapy, as well as follow-up and supportive care. No major omissions or errors are present."
  },
  "609": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在随访频率、内容、影像学检查及不推荐常规PET/CT或脑MRI方面内容一致，无重大遗漏或错误，临床要点均有覆盖。"
  },
  "610": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging, rationale, and treatment options clearly addressed and no significant omissions or errors."
  },
  "611": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期,评估, and脑MRI的必要性 with no major omissions or errors. It provides detailed reasoning and aligns with current guidelines."
  },
  "612": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上完全一致，均明确推荐达拉非尼联合曲美替尼为首选方案，并合理解释了靶向治疗优先于免疫治疗，未有重大遗漏或错误。"
  },
  "613": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the TNM staging, and provides a nuanced, guideline-based discussion of treatment options, including MDT evaluation, chemoradiotherapy, surgical considerations, and consolidation immunotherapy, with no major omissions or errors."
  },
  "614": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering the key steps of diagnosis and treatment, including neoadjuvant therapy, HER2-targeted therapy, surgery, and post-op management. However, it omits some minor details such as the need for pre-treatment systemic evaluation and axillary lymph node biopsy, and is less specific about the criteria for T-DM1 use."
  },
  "615": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering all key aspects of disease staging and pathological assessment, including imaging, laboratory tests, biopsy, and molecular testing. However, it omits explicit mention of genetic counseling referral and does not specify whole exome or targeted genomic sequencing as in the reference answer."
  },
  "616": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了ALK-TKI为首选，解释了原因，并补充了指南依据和具体药物，无重大遗漏或错误。"
  },
  "617": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommended platinum-based doublet chemotherapy plus immunotherapy, rationale, alternatives if immunotherapy is contraindicated, and relevant guidelines, with no major omissions or errors."
  },
  "618": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed TNM staging and appropriate treatment recommendations. However, it uses the more granular IA3 (T1cN0M0) stage per AJCC 8th edition, while the reference answer uses IA (T1bN0M0), and it includes more detail on surgical options and risk factors for adjuvant therapy, which, while not incorrect, slightly diverges from the reference's simplicity. No major omissions or errors are present."
  },
  "619": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期（IIIB/T4N2M0）、同步放化疗、巩固免疫治疗（durvalumab）、以及分子检测等所有要点，无重大遗漏或错误。"
  },
  "620": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indication for NTRK inhibitors, naming both recommended drugs, and providing appropriate guideline-based justification without omissions or errors."
  },
  "621": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed TNM staging, rationale, and updated treatment recommendations, including durvalumab maintenance. However, it assigns stage IIIC (AJCC 8th edition) rather than IIIB as in the reference, which is a minor discrepancy but does not significantly affect the overall clinical content."
  },
  "622": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive and accurate staging, appropriate surgical recommendations, and correct discussion of postoperative management. No major omissions or errors are present."
  },
  "623": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps, including surgical evaluation, multidisciplinary discussion, and adjuvant therapy. However, it adds molecular testing and immunotherapy considerations, which, while up-to-date, are not strictly required by the reference answer and omits the specific mention of preoperative纵隔淋巴结取样以排除微小转移, a minor but relevant detail."
  },
  "624": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the clinical staging and next steps, including surgery and adjuvant therapy considerations. However, it omits some minor but relevant preoperative steps such as recommending breast MRI, routine preoperative labs, and tumor localization, which are mentioned in the reference answer."
  },
  "625": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, symptom assessment, and attention to recurrence and treatment side effects. However, it omits the specific recommendation for low-dose CT after 5 years and does not explicitly mention the importance of smoking cessation guidance and early use of PET/CT or brain MRI for suspicious findings, which are present in the reference answer."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the indications for PET-CT/brain MRI, with no major omissions or errors."
  },
  "627": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points on staging, treatment recommendations, and the need for molecular testing, with no major omissions or errors."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modalities, and the non-recommendation of routine FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "629": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate further investigations. However, it differs from the reference answer in TNM分期（IA3期 vs IB期）和T分期（T1c vs T2a），且未强调高危因素对脑MRI的选择性，略有分歧。"
  },
  "630": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommended platinum-based doublet chemotherapy, the addition of immunotherapy, and the rationale for not using single-agent immunotherapy in PD-L1 <1%. No major omissions or errors."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and includes all key clinical content without major omissions or errors. It also provides additional relevant details and rationale, fully meeting the requirements."
  },
  "632": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing correct staging (though it uses stage IIIC per AJCC 8th edition, while the reference uses IIIB, which may reflect edition differences), and outlines the standard treatment approach with appropriate detail. Minor differences in staging terminology and expanded chemotherapy options are present but do not affect the core clinical content."
  },
  "633": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the non-mandatory but recommended nature of adjuvant chemotherapy and a detailed follow-up plan. However, it slightly overstates the strength of the recommendation for adjuvant chemotherapy (using \"推荐\" and \"category 1 evidence\") where the reference answer emphasizes that it is optional and not mandatory, and it omits specific mention of smoking cessation and survivorship care in follow-up."
  },
  "634": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including优选二次手术, 放疗作为备选, 不推荐辅助化疗, 以及详细的随访方案。内容全面，无重大遗漏或错误。"
  },
  "635": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach to staging and management but incorrectly assigns T3 instead of T4 (chest wall invasion) and IIIA instead of IIIB, which are significant errors. It also omits the recommendation for brain MRI and molecular/PD-L1 testing."
  },
  "636": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, and postoperative management without omissions or errors."
  },
  "637": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies SVC stent placement as a rapid symptomatic measure but omits the key recommendation of concurrent chemoradiation as the primary local control strategy in patients who have not previously received it. It also incorrectly assumes prior radiotherapy precludes further radiotherapy without clarifying the extent or feasibility, and does not emphasize the importance of starting concurrent chemoradiation after stenting."
  },
  "638": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the rationale for neoadjuvant therapy, specific regimens, surgical planning, and post-operative management, with no major omissions or errors."
  },
  "639": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including cardiac assessment, imaging, and lab tests, but omits the specific mention of置入影像标记物（clip）于肿块及腋下可疑淋巴结, which is important for lesion localization after neoadjuvant therapy. Minor optional items (如肿瘤标志物、遗传咨询) are included but not essential."
  },
  "640": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including prioritization of ROS1-targeted therapy, the limited role of immunotherapy despite high PD-L1, chemotherapy as a backup, and symptom management. There are no major omissions or errors."
  },
  "641": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the main points, including endocrine therapy with CDK4/6 inhibitors and ovarian suppression. However, it omits the recommendation for bone-modifying agents in patients with bone metastases and the need for regular efficacy and tolerance assessment."
  },
  "642": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant chemotherapy, follow-up intervals, and supportive care. However, it introduces more detail on targeted/immune therapy and follow-up frequency, and omits the explicit mention that observation alone is also an option, as well as the recommendation against routine PET/CT or brain MRI, which are minor but relevant omissions."
  },
  "643": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable and guideline-based approach for squamous NSCLC with HER2 mutation and high PD-L1, but it omits the current NCCN-recommended HER2-targeted therapy (fam-trastuzumab deruxtecan) as first-line for HER2-mutant NSCLC, and incorrectly states there is no standard targeted therapy for HER2 mutation in this context. It also overemphasizes histology-based limitations without acknowledging the latest evidence, leading to partial but not complete coverage."
  },
  "644": {
    "score": 5.0,
    "explanation": "5: The model answer provides a thorough and accurate clinical staging based on AJCC criteria, correctly identifies the need to clarify tumor size for precise staging, and comprehensively lists additional necessary assessments, including mediastinal lymph node evaluation and molecular pathology, matching and expanding upon the reference answer with no major omissions or errors."
  },
  "645": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including follow-up intervals, imaging modalities, and management steps for recurrence/metastasis, with additional relevant details and no major omissions or errors."
  },
  "646": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including TNM staging, the need for brain MRI, mediastinal lymph node assessment, and treatment planning. However, it incorrectly classifies T3N1M0 as stage IIIB (it is stage IIIA per the reference and current guidelines), which is a minor but notable error."
  },
  "647": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including follow-up intervals, imaging recommendations, and the rationale for not routinely performing PET/CT or brain MRI. There are no major omissions or errors."
  },
  "648": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points addressed in detail and no significant omissions or errors."
  },
  "649": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the recommended follow-up schedule, imaging modalities, and indications for further imaging. However, it suggests a slightly more frequent follow-up interval (every 3–6 months) in the first two years than the reference answer (every 6 months), and includes optional tumor marker testing, which is not emphasized in the reference. These are minor deviations but do not constitute major omissions or errors."
  },
  "650": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including the option of adjuvant chemotherapy, individualized decision-making, and detailed follow-up recommendations. However, it slightly overemphasizes the use of brain MRI and bone scans in routine follow-up (which are not recommended unless symptomatic), and provides more detail than required about targeted/immune therapy, which is not standard for all IIA patients. Minor deviations from guideline specifics prevent a perfect score."
  },
  "651": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging (IVA, M1a), the significance of malignant pleural effusion, and the choice of EGFR-TKI for G719X mutation. However, it omits recommendations for local management of pleural effusion (如胸膜固定术或置管引流), smoking cessation, and early integration of palliative care, which are present in the reference answer."
  },
  "652": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including individualized consideration of adjuvant chemotherapy, detailed follow-up intervals, and the importance of patient communication and smoking cessation, with no major omissions or errors."
  },
  "653": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of current recommendations, including the use of amivantamab or mobocertinib and the limited role of immunotherapy. However, it omits the specific combination of amivantamab with carboplatin and pemetrexed as the preferred regimen, which is a key detail in the reference answer."
  },
  "654": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most of the required preoperative assessments, including laboratory tests and cardiac evaluation. However, it omits the important step of肿瘤床置入可见标记 (tumor bed marker placement), which is specifically emphasized in the reference answer for surgical planning after neoadjuvant therapy."
  },
  "655": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of follow-up frequency, imaging modality, and indications for PET/CT and brain MRI, but it slightly differs in the recommended duration and frequency of chest CT compared to the reference answer and adds some minor details not present in the reference."
  },
  "656": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach and covers standard second-line options and the role of clinical trials, but it omits the current preferred HER2-targeted ADC therapy (fam-trastuzumab deruxtecan) as recommended in the reference answer, and underestimates its applicability in squamous NSCLC with HER2 mutation."
  },
  "657": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, but it incorrectly states the clinical stage as IIB instead of IIA (T2aN1M0 is IIA per AJCC 8th edition). Otherwise, the treatment recommendations are appropriate and detailed."
  },
  "658": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including adjuvant radiotherapy, chemotherapy, possible immunotherapy, and MDT discussion. However, it does not clearly state that re-operation for R0 resection is the first choice, instead listing it as a later consideration, which is a minor but important omission compared to the reference answer."
  },
  "659": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访时间表、内容和特殊注意事项，但对随访间隔的具体年限分段与参考答案略有不同（如前2年每3个月，未明确3-6个月的灵活性），且未强调戒烟建议，部分细节如PET/CT的具体应用也略有遗漏。"
  },
  "660": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical steps including MDT评估,手术可切除性评估,分子病理检测, and新辅助治疗策略, and contains no major omissions or errors compared to the reference answer."
  },
  "661": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps (re-resection as first choice, radiotherapy if not operable, no routine adjuvant chemotherapy, follow-up, and smoking cessation), with additional detail and guideline references but no major omissions or errors."
  },
  "662": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, imaging modalities, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "663": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for best supportive care, the lack of indication for systemic therapy, and the consideration of reversible factors, with no major omissions or errors."
  },
  "664": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately references guidelines and key studies, and clearly applies the evidence to the patient scenario with no major omissions or errors."
  },
  "665": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging recommendations, and the non-routine use of PET-CT/brain MRI, with no major omissions or errors."
  },
  "666": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it differs from the reference answer in分期（IA3 vs IB）—the reference uses T2a (2–3 cm), while the model uses T1c (2–3 cm), reflecting a minor discrepancy in AJCC 8th edition interpretation. Otherwise, the treatment recommendations are appropriate and comprehensive."
  },
  "667": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale, recommended regimens, and maintenance therapy, with no major omissions or errors."
  },
  "668": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging, treatment strategy, and management of the left lung nodule, but it omits the explicit recommendation for multidisciplinary discussion and does not detail the approach if both lesions are resectable, as mentioned in the reference answer."
  },
  "669": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including分期评估、局部及全身检查、腋窝评估和新辅助治疗选择。仅在腋窝活检标记夹和术后治疗决策等细节上略有遗漏。"
  },
  "670": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional guideline references without introducing errors or omissions."
  },
  "671": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately covers the rationale for first-line therapy, the role of KRAS G12C inhibitors, and the appropriateness of immunotherapy, matching guideline recommendations."
  },
  "672": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key aspects of the reference answer, including the rationale for reoperation, adjuvant chemoradiotherapy, and consideration of immunotherapy, with no major omissions or errors."
  },
  "673": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of neoadjuvant therapy, HER2-targeted treatment, and necessary preoperative assessments. However, it omits the specific recommendation for marker clip placement in both the primary tumor and the most suspicious axillary lymph node, which is an important detail in the reference answer."
  },
  "674": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of clinical staging and treatment as outlined in the reference answer, including imaging, lymph node assessment, distant metastasis evaluation, surgical options, and adjuvant therapy based on molecular subtype, with no major omissions or errors."
  },
  "675": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key assessments, even adding relevant points such as cardiac function and fertility evaluation. However, it omits the specific mention of placing localization markers in the tumor and suspicious lymph nodes, which is a minor but important detail in the reference answer."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points, and aligns closely with the reference answer, including rationale for therapy choice, specific regimen, and appropriate sequencing of KRAS G12C inhibitors. No major omissions or errors."
  },
  "677": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, and supportive care, but it slightly overstates the frequency of follow-up in the first two years and does not explicitly mention that PET/CT and brain MRI are not routinely recommended unless clinically indicated, which is a minor omission."
  },
  "678": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and includes appropriate details on MDT评估、手术与围手术期治疗、分子检测及其意义，无重大遗漏或错误。"
  },
  "679": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including comprehensive assessment, surgical recommendation, lymph node evaluation, molecular testing, and adjuvant therapy. However, it omits explicit mention of preoperative mediastinal staging procedures (e.g., EBUS/mediastinoscopy) to rule out occult N2/N3 disease and does not emphasize smoking cessation counseling or palliative/supportive care integration."
  },
  "680": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage (IIIA, cT2aN2M0) and outlines appropriate next steps, including MDT discussion, pathological confirmation of N2, and treatment options. However, it places more emphasis on放化疗 as首选 due to多站N2, whereas the reference answer prioritizes病理性纵隔淋巴结评估 before definitive treatment, and highlights新辅助治疗后手术为首选 for可切除病灶, which is less explicit in the model answer. Minor differences in treatment sequencing"
  },
  "681": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale, guideline basis, and specific recommended regimen, with no major omissions or errors."
  },
  "682": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indication for NTRK inhibitor monotherapy as first-line treatment, with appropriate rationale and correct mention of alternative options only if targeted therapy is unavailable. No major omissions or errors."
  },
  "683": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, but it classifies the tumor as T1c (2–3 cm) and IA3, whereas the reference answer uses T1b (2–3 cm) and IA. This is a minor discrepancy in sub-staging, but the overall management and recommendations are correct."
  },
  "684": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline references, and appropriate follow-up recommendations without omissions or errors."
  },
  "685": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, surgical recommendation, lymph node dissection, and postoperative management, with no major omissions or errors."
  },
  "686": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访时间表、内容、影像学检查、戒烟干预等要点，但对随访年限分期与参考答案略有差异，并提及了实验室检查和分子靶向/免疫治疗的补充内容，虽非错误但略超出题干要求。整体无重大遗漏。"
  },
  "687": {
    "score": 4.0,
    "explanation": "4: The model answer accurately identifies the stage as T3N0M0 (Stage IIb) and covers most key aspects of preoperative assessment, including mediastinal evaluation and general fitness. However, it omits specific mention of bronchoscopy and brain/spine MRI, which are important for complete staging and assessment in this context."
  },
  "688": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the TNM staging, emphasizes the need for pathological confirmation of N2 disease, includes appropriate imaging and functional assessments, outlines MDT discussion, and provides a nuanced, guideline-concordant treatment plan including molecular testing and immunotherapy considerations. No major omissions or errors."
  },
  "689": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including EGFR-TKI as first-line therapy, management of pleural effusion, supportive care, follow-up, and smoking cessation advice, with no major omissions or errors."
  },
  "690": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, recommending dabrafenib plus trametinib as the preferred next-line therapy. However, it omits mention of encorafenib plus binimetinib as an alternative, and does not explicitly address multidisciplinary management, smoking cessation, or palliative support."
  },
  "691": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately determines the clinical stage, details the TNM classification, and outlines the standard treatment principles including chemoradiotherapy and consolidation immunotherapy, with no major omissions or errors."
  },
  "692": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了EGFR-TKI（尤其是奥希替尼）为首选，解释了免疫治疗不推荐的原因，无重大遗漏或错误。"
  },
  "693": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the clinical scenario, including the limitations of EGFR-TKIs and the role of chemotherapy plus immunotherapy. However, it omits the explicit mention of individualized treatment based on comorbidities and multidisciplinary evaluation, and does not address smoking cessation and follow-up, which are present in the reference answer."
  },
  "694": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, covering随访频率, 检查内容, and生活方式管理. However, it omits the explicit recommendation against routine FDG-PET/CT or脑MRI in asymptomatic patients, which is a minor but relevant detail."
  },
  "695": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, symptom-based further workup, and lifestyle advice. However, it suggests a slightly more frequent follow-up schedule in the first two years and includes optional tumor marker testing, which is not emphasized in the reference answer. Minor differences in detail, but no major omissions."
  },
  "696": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up management, including frequency, content, imaging, and supportive care, with appropriate emphasis on the higher recurrence risk due to R1 resection. However, it slightly differs in the recommended CT protocol (suggesting low-dose CT rather than contrast-enhanced CT) and provides a broader time frame for follow-up intervals, which are minor deviations from the reference answer."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and follow-up recommendations, with no significant omissions or errors."
  },
  "698": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including preoperative assessment (lung and cardiac function, MDT discussion), surgical approach (lung and chest wall resection with lymph node dissection), adjuvant therapy considerations, and alternatives if surgery is contraindicated. There are no major omissions or errors."
  },
  "699": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the guidelines, but it underemphasizes the current recommendation to perform broad molecular profiling (including EGFR, ALK, ROS1, etc.) in all advanced NSCLC patients regardless of histology, as per the reference answer. Minor omissions regarding the routine use of large panel testing and the rationale for testing in all advanced cases are noted."
  },
  "700": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of staging and preoperative assessment, including PET/CT, pulmonary function, and the rationale for not routinely sampling mediastinal nodes. However, it includes some additional tests (e.g., brain MRI, tumor markers) that are not strictly necessary in all cases and could be considered minor deviations from the reference answer."
  },
  "701": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了风险分层、随访时间、进一步处理及不需立即侵袭性操作等要点，无明显遗漏或错误。"
  },
  "702": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (T1bN0M0, IA2), surgical recommendation, and considerations for adjuvant therapy, with no major omissions or errors."
  },
  "703": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of need for adjuvant therapy and providing a detailed, guideline-consistent follow-up plan with no major omissions or errors."
  },
  "704": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, management recommendations, and appropriate guideline references, with no major omissions or errors."
  },
  "705": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and health management. However, it slightly differs in the timing of follow-up intervals and includes some additional but non-essential details (e.g., lab tests, other imaging), and does not explicitly mention not routinely recommending PET/CT or brain MRI in the absence of indications."
  },
  "706": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including risk assessment, follow-up intervals, and escalation criteria, with no major omissions or errors. It also appropriately references relevant guidelines."
  },
  "707": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the case, including correct identification of synchronous primary lung cancers, appropriate staging, and individualized treatment principles. However, it omits the explicit mention of the overall NSCLC clinical stage as IVA (M1a) and does not clearly state that both tumors should be managed as potentially curable with a multidisciplinary approach, as emphasized in the reference answer."
  },
  "708": {
    "score": 3.0,
    "explanation": "3: The model answer covers the clinical staging accurately and outlines the main treatment options, but it omits the guideline-recommended preference for neoadjuvant (preoperative) chemotherapy in triple-negative breast cancer, lacks detail on necessary pre-treatment evaluations, and does not mention the role of immunotherapy (e.g., pembrolizumab) for high-risk patients."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and recommended treatment, with no significant omissions or errors."
  },
  "710": {
    "score": 0.0,
    "explanation": "0: The model answer does not address the clinical question or provide any relevant information; it is a generic response to a formatting error."
  },
  "711": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including endocrine therapy, chemotherapy, radiotherapy, and the role of 21-gene RT-PCR testing. However, it slightly overemphasizes the routine use of chemotherapy and radiotherapy without as clearly stating that 21-gene testing is specifically to guide chemotherapy decisions when benefit is uncertain, as highlighted in the reference answer."
  },
  "712": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the rationale for local versus systemic therapy, specific chemotherapy regimens, and the role of immunotherapy. However, it introduces additional discussion about local treatment feasibility and immunotherapy combinations, which, while accurate, slightly diverges from the reference answer's focus and omits explicit mention of early palliative care integration and smoking cessation advice."
  },
  "713": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, differential diagnosis (双原发 vs. 转移), and management, but it omits a clear, direct statement that—based on现有证据—应按M1a（IV期）处理，并未强调多学科讨论的重要性。"
  },
  "714": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage and appropriate treatment. However, it differs from the reference answer in TNM staging (T1c vs. T2a) and stage grouping (IA3 vs. IB), reflecting a minor discrepancy in tumor size classification."
  },
  "715": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the clinical scenario, but it incorrectly classifies the T stage as T3 instead of T4 (since同侧不同肺段结节应为T4), which is a minor but important omission. Otherwise, the treatment recommendations and staging workup are appropriate."
  },
  "716": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (cT1bN0M0/IA2), surgical recommendations, alternatives, and the rationale, with no significant omissions or errors."
  },
  "717": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of recommending re-resection or radiotherapy for R1 margin, and outlines an appropriate follow-up plan. However, it slightly overstates the follow-up frequency (suggesting every 3–6 months initially rather than every 6 months as per the reference) and omits lifestyle advice such as smoking cessation."
  },
  "718": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for NTRK inhibitors, specific drug names, guideline recommendations, and rationale, with no major omissions or errors."
  },
  "719": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and additional considerations. However, it omits the specific recommendation for low-dose non-contrast CT after 5 years and does not explicitly mention adjusting the interval or adding tests if new or residual imaging abnormalities are found."
  },
  "720": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred agent (trastuzumab deruxtecan), alternative options, rationale, and relevant guidelines, with no major omissions or errors."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including follow-up intervals, imaging recommendations, the non-routine use of PET/CT and brain MRI, and smoking cessation advice, with no major omissions or errors."
  },
  "722": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the rationale for EGFR-TKI therapy, the role of osimertinib, and the limited value of immunotherapy in EGFR-mutant NSCLC. However, it omits explicit mention of multidisciplinary evaluation and palliative care, which are present in the reference answer."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including BRAF靶向治疗优先、免疫/化疗备选、吸烟戒断和姑息治疗整合，无明显遗漏或错误。"
  },
  "724": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough general preoperative assessment but omits the critical need for支气管镜和纵隔淋巴结病理性评估, which are essential for staging and surgical planning. The postoperative adjuvant therapy section is accurate and complete."
  },
  "725": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately analyzes the staging, and provides a detailed, guideline-consistent treatment plan including consolidation immunotherapy, with no major omissions or errors."
  },
  "726": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it differs from the reference answer by recommending afatinib as the preferred EGFR-TKI rather than osimertinib, which is the reference's choice. This is a minor omission given current evidence, but the overall clinical content is accurate and thorough."
  },
  "727": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modality, and the lack of indication for routine PET/CT or brain MRI, with no major omissions or errors."
  },
  "728": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the rationale for switching to EGFR TKI (especially afatinib), addresses the limited role of immunotherapy, and includes appropriate recommendations for bone metastases, matching and expanding upon the reference answer without major omissions or errors."
  },
  "729": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of routine adjuvant therapy, consideration of high-risk factors, and detailed, guideline-consistent follow-up recommendations. No major omissions or errors are present."
  },
  "730": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and closely matches the reference answer, covering re-resection, radiotherapy, chemotherapy, imaging recommendations, and follow-up intervals, with no major omissions or errors."
  },
  "731": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and covers all key aspects from the reference answer, including targeted therapy, bone metastasis management, local and supportive treatments, and consideration of immunotherapy/chemotherapy. No major omissions or errors are present."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including accurate staging, rationale for unresectability, standard treatment (concurrent chemoradiotherapy), consideration of consolidation immunotherapy, and the need for molecular testing. There are no major omissions or errors."
  },
  "733": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale, drug choices, and guideline references without any major omissions or errors."
  },
  "734": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage as IIB (T3N0M0), but it underemphasizes the guideline-based recommendation for neoadjuvant (perioperative) chemotherapy, instead favoring direct surgery as the standard. This is a minor omission, as current guidelines generally recommend perioperative chemotherapy for stage IIB."
  },
  "735": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describes the staging, surgical recommendation, and considerations for adjuvant therapy, with no major omissions or errors."
  },
  "736": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including patient summary, rationale for chemotherapy, endocrine therapy, and radiotherapy. However, it places more emphasis on age as a high-risk factor and leans toward recommending chemotherapy or gene testing, whereas the reference answer suggests chemotherapy is generally not needed given the low-intermediate Ki67 and absence of other high-risk features. Minor differences in risk stratification and decision-making account for the deduction."
  },
  "737": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies trastuzumab deruxtecan (DS-8201) as the first-line treatment for HER2-mutant NSCLC, with appropriate alternatives and rationale. However, it omits mention of ado-trastuzumab emtansine (T-DM1) as a secondary HER2-targeted option, which is present in the reference answer."
  },
  "738": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly identical to the reference answer, correctly identifying trastuzumab deruxtecan as the first-line therapy and providing rationale and alternatives. However, it introduces more detail about chemotherapy and immunotherapy options, which, while accurate, slightly overemphasizes alternatives compared to the reference, and does not mention T-DM1 specifically as an alternative HER2-targeted agent."
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of KRAS G12C inhibitors as second-line therapy, alternative options, and relevant guidelines, with no major omissions or errors."
  },
  "740": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including invasive mediastinal staging, pulmonary function testing, and rationale, with no major omissions or errors."
  },
  "741": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, providing appropriate rationale, drug regimens, and monitoring advice. However, it omits mention of encorafenib + binimetinib as an alternative regimen and does not explicitly state the need to complete or interrupt the current systemic therapy before switching, which are minor omissions."
  },
  "742": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up and management, including surveillance intervals, imaging modality, lifestyle advice, and management of complications. However, it slightly overstates the frequency of follow-up in years 3–5 (every 6 months instead of annually after 2–3 years as per the reference), and includes some additional but non-essential details."
  },
  "743": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including local and systemic staging, pathology review, organ function assessment, and additional relevant considerations, with no major omissions or errors."
  },
  "744": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for ALK-TKI therapy, specific drug recommendations, rationale, and consideration of prior treatments, with no major omissions or errors."
  },
  "745": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it slightly underemphasizes the need for regular chest CT at every follow-up in the first 3 years and does not specify low-dose CT after 5 years. Minor differences in the timing and imaging details are present, but overall clinical content is accurate."
  },
  "746": {
    "score": 5.0,
    "explanation": "5: The model answer is nearly identical to the reference answer, covering分期,治疗方案, and注意事项 comprehensively, with no major omissions or errors. Minor additions (如靶向治疗) do not detract from the core clinical content."
  },
  "747": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical steps, including pathology and molecular typing, systemic neoadjuvant therapy, surgical and radiotherapy options, and follow-up, with no major omissions or errors compared to the reference answer."
  },
  "748": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including re-resection as first choice, adjuvant radiotherapy if re-resection is not feasible, consideration of adjuvant chemotherapy, and referencing relevant guidelines. No major omissions or errors are present."
  },
  "749": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of the reference answer, and includes appropriate details on imaging, clinical follow-up, and additional considerations, with no major omissions or errors."
  },
  "750": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including tissue acquisition, comprehensive molecular testing (with most relevant genes listed), PD-L1 assessment, and the rationale for testing. It omits a few less common targets (NTRK, ERBB2) and the explicit mention of liquid biopsy as an alternative, but these are minor omissions."
  },
  "751": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, includes all key elements from the reference answer (molecular testing, PD-L1, MDT, treatment options, and supportive care), and adds appropriate clinical context without any major omissions or errors."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of MET抑制剂为首选、具体药物、指南依据、注意事项及替代方案，无重大遗漏或错误。"
  },
  "753": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, new adjuvant therapy with dual HER2-targeted agents plus chemotherapy, post-treatment evaluation, surgery, and completion of targeted and endocrine therapy. No major omissions or errors are present."
  },
  "754": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the TNM分期（T4N0M0），治疗策略（手术评估、放化疗、辅助治疗），并补充了分子检测等细节，无重大遗漏或错误。"
  },
  "755": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of treatment and rationale, but incorrectly assigns the clinical stage as IIIC instead of IIIB for T2N3M0, which is a significant error. Otherwise, the treatment recommendations are appropriate and detailed."
  },
  "756": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps including surgical resection, systematic lymph node dissection, and adjuvant chemotherapy, with no major omissions or errors."
  },
  "757": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the general non-recommendation of adjuvant chemotherapy for stage IB NSCLC without high-risk features, and provides a detailed follow-up plan. However, it introduces more detail about high-risk factors and slightly differs in the follow-up intervals and imaging recommendations compared to the reference answer, which are minor omissions."
  },
  "758": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, imaging modalities, and the non-recommendation of routine FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "759": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, content, imaging modality, and indications for advanced imaging, with no major omissions or errors."
  },
  "760": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and rationale. However, it omits the specific recommendation against routine brain MRI and FDG-PET/CT in asymptomatic patients and does not mention smoking cessation advice, which are present in the reference answer."
  },
  "761": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the option of observation versus adjuvant chemotherapy, the rationale for adjuvant therapy in tumors >4cm, and consideration of patient factors. It also adds relevant, guideline-based details about targeted and immunotherapy, which are appropriate and do not detract from the core answer. No major omissions or errors."
  },
  "762": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the staging and main management steps, but it omits the specific recommendation for preoperative mediastinal lymph node assessment to rule out occult nodal disease, which is an important detail in the reference answer."
  },
  "763": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the case, but it incorrectly assigns stage IIIA instead of IIB (T3N0M0 per AJCC 8th edition is stage IIB), and does not explicitly mention the need for preoperative mediastinal lymph node assessment (e.g., EBUS or mediastinoscopy) to rule out occult nodal disease. Otherwise, the management plan is appropriate."
  },
  "764": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up frequency and content, but it omits specific recommendations against routine use of PET/CT and brain MRI unless symptomatic, and does not explicitly mention ongoing smoking cessation counseling and survivorship care."
  },
  "765": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the case, but it incorrectly assigns stage IIIC (which does not exist for NSCLC; N3 with M0 is IIIB per AJCC 8th edition) and provides some extra detail not required. Otherwise, the treatment recommendations and reasoning are accurate and comprehensive."
  },
  "766": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for RET inhibitor monotherapy, naming both recommended agents, and appropriately addressing the roles of immunotherapy and chemotherapy. No major omissions or errors are present."
  },
  "767": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key details on staging, surgical recommendations, and postoperative considerations, with no significant omissions or errors."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps including brain MRI, pulmonary function testing, and MDT discussion, with no major omissions or errors."
  },
  "769": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the stage and main management steps, but it omits the recommendation for病理性纵隔淋巴结评估（如EBUS-TBNA或纵隔镜） and脑MRI to rule out occult metastasis, which are important details in the reference answer."
  },
  "770": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical content, including staging rationale, the need to distinguish between multiple primaries and intrapulmonary metastasis, and outlines appropriate next steps such as MDT discussion and further molecular analysis. However, it omits some specific recommendations from the reference answer, such as mediastinal lymph node pathological assessment (EBUS-TBNA/mediastinoscopy), preoperative pulmonary function testing, and explicit mention of individualized adjuvant/targeted/immunotherapy planning."
  },
  "771": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, providing correct staging and a detailed, guideline-based treatment plan. However, it slightly overemphasizes the preference for chemoradiotherapy over neoadjuvant therapy plus surgery, whereas the reference answer more clearly presents both options depending on resectability and MDT assessment. Minor omissions regarding the possibility of neoadjuvant therapy followed by surgery in select cases prevent a perfect score."
  },
  "772": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (IIIB, T2aN3M0), rationale, and stepwise treatment recommendations, including chemoradiotherapy and immunotherapy, with no significant omissions or errors."
  },
  "773": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately identifies the stage as IIIB (N3), correctly outlines the standard of care (concurrent chemoradiotherapy with possible consolidation immunotherapy), and provides appropriate justification and references, with no major omissions or errors."
  },
  "774": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且补充了奥希替尼作为首选的最新循证依据，并详细说明了脑转移处理和随访，内容无重大遗漏或错误。"
  },
  "775": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including surgery as first choice, preoperative assessment, and alternative radiotherapy if surgery is not feasible. However, it adds details about molecular testing and adjuvant therapy options not specified in the reference, and omits the specific mention of brain MRI for metastasis exclusion, which is a minor but relevant omission."
  },
  "776": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately identifies the stage as IIIC (using the latest AJCC 8th edition), and details the next steps including molecular testing, MDT discussion, and standard treatment options, with no major omissions or errors."
  },
  "777": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including HER2靶向治疗、化疗、免疫治疗的考量及局部治疗评估，但对“吸烟戒断、姑息治疗团队早期介入、定期随访”等全程管理内容略有遗漏。"
  },
  "778": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding of current guidelines, including the limitations of BRAF/MEK inhibitors in squamous cell carcinoma and the role of immunotherapy. However, it omits a clear, guideline-based statement that BRAF/MEK inhibitors can be considered as first-line in BRAF V600E-mutant NSCLC regardless of histology, as per the latest recommendations, and is slightly conservative regarding their use in squamous histology."
  },
  "779": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the indication for neoadjuvant therapy, rationale, and most recommended preoperative assessments. However, it omits some specific details such as the need for tumor bed marker placement and does not fully list all imaging options (e.g., bone scan or PET/CT as alternatives), resulting in minor omissions."
  },
  "780": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and no major omissions or errors."
  },
  "781": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, clinical and imaging assessments, and lifestyle advice. However, it introduces some minor deviations, such as more frequent early follow-up and optional use of tumor markers and abdominal imaging, which are not standard in the reference answer."
  },
  "782": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommendation of afatinib as first-line therapy, rationale for its use, discussion of alternative options, and the limited role of immunotherapy. No major omissions or errors are present."
  },
  "783": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but the recommended CT frequency in the first 3 years (every 6 months vs. every 3–6 months) and the inclusion of abdominal imaging are minor deviations. The answer correctly states that PET-CT and brain MRI are not routinely needed."
  },
  "784": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides guideline references and appropriate negative recommendations."
  },
  "785": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了术前评估、手术治疗、辅助治疗及随访，且补充了分子检测和MDT讨论，内容更为全面，无重大遗漏或错误。"
  },
  "786": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers staging, rationale, and recommended neoadjuvant therapy (including HER2-targeted agents and chemotherapy), and outlines subsequent surgical and adjuvant management, with no major omissions or errors."
  },
  "787": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps (re-resection, adjuvant radiotherapy, adjuvant chemotherapy, and follow-up), with no major omissions or errors."
  },
  "788": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical content, including correct staging, treatment options, and the need for preoperative assessment. However, it omits the specific recommendation for further pathological evaluation of mediastinal lymph nodes (e.g., EBUS-TBNA or mediastinoscopy) to rule out occult nodal metastasis, which is an important detail in the reference answer."
  },
  "789": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including accurate staging (cT1cN3M0, III C per AJCC 8th), appropriate initial treatment (concurrent chemoradiotherapy, consolidation immunotherapy), and additional recommendations (molecular testing, alternative regimens if unfit). No major omissions or errors."
  },
  "790": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it differs from the reference answer in TNM staging interpretation (IA2 vs. IB), likely due to referencing different editions of the AJCC staging system, and omits mention of R1/R2 resection management. Minor differences in staging and omission of re-resection or adjuvant therapy for positive margins prevent a perfect score."
  },
  "791": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging, further molecular testing, and standard treatment (concurrent chemoradiotherapy), but it omits explicit mention of supportive/palliative care and pre-treatment laboratory/organ function assessments, which are present in the reference answer."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of actionable mutations, PD-L1 status, preference for immunotherapy plus chemotherapy, and consideration of patient tolerance, with no major omissions or errors."
  },
  "793": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, but it overemphasizes同步放化疗 (concurrent chemoradiotherapy) as the first choice, whereas guidelines generally recommend新辅助化疗 (neoadjuvant chemotherapy) ±放疗, with surgery considered after response. Minor differences in sequencing and emphasis, but no major omissions."
  },
  "794": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了患者分期、分子特征、PS评分、推荐的含铂双药化疗方案，并补充了联合免疫治疗的最新循证依据，无重大遗漏或错误。"
  },
  "795": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，随访频率、内容及脑MRI的适应证均有详细说明，无明显遗漏或错误。"
  },
  "796": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including clinical staging, indication for neoadjuvant therapy, and next steps. However, it incorrectly states the clinical stage as IIA instead of IIB, which is a minor but important omission. Other details are well addressed."
  },
  "797": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the consideration of synchronous multiple primary lung cancers, the need for MDT discussion, and local radical treatment options. However, it omits the formal mention of stage IVA (M1a) per TNM for multiple lesions in different lungs and does not explicitly discuss the need to consider molecular pathology for systemic therapy decisions."
  },
  "798": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including diagnosis, first-line ALK-TKI therapy, symptom management, and guideline references, with no major omissions or errors."
  },
  "799": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including patient summary, endocrine therapy recommendations, chemotherapy considerations, and the role/indication of 21-gene testing. However, it omits explicit mention of the recurrence score cutoffs (e.g., 16–25 as intermediate risk) and the direct statement that 21-gene testing is strongly recommended if chemotherapy is considered, as in the reference answer."
  },
  "800": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and closely matches the reference answer, covering imaging, clinical follow-up, unnecessary routine PET/CT or MRI, smoking cessation, and follow-up intervals, with no major omissions or errors."
  },
  "801": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of diagnosis, staging (T4dN0M0, stage IIIB), and the recommended initial treatment (neoadjuvant anthracycline-taxane chemotherapy, surgery, radiotherapy, endocrine therapy). However, it omits explicit mention of post-operative radiotherapy to the chest wall and regional lymphatics, and the continuation of endocrine therapy post-operatively, which are clearly stated in the reference answer."
  },
  "802": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed clinical staging and appropriate standard treatment recommendations. However, it slightly over-specifies the T stage (T1c vs. T1b in the reference) and includes more detail than required, but omits the explicit statement that preoperative mediastinal lymph node sampling is not routinely needed unless imaging is suspicious."
  },
  "803": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, additional tests if symptomatic, and supportive care, with no major omissions or errors."
  },
  "804": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、分期分型、治疗建议及随访，无重大遗漏或错误。"
  },
  "805": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, molecular findings, PD-L1 status, ECOG score, and both immunotherapy and chemoimmunotherapy options, with no major omissions or errors."
  },
  "806": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, chest CT as the primary imaging, and lifestyle advice. However, it slightly overemphasizes the frequency of follow-up (suggesting every 3–6 months vs. every 6 months in the reference) and includes optional tests (tumor markers, other imaging) that are not routinely recommended, which are minor deviations."
  },
  "807": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the use of EGFR-TKI (afatinib or osimertinib), guideline recommendations, and the rationale for not choosing immunotherapy or chemotherapy first-line. However, it does not emphasize osimertinib as the preferred agent as clearly as the reference answer, and gives equal weight to afatinib, which is a minor omission."
  },
  "808": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the rationale for adjuvant chemotherapy, specific regimens, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "809": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of adjuvant therapy (chemotherapy, HER2-targeted therapy, endocrine therapy, and radiotherapy), and provides appropriate regimen details without major omissions or errors."
  },
  "810": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps of neoadjuvant chemo + dual anti-HER2 therapy, assessment, surgery, and adjuvant treatment. However, it omits the specific recommendation to place markers in the primary tumor and biopsied axillary node before neoadjuvant therapy, which is an important detail in the reference answer."
  },
  "811": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the priority of reoperation for negative margins, the alternative of postoperative radiotherapy if reoperation is not feasible, and the consideration of adjuvant chemotherapy in certain high-risk cases. No major omissions or errors are present."
  },
  "812": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate management recommendations. However, it assigns stage IA3 (AJCC 8th) rather than IB as in the reference, and omits the suggestion for bronchoscopy to rule out central lesions and the optional preoperative brain MRI, which are minor but relevant omissions."
  },
  "813": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including molecular subtyping, MDT discussion, and systemic evaluation. However, it omits the specific recommendation for axillary ultrasound and possible biopsy of suspicious lymph nodes, which is a minor but important omission in preoperative assessment."
  },
  "814": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for ALK-TKI, preferred agents, rationale, and avoidance of further chemotherapy or immunotherapy. No major omissions or errors are present."
  },
  "815": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including pathological confirmation and marking of both the primary tumor and positive axillary nodes, as well as the rationale for these steps. No major omissions or errors are present."
  },
  "816": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and recommends SBRT as the primary treatment, which is appropriate for early-stage, inoperable, localized lung cancers. However, the reference answer emphasizes systemic palliative chemotherapy as the first choice, with local palliative therapy as adjunct, reflecting a different standard approach for multifocal, histologically distinct tumors. The model omits systemic therapy as the mainstay, leading to a partial but not complete answer."
  },
  "817": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including分期、手术建议、术前评估、术后处理及替代方案，但分期为IA2期（AJCC第8版），而参考答案为IB期（较常用分期），存在分期标准不一致这一小误差。"
  },
  "818": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM staging, correct clinical stage (IA2/T1bN0M0), and appropriate first-line and alternative treatment options, with no major omissions or errors."
  },
  "819": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately identifies the stage, details the rationale for staging, lists appropriate further tests (molecular pathology, functional assessment), and outlines standard treatment strategies, including MDT, chemoradiotherapy, and consideration of surgery, matching the reference answer with no major omissions or errors."
  },
  "820": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes additional relevant details such as molecular testing and MDT讨论, with no major omissions or errors."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including病理复核、全面评估、MDT、治疗方案选择（抗HER2靶向+化疗±内分泌）、治疗依据（如内脏危象）、以及治疗流程，内容详实且无重大遗漏或错误。"
  },
  "822": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including局部和全身评估、实验室检查、心脏功能评估等，但未明确提及肿瘤及腋窝淋巴结穿刺活检后需放置影像定位标记这一重要细节。"
  },
  "823": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including staging, further imaging to rule out metastasis, lab work, the rationale and details of neoadjuvant therapy, and post-treatment surgical planning, with no major omissions or errors."
  },
  "824": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, covering re-resection as first choice, radiotherapy if not operable, and appropriate follow-up intervals. However, it omits specific recommendations such as not routinely performing FDG-PET/CT or brain MRI, and does not mention smoking cessation or survivorship care."
  },
  "825": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging, rationale, and treatment recommendations clearly and accurately addressed, and no significant omissions or errors."
  },
  "826": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging (cT1cN0M1a, IVa), rationale for M1a classification, and the need for MDT evaluation. However, it places较多 emphasis on系统治疗 and does not充分讨论“可治愈局限性双原发肿瘤”及手术/局部治疗的可能性，略有遗漏。"
  },
  "827": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the indication for neoadjuvant therapy and the need for comprehensive preoperative assessment. However, it omits specific recommendations for core needle biopsy marker placement and detailed axillary imaging/biopsy, which are present in the reference answer."
  },
  "828": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including no need for adjuvant therapy, rationale, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "829": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps, including reoperation, consideration of radiotherapy if surgery is not feasible, follow-up, and the lack of indication for adjuvant chemotherapy. It also appropriately references guidelines and emphasizes MDT discussion, with no major omissions or errors."
  },
  "830": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the clinical scenario, correctly identifying the stage, discussing the rationale for chemoradiotherapy, and addressing the role of molecular testing. However, it omits the possibility of perioperative (neoadjuvant) therapy and surgery in potentially resectable N2 disease, which is mentioned in the reference answer, and is somewhat more conservative regarding molecular testing recommendations."
  },
  "831": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, recommended first-line regimen (platinum-based doublet chemotherapy plus PD-1 inhibitor), rationale, and alternative for immunotherapy contraindication, with no major omissions or errors."
  },
  "832": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the TNM stage as cT3N2M0 (IIIB) and outlining appropriate next steps, including molecular testing and MDT discussion. However, it incorrectly classifies the tumor as T3 (6 cm), while the reference answer uses T4 (>7 cm), which is a minor but relevant discrepancy; otherwise, the clinical reasoning and recommendations are sound."
  },
  "833": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the clinical scenario, including the significance of the EGFR G719X mutation and the rationale for EGFR-TKI therapy. However, it differs from the reference answer by prioritizing afatinib (a second-generation EGFR-TKI) over osimertinib (a third-generation EGFR-TKI), which is the preferred option in the reference answer. This constitutes a minor but important omission in aligning with the most current recommendations."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality recommendations, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "835": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing the importance of salvage radiotherapy and discussing the rationale. However, it omits the recommendation for salvage reoperation as the first choice and does not mention the specific follow-up schedule, which are minor but relevant omissions."
  },
  "836": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and treatment recommendations, including new adjuvant therapy and HER2-targeted treatment. However, it omits the specific mention of Ado-trastuzumab emtansine (T-DM1) as adjuvant therapy for patients with residual disease after neoadjuvant treatment, which is a key detail in the reference answer."
  },
  "837": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and standard treatment (concurrent chemoradiotherapy and consolidation immunotherapy), with no significant omissions or errors."
  },
  "838": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical and adjuvant therapy recommendations, and alternative options, with no major omissions or errors."
  },
  "839": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，涵盖了ALK-TKI为首选、对症处理胸腔积液、化疗和免疫治疗非首选、多学科管理等要点，无重大遗漏或错误。"
  },
  "840": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage and main treatment recommendations. However, it omits the suggestion for preoperative mediastinal lymph node staging (e.g., EBUS or mediastinoscopy) and does not mention the consideration of perioperative evaluation as explicitly as the reference answer."
  },
  "841": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indications for neoadjuvant therapy, patient-specific considerations, and the need for further multidisciplinary evaluation. There are no major omissions or errors."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the lack of efficacy of first/second-generation EGFR-TKIs, the recommendation for platinum-based chemotherapy, and the use of Exon 20-specific targeted agents, with no major omissions or errors."
  },
  "843": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guideline recommendations, and specific drug choices without omissions or errors."
  },
  "844": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the recommendation of selpercatinib and pralsetinib as selective RET inhibitors, guideline support, and clinical considerations. However, it omits mention of cabozantinib as an alternative in case of contraindications or drug shortages, which is a minor omission."
  },
  "845": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including分期、腋窝和全身评估、乳腺MRI等，但对金属标记夹的置入未明确提及，且部分内容如知情同意和遗传咨询虽有参考价值，但非必答要点。"
  },
  "846": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including MDT discussion, preoperative assessment, surgical approach, adjuvant therapy, and alternative strategies if resection is not feasible, with no major omissions or errors."
  },
  "847": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing NTRK inhibitors, listing appropriate agents, and discussing the roles of immunotherapy and chemotherapy. It also references guidelines and addresses alternative options, with no major omissions or errors."
  },
  "848": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the staging (IIIA, cT?N2M0) and outlining appropriate next-step management options, including neoadjuvant chemoradiotherapy, surgical evaluation, and multidisciplinary discussion, with no major omissions or errors."
  },
  "849": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately identifies the stage as cT1bN0M0 (IA2), and lists appropriate preoperative assessments. However, it does not emphasize the importance of routine preoperative bronchoscopy and intraoperative mediastinal lymph node evaluation as clearly as the reference answer."
  },
  "850": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, content, and lifestyle advice. However, it slightly deviates from the reference answer regarding the recommended frequency and type of chest CT (suggesting every 6–12 months rather than strictly every 3–6 months in the first 3 years), and does not explicitly mention the adjustment of imaging intervals if abnormalities are found."
  },
  "851": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and adds appropriate detail without introducing errors or omissions."
  },
  "852": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of mediastinal lymph node assessment and standard treatment pathway, with appropriate detail and guideline references. However, it is slightly incomplete as it cuts off before fully describing the management if N2 disease is found."
  },
  "853": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the lack of actionable mutations, low PD-L1, ECOG status, chemotherapy as the mainstay, possible immunotherapy combination, management of brain metastases, and supportive care. There are no major omissions or errors."
  },
  "854": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers所有主要治疗措施（再次手术、放疗、化疗）、分子检测、随访方案等，内容详实。仅在随访频率和细节上与参考答案略有不同（如随访时间节点、CT增强选择、吸烟干预未明确强调），但无重大遗漏或错误。"
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging and treatment strategy clearly and accurately addressed, and no significant omissions or errors."
  },
  "856": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering all key preoperative assessments and correctly identifying the stage as IIb (T3N0M0). It includes some additional general preoperative evaluations (e.g., nutrition, anesthesia) not specified in the reference, but omits the specific mention of spinal or thoracic inlet MRI for suspected invasion, which is a minor omission."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for ALK-TKI monotherapy, specific drug recommendations, and the limited role of immunotherapy, with no major omissions or errors."
  },
  "858": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the indication for neoadjuvant therapy and most recommended preoperative assessments. However, it omits some specific details such as marker clip placement in the tumor and axilla, and does not explicitly mention the need for enhanced CT/MRI for metastasis exclusion or bone scan/PET-CT indications, which are present in the reference answer."
  },
  "859": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, preoperative assessment, and alternative treatments, with no major omissions or errors."
  },
  "860": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemotherapy and postoperative radiotherapy for R1 resection in stage IIB NSCLC. It also mentions molecular and immunotherapy options, which are reasonable additions. However, it omits the recommendation for regular follow-up and smoking cessation counseling, which are present in the reference answer."
  },
  "861": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including endocrine therapy adjustment, ovarian function suppression, CDK4/6 inhibitor use, and bone protection, with no major omissions or errors."
  },
  "862": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including reoperation, radiotherapy, and follow-up, with some additional detail. However, it slightly overemphasizes adjuvant chemotherapy and molecular testing, which are not standard in this scenario, and the follow-up intervals differ somewhat from the reference answer."
  },
  "863": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the priority of re-resection, the role of postoperative radiotherapy, individualized consideration of adjuvant chemotherapy, and detailed follow-up recommendations. No major omissions or errors are present."
  },
  "864": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up, imaging, lifestyle management, and lack of need for adjuvant therapy. However, it slightly overextends the follow-up interval (suggesting annual CT from year 2–5 instead of from year 3), and includes some extra but non-essential lifestyle advice, making it slightly less precise than the reference."
  },
  "865": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it incorrectly classifies T分期为T1c（2.2cm应为T1c而非T1b），导致分期为IA3期而非IA期（T1bN0M0）。此外，增加了组织学诊断的讨论，虽合理但非必需。整体内容与参考答案高度一致，仅有细微分期差异。"
  },
  "866": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging modality, and additional considerations. However, it slightly differs in the recommended follow-up intervals (e.g., 2–5 years every 6–12 months vs. reference's 3–5 years every 6 months), and does not specify the transition to low-dose non-contrast CT after 5 years, which is a minor omission."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline recommendations, and appropriate drug choices, with no major omissions or errors. It even adds relevant local drug options and contingency plans, matching and expanding upon the reference answer."
  },
  "868": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed TNM staging and appropriate treatment recommendations. However, it differs from the reference answer in T分期（T2b vs T2a）和分期（IIA vs IB），反映了对肿瘤大小分期的不同理解，属于细微分歧，但整体临床内容无重大遗漏。"
  },
  "869": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based approach, including the option of re-operation, which is a valid consideration but not emphasized in the reference answer. It covers adjuvant chemoradiotherapy and follow-up, but the order of recommendations and emphasis differ slightly from the reference, and the follow-up details are less specific."
  },
  "870": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including imaging, laboratory, and pathology assessments, as well as additional relevant pre-treatment evaluations. However, it omits the specific mention of tumor and lymph node marker placement, which is an important detail in the reference answer."
  },
  "871": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and includes all relevant clinical content without omissions or errors. It even expands on guideline details and follow-up recommendations, matching and exceeding the reference answer's depth."
  },
  "872": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, correctly identifies MET抑制剂为首选一线治疗, lists appropriate drugs, and explains the rationale, with no major omissions or errors."
  },
  "873": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended examinations, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "874": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommendation for concurrent chemoradiotherapy, rationale, specific regimens, and consideration of immunotherapy maintenance. No major omissions or errors are present."
  },
  "875": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging and main management steps, but it omits the recommendation for preoperative pathological mediastinal lymph node assessment (e.g., EBUS or mediastinoscopy) to rule out occult N2 disease, which is an important detail in the reference answer."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indication for BRAF/MEK inhibitor therapy, alternative options, and referencing guidelines, with no major omissions or errors."
  },
  "877": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要治疗策略（补充辅助化疗、残端放疗、多学科会诊）及随访计划，内容详实。仅在随访频率和影像学随访细节上与参考答案略有不同，未明确强调FDG-PET/CT和脑MRI不常规推荐，且随访时间点略有扩展。"
  },
  "878": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, and the lack of indication for routine PET/CT or brain MRI in asymptomatic patients, with no major omissions or errors."
  },
  "879": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, further molecular testing, brain MRI, and functional assessments. However, it assigns N3/IIIC stage based on supraclavicular lymph node involvement, which is not explicitly supported by the reference (which considers N2/IIIA), and does not emphasize the need for pathological confirmation of mediastinal nodes (e.g., EBUS-TBNA), which is a minor but important omission."
  },
  "880": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including HER2-targeted therapy, chemotherapy options, the lack of indication for endocrine therapy, and the rationale for omitting radiotherapy. There are no major omissions or errors."
  },
  "881": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations of re-resection as first choice and postoperative radiotherapy if surgery is not feasible. However, it omits details about follow-up protocols and smoking cessation advice, which are present in the reference answer."
  },
  "882": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging modality, and lifestyle advice. However, it suggests a slightly more frequent follow-up schedule and includes optional tumor marker testing, which is not standard per the reference, and does not explicitly mention the avoidance of routine PET/CT or brain MRI unless symptomatic."
  },
  "883": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of adjuvant therapy and follow-up, including chemotherapy, targeted therapy, and immunotherapy considerations, as well as detailed follow-up intervals and content. It also addresses smoking cessation and additional supportive care, with no major omissions or errors."
  },
  "884": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately describes the standard of care (synchronous chemoradiotherapy), addresses the role of SVC stenting based on symptom severity, and adds appropriate details about immunotherapy consolidation, all without major omissions or errors."
  },
  "885": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including imaging intervals, clinical assessment, and survivorship care. However, it slightly deviates from the reference by recommending 6–12 month intervals (rather than 3–6 months) for years 2–3, and does not specify the transition at the 3-year mark as clearly as the reference answer."
  },
  "886": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including patient characteristics, guideline-based recommendations, and rationale. However, it slightly overemphasizes the preference for combination therapy over monotherapy despite PD-L1 ≥1% (not ≥50%), and omits explicit mention of palliative care and smoking cessation guidance, which are present in the reference answer."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，涵盖了MET抑制剂为首选、具体药物名称、指南依据及PD-L1状态无影响等要点，无明显遗漏或错误。"
  },
  "888": {
    "score": 3.0,
    "explanation": "3: The model answer provides a structured approach and covers most key points, but it incorrectly assigns the T stage as T3 instead of T4, leading to an incorrect overall stage (IIb instead of IIIB). This is a significant inaccuracy, though the treatment principles are otherwise appropriate."
  },
  "889": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes re-resection, appropriately discusses adjuvant radiotherapy, and reasonably mentions individualized consideration of chemotherapy. It covers all key points from the reference answer with no major omissions or errors."
  },
  "890": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key genes and PD-L1, with clear rationale and no major omissions or errors."
  },
  "891": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including the ineffectiveness of traditional EGFR-TKIs, the preferred use of platinum-based chemotherapy plus immunotherapy, and the consideration of amivantamab or mobocertinib if available. However, it omits some supportive care measures (e.g., pleural effusion management, smoking cessation) and does not explicitly mention bevacizumab as an option, which are minor but relevant details."
  },
  "892": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, detailed rationale, and a comprehensive, guideline-based treatment plan with no major omissions or errors."
  },
  "893": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, correctly recommending EGFR-TKI monotherapy (osimertinib or afatinib) and citing relevant guidelines, but it omits specific mention of supportive care for bone metastases and ongoing assessment of efficacy and tolerability, which are included in the reference answer."
  },
  "894": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key steps (病理学活检、腋窝淋巴结及全身分期评估)，并补充了影像学和辅助检查的细节，无重大遗漏或错误，内容与参考答案一致。"
  },
  "895": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, rationale for non-surgical management, concurrent chemoradiotherapy, durvalumab consolidation, and the non-recommendation of surgery. No major omissions or errors."
  },
  "896": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including systemic therapy, molecular testing, and consideration of palliative care. However, it is slightly more detailed than required and does not explicitly mention palliative local therapy for symptom relief, which is a minor omission."
  },
  "897": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, providing clear rationale against routine adjuvant therapy and detailed follow-up recommendations. However, it omits specific mention of discouraging routine FDG-PET/CT or brain MRI screening, and does not explicitly address smoking cessation and tumor rehabilitation management."
  },
  "898": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, rationale for Stage IIIA, and outlining appropriate multidisciplinary, neoadjuvant, surgical, and adjuvant treatment strategies without major omissions or errors."
  },
  "899": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，分期、治疗方案及替代方案均有详细说明，无明显遗漏或错误。"
  },
  "900": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, correctly identifying the stage and recommending HER2靶向治疗联合化疗为首选，并提及内分泌治疗作为后续维持。唯一小的遗漏是未明确提及骨改良剂的使用和绝经前女性卵巢抑制的细节。"
  },
  "901": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, MDT discussion, treatment options (including chemoradiotherapy, neoadjuvant therapy, and immunotherapy), and the rationale for each step, with no major omissions or errors."
  },
  "902": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including precise TNM staging, detailed treatment recommendations, and appropriate discussion of both surgical and non-surgical options, with no major omissions or errors."
  },
  "903": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and includes appropriate details on endocrine therapy, bone-targeted agents, and supportive care, with no major omissions or errors."
  },
  "904": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including chemotherapy, anti-HER2 therapy, radiotherapy, and the lack of need for endocrine therapy. However, it introduces options such as anthracycline-based regimens and dual-targeted therapy (pertuzumab), which are not specifically mentioned in the reference answer, and does not emphasize the platinum-based regimen as in the reference. These are minor deviations but do not constitute major omissions or errors."
  },
  "905": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "906": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (IIIA, T2a/bN2M0), the rationale for treatment selection, and the sequence of recommended therapies, including the role of chemoradiotherapy, surgery, and consolidation immunotherapy, with no major omissions or errors."
  },
  "907": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of comprehensive molecular testing (including the relevant genes and PD-L1), and outlines treatment strategies based on results. However, it is somewhat verbose, introduces minor nuances (e.g., more detailed stratification by PD-L1 level), and slightly overemphasizes the likelihood of actionable mutations in squamous cell carcinoma, which is less common, but overall contains no major omissions or errors."
  },
  "908": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including staging, differential diagnosis between metastasis and second primary, need for pathological confirmation, and appropriate treatment pathways. There are no major omissions or errors."
  },
  "909": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly identifying RET抑制剂（selpercatinib或pralsetinib）为首选一线治疗，并补充了指南依据和药物信息，无重大遗漏或错误。"
  },
  "910": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, including detailed discussion of differential diagnosis (多原发 vs. 转移) and specific surgical recommendations. However, it omits explicit mention of multidisciplinary team (MDT) discussion and alternative local therapies (如立体定向放疗) for non-surgical candidates, which are present in the reference answer."
  },
  "911": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and adds relevant, guideline-supported details (e.g., CDK4/6 inhibitors, supportive care), with no major omissions or errors."
  },
  "912": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly recommends NTRK抑制剂（larotrectinib或entrectinib） as the next step, with appropriate rationale. However, it omits mention of repotrectinib as an alternative NTRK inhibitor and does not address the scenario of progression after NTRK inhibitor use, which are included in the reference answer."
  },
  "913": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up management, including frequency, imaging, symptom assessment, and lifestyle advice. However, it introduces optional laboratory tests and immunotherapy considerations not emphasized in the reference, and the follow-up intervals after 3 years are less precisely aligned with the reference answer. Minor omissions include the explicit recommendation for low-dose non-contrast CT after 5 years and the clear statement that routine PET/CT or brain MRI is not needed unless symptomatic."
  },
  "914": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations of adjuvant chemoradiotherapy (synchronous or sequential), but it includes additional details about molecular testing and immunotherapy, which, while relevant, are not core to the immediate next step per the reference answer. There are no major omissions or errors."
  },
  "915": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and primary treatment, with appropriate mention of alternatives for special situations. No major omissions or errors are present."
  },
  "916": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable alternative (经皮穿刺消融) and references guidelines, but it omits the reference answer’s emphasis on姑息化疗为主的全身治疗 and the role of姑息放疗 or密切随访, which are more appropriate for多发性肺癌主灶进展且无法耐受根治性局部治疗的患者. The model answer also incorrectly assumes单一主灶而忽略了多发性病灶的背景。"
  },
  "917": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including indications and regimens for chemotherapy, anti-HER2 therapy, endocrine therapy, and radiotherapy, with no major omissions or errors. It even provides additional detail on treatment sequencing and drug choices, fully aligning with clinical guidelines."
  },
  "918": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate staging, rationale, and detailed standard treatment recommendations, including the option of consolidation immunotherapy. No major omissions or errors are present."
  },
  "919": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear understanding of TNM分期和鳞癌分子检测的临床要点，但对分子检测部分的推荐略显保守，未提及部分指南建议对局部晚期鳞癌也可考虑广泛分子检测以指导治疗，存在轻微遗漏。"
  },
  "920": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, clinical and imaging assessments, and supportive care. However, it suggests PET-CT and laboratory tumor markers more broadly than recommended (should be reserved for clinical suspicion), and does not explicitly state that routine brain MRI and PET-CT are not recommended without clinical indication, which are minor omissions."
  },
  "921": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including eligibility for neoadjuvant therapy, further recommended tests (HER2 confirmation, cardiac function, labs), and treatment strategy. However, it omits the recommendation for tumor marker placement for surgical localization and does not mention multidisciplinary team evaluation or sentinel lymph node biopsy planning, which are present in the reference answer."
  },
  "922": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including detailed preoperative assessments and appropriate recommendations regarding molecular and PD-L1 testing. However, it omits the need for systematic mediastinal lymph node evaluation (e.g., mediastinoscopy or EBUS), which is a significant aspect of the reference answer."
  },
  "923": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors. It accurately explains the rationale and provides appropriate recommendations for adjuvant therapy."
  },
  "924": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging modality, and additional management. However, it differs slightly in the recommended frequency and timing of CT scans and follow-up visits compared to the reference answer, and does not explicitly mention that routine PET/CT or brain MRI is not recommended unless clinically indicated. Minor omissions prevent a perfect score."
  },
  "925": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up frequency, content, and special considerations, including the higher risk due to R2 resection. However, it suggests a slightly more frequent follow-up interval (every 3–6 months vs. every 6 months) and includes additional laboratory and imaging tests not routinely recommended, which are minor deviations from the reference answer."
  },
  "926": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of KRAS G12C inhibitors, alternative options if unavailable, and appropriate exclusions. There are no major omissions or errors."
  },
  "927": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, with no major omissions or errors, and even provides additional relevant details and guideline references."
  },
  "928": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modality, and indications for brain MRI or PET/CT, with no major omissions or errors."
  },
  "929": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of clinical staging, molecular typing, and detailed next-step management, including neoadjuvant therapy, surgical considerations, adjuvant therapy, and radiotherapy, with no major omissions or errors."
  },
  "930": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including reoperation, radiotherapy, and follow-up. However, it introduces additional content (molecular testing, immunotherapy) that is not standard for Stage IB with R1 resection and not mentioned in the reference, and the follow-up intervals are slightly broader than the reference answer. Minor omissions include not specifically mentioning smoking cessation and rehabilitation advice."
  },
  "931": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了指南依据、分子检测建议及详细随访方案，内容更为详尽。"
  },
  "932": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, rationale, and management steps with no significant omissions or errors."
  },
  "933": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up frequency, content, and additional management. However, it slightly overstates the frequency (every 3–6 months vs. every 6 months in the first 2–3 years) and does not specify the preference for enhanced CT in the first 2–3 years, which are minor omissions."
  },
  "934": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing MET抑制剂一线治疗, addressing PD-L1 status, and referencing current guidelines, with no major omissions or errors."
  },
  "935": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including ROS1靶向治疗为首选、骨保护治疗、免疫/化疗的次要地位，并有详细解释和文献支持，无明显遗漏或错误。"
  },
  "936": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including re-resection as first choice, radiotherapy if surgery is not feasible, consideration of systemic therapy, and the importance of MDT and follow-up, with no major omissions or errors."
  },
  "937": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the recommendation for concurrent chemoradiation, consideration of immunotherapy maintenance, MDT evaluation, and additional molecular testing, with no major omissions or errors."
  },
  "938": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the key clinical content, including the recommendation of ROS1 TKI as first-line therapy, rationale, and guideline references. However, it omits mention of repotrectinib and ceritinib as additional ROS1 inhibitor options, which are included in the reference answer."
  },
  "939": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed TNM staging and appropriate preoperative assessments. However, it slightly overstates the need for invasive mediastinal staging in a clear-cut peripheral, early-stage (IA) case with negative PET/CT and bronchoscopy, which is not routinely required per guidelines unless there are suspicious findings. Minor staging detail (T1b vs T1c) differs from the reference but does not affect overall correctness."
  },
  "940": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based rationale, but it prioritizes osimertinib as the first-line agent, which is not explicitly listed in the reference answer (which focuses on first- and second-generation TKIs). This is a minor omission given current guidelines, but otherwise, the clinical content is accurate and comprehensive."
  },
  "941": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, providing appropriate follow-up intervals and correctly stating that routine FDG-PET/CT and brain MRI are not recommended without symptoms or evidence of recurrence. However, it includes some additional details (e.g., upper abdominal CT, tumor markers) not present in the reference and slightly differs in the timing of follow-up intervals, which are minor deviations."
  },
  "942": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, main assessments, and lifestyle advice. However, it slightly overemphasizes laboratory and tumor marker testing (which are not standard per guidelines) and does not specify that routine PET/CT or brain MRI are not recommended unless symptomatic, which are minor omissions."
  },
  "943": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it assigns stage IIIC (AJCC 8th edition), while the reference answer uses stage IIIB, which may reflect a minor discrepancy in staging conventions. Otherwise, clinical content and management are well covered."
  },
  "944": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and guideline-consistent recommendations for post-operative management, including the rationale for not recommending adjuvant therapy, detailed follow-up intervals, and additional considerations, with no major omissions or errors compared to the reference answer."
  },
  "945": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including MET抑制剂为首选、骨转移管理、对症镇痛、局部放疗、免疫/化疗为后续选择，并无重要遗漏或错误。"
  },
  "946": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且补充了指南依据和检测的临床意义，无重大遗漏或错误。"
  },
  "947": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding staging, first-line treatment, and rationale, with no major omissions or errors."
  },
  "948": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating the stage, rationale, and guideline-based recommendations, with no significant omissions or errors."
  },
  "949": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including accurate staging (IVA/M1a), appropriate targeted therapy recommendations (BRAF/MEK inhibitors), the role of chemotherapy and immunotherapy, and the necessity of PD-L1 testing. There are no major omissions or errors."
  },
  "950": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach to staging and management, but it incorrectly classifies the T stage (T3 instead of T4) and the overall stage (IIB instead of IIIB), which are significant errors. The management plan is otherwise appropriate and covers most key points."
  },
  "951": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including endocrine therapy with CDK4/6 inhibitors, ovarian suppression, bone-modifying agents, and supportive care. However, it slightly overstates the presence of \"内脏危象\"（visceral crisis） despite the case not meeting criteria, and lacks explicit mention of regular efficacy and toxicity assessment or shared decision-making with the patient."
  },
  "952": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including further imaging (MRI), surgical options, and postoperative adjuvant therapy. However, it omits mentioning the possibility of image-guided core needle biopsy for suspicious lesions and does not explicitly reference the use of clinical guidelines (e.g., NCCN), which are present in the reference answer."
  },
  "953": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including imaging frequency, follow-up content, and lifestyle advice. However, it slightly differs in the recommended intervals for years 3–5 (every 6–12 months vs. every 6 months in the reference) and does not specify the transition to low-dose non-contrast CT after year 6, which are minor omissions."
  },
  "954": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including accurate staging, rationale, and detailed, guideline-based treatment recommendations, with no major omissions or errors."
  },
  "955": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it incorrectly assigns the stage as IIA (cT2aN0M0) instead of IB, which is the correct stage for a 3.5cm tumor without nodal involvement or metastasis. Otherwise, the treatment recommendations are appropriate and comprehensive."
  },
  "956": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating the stage (IIIB), the rationale, and the recommended initial treatment (concurrent chemoradiotherapy, platinum-based regimens, and consolidation immunotherapy), with no major omissions or errors."
  },
  "957": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately covers staging, guideline recommendations, and appropriate follow-up, matching the reference in all key aspects."
  },
  "958": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key points from the reference answer, including follow-up observation, wound healing, consideration of re-biopsy if symptoms persist, and adds appropriate details about dermatology referral and symptomatic management, with no major omissions or errors."
  },
  "959": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modality, and indications for enhanced or additional imaging, with no major omissions or errors."
  },
  "960": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including maintenance therapy and the role of HER2-targeted agents. However, it omits the guideline-supported preference for immediate HER2-targeted therapy after initial chemoimmunotherapy in HER2-mutant NSCLC, as well as the need for pre-treatment cardiac assessment and close monitoring of side effects."
  },
  "961": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key aspects, including pathology, systemic and local assessment, and additional considerations like fertility. However, it omits the specific recommendation for image-guided marker placement in the primary tumor and suspicious lymph nodes, and does not explicitly mention the use of enhanced CT for chest/abdomen or the rationale for certain imaging choices."
  },
  "962": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key investigations (including molecular testing, brain MRI, and systemic assessment), accurately stages the disease, and details appropriate systemic treatment options based on molecular and PD-L1 status, with no major omissions or errors."
  },
  "963": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "964": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, main examinations, and additional considerations. However, it slightly overemphasizes laboratory and tumor marker testing (which are not routinely recommended), and the CT interval recommendations are less precise than the reference answer. Minor details about imaging modality selection and the non-routine use of PET/CT and brain MRI could be clearer."
  },
  "965": {
    "score": 4.0,
    "explanation": "4: The model answer covers almost all key points from the reference answer, including follow-up intervals, imaging modalities, and the non-routine use of FDG-PET/CT and brain MRI. However, it introduces extra detail about preoperative assessment not directly asked in the question and slightly differs in the recommended follow-up intervals, which are more frequent than the reference answer. Minor omissions include less emphasis on survivorship care and smoking intervention."
  },
  "966": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期和首选治疗方案均准确，且补充了分期依据和手术方式的细节，无重大遗漏或错误。"
  },
  "967": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including staging, further investigations, and initial systemic therapy, with no major omissions or errors. Minor differences in wording and additional details do not detract from the clinical completeness."
  },
  "968": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive and covers all the key molecular tests listed in the reference answer, including EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, HER2, NTRK, and PD-L1, and also discusses NGS and guideline references. There are no major omissions or errors."
  },
  "969": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, new adjuvant therapy with anti-HER2 agents and chemotherapy, surgical planning, post-treatment evaluation, and the rationale for omitting endocrine therapy. No major omissions or errors are present."
  },
  "970": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期影像学检查、纵隔淋巴结评估及基础评估，但未明确提及分子检测（如EGFR、ALK等驱动基因及PD-L1表达），这是制定个体化治疗的重要内容，属于轻微遗漏。"
  },
  "971": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and provides detailed rationale and options without any major omissions or errors."
  },
  "972": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major aspects of the reference answer, including local and systemic imaging, laboratory tests, and molecular pathology. However, it omits the specific mention of placing a marker clip in the tumor and axillary node during biopsy, which is a minor but important detail in the reference answer."
  },
  "973": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of neoadjuvant therapy, surgical planning, and post-operative management, but it omits the explicit recommendation for comprehensive staging (e.g., liver/kidney function, bone scan/PET-CT) before neoadjuvant therapy, which is present in the reference answer."
  },
  "974": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床分期、首选治疗策略及缓解症状措施方面内容完全一致，且补充了骨改良药物等细节，无重大遗漏或错误。"
  },
  "975": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including chemotherapy, endocrine therapy with ovarian suppression, and even mentions radiotherapy (though not a systemic therapy). It provides more detail than the reference but does not contain major omissions or errors. Minor extra details do not detract from the core content."
  },
  "976": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of the reference answer, including the preference for reoperation to achieve R0 resection, the alternative of postoperative radiotherapy if surgery is not feasible, and the need for follow-up. However, it introduces the option of adjuvant chemotherapy, which is not standard for Stage IA and is only considered in select high-risk cases, making this a minor deviation. The follow-up details are less specific than in the reference answer."
  },
  "977": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects guideline-based follow-up strategies, and correctly addresses the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "978": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the use of KRAS G12C抑制剂 as first choice, alternative options, and clinical trial participation. However, it introduces additional details (e.g., second-line chemotherapy and clinical trials) not present in the reference and does not explicitly mention best supportive care for poor PS patients, which is a minor omission."
  },
  "979": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers随访时间安排 and主要随访手段 in detail, but it slightly overemphasizes实验室检查（如肿瘤标志物）和低剂量CT，并未明确指出常规不推荐FDG-PET/CT或脑MRI，只有在怀疑复发时才考虑，这与参考答案有细微差别。"
  },
  "980": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed, up-to-date systemic treatment approach, including molecular testing and immunotherapy options, which are appropriate. However, it omits that close observation may be acceptable in select patients with minimal symptoms and slow progression, as mentioned in the reference answer."
  },
  "981": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the stage (IIIA, T4N1M0) and the main treatment approach (surgical resection with consideration of perioperative therapy). However, it introduces neoadjuvant chemotherapy as the preferred initial step, which, while guideline-supported, is not strictly required in all cases and was not specified in the reference answer. The reference answer prioritizes surgery first, with adjuvant therapy based on pathology, so this is a minor deviation."
  },
  "982": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including the recommendation for adjuvant chemoradiotherapy, alternative options based on patient tolerance, the need for MDT discussion, and consideration of patient factors. It also adds relevant guideline references and discusses immunotherapy as an emerging option, without introducing errors or major omissions."
  },
  "983": {
    "score": 3.0,
    "explanation": "3: The model answer provides a standard approach for advanced squamous cell lung cancer with immunotherapy plus chemotherapy, but it omits the current guideline-recommended first-line use of HER2-targeted therapy (fam-trastuzumab deruxtecan) for HER2-mutant cases, which is a significant omission. It also incorrectly downplays the role of HER2-targeted agents in this context."
  },
  "984": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for NTRK抑制剂、后续治疗选择、指南依据、对脑转移的疗效、以及支持治疗建议，无明显遗漏或错误。"
  },
  "985": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential points of the reference answer, including follow-up intervals, necessary examinations, and lifestyle advice. However, it introduces minor additional details (e.g., tumor markers, extended follow-up beyond 5 years) and slightly differs in CT recommendations, but these do not significantly detract from the overall accuracy."
  },
  "986": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points including the indication forSBRT/SABR, rationale, and guideline support, with no major omissions or errors."
  },
  "987": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the staging (IIIA, T2N2M0), and outlining the appropriate next steps in management, including neoadjuvant therapy, surgery, and postoperative considerations, with no major omissions or errors."
  },
  "988": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indication for neoadjuvant therapy, detailed rationale, and comprehensive pre-treatment assessments (imaging, cardiac evaluation, labs, MDT discussion). No major omissions or errors are present."
  },
  "989": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, management of complications, and lifestyle advice. However, it slightly deviates from the reference in the recommended follow-up intervals (e.g., 3–5 years every 6–12 months instead of every 6 months), and does not specifically mention the use of FDG-PET/CT for suspected recurrence or the exact imaging protocol after 5 years."
  },
  "990": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies RET抑制剂为首选，并提及具体药物及相关指南，但未详细提及骨转移的骨保护措施（如双膦酸盐/地诺单抗）和姑息支持等内容。"
  },
  "991": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and provides additional guideline-based rationale without introducing errors or major omissions."
  },
  "992": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including bone metastasis management (orthopedic intervention, radiotherapy, bone-modifying agents), EGFR-TKI as first-line systemic therapy for G719X mutation, the limited role of immunotherapy despite high PD-L1, and subsequent chemotherapy options. Minor expansions (e.g., calcium/vitamin D supplementation) do not detract from completeness."
  },
  "993": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly prioritizes ROS1靶向治疗 with crizotinib, provides rationale, and references guidelines. However, it omits mentioning other recommended ROS1抑制剂（如entrectinib、repotrectinib）和戒烟及姑息治疗等综合管理建议。"
  },
  "994": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, covering follow-up intervals, recommended imaging, and the non-routine use of PET-CT/brain MRI. However, it omits specific mention of smoking cessation counseling and comprehensive survivorship health management."
  },
  "995": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major steps, including neoadjuvant therapy, surgery, post-op therapy, and radiotherapy, but it introduces the possibility of breast-conserving surgery, which is less favored given the tumor size and nodal status per the reference answer. Minor details such as the specific recommendation for modified radical mastectomy are less emphasized."
  },
  "996": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up and management, including surveillance intervals, imaging modality, lifestyle advice, and psychological support. However, it slightly differs from the reference in the timing of follow-up (extends annual follow-up to 5 years instead of specifying a 3-year mark) and omits the explicit mention of increasing imaging frequency if abnormalities are found."
  },
  "997": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, key examinations (history, physical, chest CT), and additional considerations. However, it introduces some minor deviations (e.g., routine lab tests and tumor markers, which are not standard per guidelines) and is less explicit about not recommending PET/CT or brain MRI for asymptomatic patients, resulting in minor omissions."
  },
  "998": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including imaging modality, frequency, and additional management, but it slightly overstates the frequency of imaging (every 3–6 months vs. every 6 months in the reference) and suggests routine use of enhanced CT throughout, whereas the reference recommends non-contrast CT after 2–3 years. Minor details about PET/CT and brain MRI as non-routine are also less explicit."
  },
  "999": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the recommendation for adjuvant chemotherapy, the nuanced discussion of postoperative radiotherapy, and the consideration of molecular testing and targeted/immune therapies, with no major omissions or errors."
  },
  "1000": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the diagnosis as synchronous multiple primary lung cancers, correctly assigning the M1a (IVA) stage, and outlining appropriate individualized, surgery-based treatment strategies with consideration for patient status and multidisciplinary input. No major omissions or errors are present."
  },
  "1001": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the case, but it assigns stage IIIC (cT2aN3M0) instead of stage IIIB, which is the correct stage for T1–2, N3, M0 disease per the reference answer. Otherwise, the treatment approach is accurate and comprehensive."
  },
  "1002": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points regarding staging, surgical management, and follow-up included and no significant omissions or errors."
  },
  "1003": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, and lifestyle advice. However, it slightly overstates the frequency of follow-up (every 3–6 months vs. every 6 months in the reference) and does not explicitly mention that routine PET-CT or brain MRI are not recommended unless symptomatic, which are minor omissions."
  },
  "1004": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, including the rarity and significance of ALK rearrangement in squamous cell carcinoma, the prioritization of ALK-TKI therapy after chemotherapy progression, and the limited role of immunotherapy despite high PD-L1 expression. There are no major omissions or errors."
  },
  "1005": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering BRAF/MEK抑制剂联合治疗为首选，并补充了指南依据、替代方案及治疗前评估，无重大遗漏或错误。"
  },
  "1006": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points (TNM分期、IIIB期、不可手术、同步放化疗、巩固性免疫治疗) clearly and accurately addressed, and no major omissions or errors."
  },
  "1007": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable summary of the patient's situation and covers maintenance immunotherapy and follow-up, but it omits the key recommendation from the reference answer: to initiate HER2-targeted therapy (fam-trastuzumab deruxtecan) after chemoimmunotherapy stabilization. It also incorrectly downplays the role of HER2-targeted therapy in this context, which is a significant omission."
  },
  "1008": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemoradiotherapy, rationale, and specific regimens, but it omits the importance of multidisciplinary team evaluation, structured follow-up recommendations, and smoking cessation/rehabilitation advice, which are present in the reference answer."
  },
  "1009": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant chemoradiotherapy, necessary pre-treatment assessments, and additional molecular testing. However, it slightly overemphasizes the role of routine PET-CT/brain MRI (which the reference suggests only if symptomatic) and expands on targeted/immunotherapy, which, while evidence-based, is not strictly required per the reference answer. Minor differences in emphasis and detail prevent a perfect score."
  },
  "1010": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of treatment options and acknowledges the presence of an EGFR G719X mutation, but it incorrectly states that EGFR-TKI is not recommended as first-line therapy in this context, which contradicts current guidelines for rare EGFR mutations in squamous NSCLC. It omits that EGFR-TKI can be considered first-line per NCCN/CSCO and overemphasizes chemo-immunotherapy, leading to partial but not complete or fully accurate coverage."
  },
  "1011": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key elements of follow-up frequency, imaging, clinical assessment, and lifestyle advice. However, it suggests a slightly more frequent follow-up interval (every 3–6 months) than the reference (every 6 months), and includes optional use of other imaging modalities and tumor markers, which are not routinely recommended. Minor differences in detail, but no major omissions."
  },
  "1012": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemoradiotherapy (with details on sequence and regimen), but it adds content on targeted/immune therapy that is not standard in this context and omits specific follow-up recommendations and imaging modalities mentioned in the reference answer."
  },
  "1013": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical steps, including neoadjuvant therapy with HER2-targeted agents, surgical planning, post-operative adjuvant therapy, and radiotherapy, with no major omissions or errors. It is highly detailed and aligns closely with the reference answer."
  },
  "1014": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical stage and main treatment recommendations, including the rationale for preferring concurrent chemoradiotherapy and mentioning consolidation immunotherapy. However, it omits the specific mention of EGFR mutation testing and the potential use of osimertinib as adjuvant therapy, which is present in the reference answer."
  },
  "1015": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including precise staging, preoperative assessment, surgical recommendations, postoperative adjuvant therapy, and alternatives for non-surgical candidates, with no major omissions or errors."
  },
  "1016": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points covered, including precise staging, MDT discussion, concurrent chemoradiotherapy, molecular testing, and consolidation immunotherapy, with no major omissions or errors."
  },
  "1017": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including staging, surgical approach, and adjuvant therapy. However, it omits the need for术前脑MRI和纵隔淋巴结病理评估 to rule out occult metastasis, which are important steps in the reference answer."
  },
  "1018": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately details the clinical stage (IIIB, T2N3M0), outlines the standard management (synchronous chemoradiotherapy, assessment of operability, and consideration of immunotherapy), and even adds appropriate details about molecular testing, with no major omissions or errors."
  },
  "1019": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed reasoning, but it incorrectly stages the tumor as IIA instead of IB, which leads to a slightly more aggressive recommendation for adjuvant chemotherapy. Otherwise, the follow-up plan and discussion of adjuvant therapy are appropriate and well-supported."
  },
  "1020": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up frequency and content, including history, physical exam, and chest CT. It adds some extra details (e.g., 5-year follow-up, optional tests based on symptoms) but slightly overemphasizes additional imaging and tumor markers, which are not routinely recommended, and does not explicitly state that routine PET/CT or brain MRI are unnecessary. Minor omissions and slight over-inclusiveness prevent a perfect score."
  },
  "1021": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在随访频率和检查项目上内容一致，涵盖了病史、体格检查、胸部CT的具体时间节点，并明确指出不推荐常规PET-CT或脑MRI，无明显遗漏或错误。"
  },
  "1022": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and treatment strategy with no major omissions or errors."
  },
  "1023": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes appropriate recommendations for management and follow-up, with no major omissions or errors."
  },
  "1024": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key management steps, including reoperation, consideration of radiotherapy, and not recommending adjuvant chemotherapy. However, it omits specific details about the recommended imaging modality (如低剂量无增强胸CT vs.增强CT)和随访时间点的精确性，以及戒烟干预和幸存者管理等内容。"
  },
  "1025": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期、影像学、实验室、病理复核、治疗建议等关键内容，但略有遗漏如全外显子/基因组检测、遗传咨询、多学科团队讨论等细节。整体内容与参考答案高度一致，仅有少量细节未及。"
  },
  "1026": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了辅助放化疗、顺序、随访及免疫治疗等要点，无重大遗漏或错误，内容更为详细但无偏离核心指导。"
  },
  "1027": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including staging, treatment recommendations, and the need for molecular testing. However, it assigns stage IIIC (cT1cN3M0) instead of IIIB, which is a minor discrepancy based on the AJCC 8th edition, but otherwise the clinical content is accurate and comprehensive."
  },
  "1028": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering diagnosis, rationale, and recommended first-line therapy, with no major omissions or errors."
  },
  "1029": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，分期判断准确，检查和治疗建议全面，涵盖分子检测、功能评估、同步放化疗及免疫巩固等要点，无明显遗漏或错误。"
  },
  "1030": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical resection (lobectomy) with systematic lymph node dissection, and appropriately mentioning alternatives for patients unable to tolerate surgery. No major omissions or errors."
  },
  "1031": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including adjuvant chemotherapy, consideration of radiotherapy, detailed follow-up intervals and modalities, smoking cessation, and survivorship care, with additional up-to-date options (targeted/immune therapy) and practical details. No major omissions or errors."
  },
  "1032": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying stage IIIB (T any, N3, M0), recommending concurrent chemoradiotherapy, and appropriately adding the current standard of care with durvalumab consolidation, with no major omissions or errors."
  },
  "1033": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the clinical stage, surgical recommendation, and rationale. However, it omits the option of解剖性肺段切除 (anatomical segmentectomy) as an alternative to lobectomy for small, peripheral tumors, which is mentioned in the reference answer."
  },
  "1034": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes EGFR-TKI (afatinib) as first-line therapy, and correctly addresses the limited role of immunotherapy and chemotherapy, fully aligning with the reference answer and current guidelines."
  },
  "1035": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, but it incorrectly states the stage as IIA instead of IIB (per AJCC 8th edition for T2aN1M0). Otherwise, the clinical content and treatment recommendations are accurate and thorough."
  },
  "1036": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps: MRI for occult lesions, central excision, and adjuvant radiotherapy. However, it omits the option of sentinel lymph node biopsy (SLNB) as a consideration, which is mentioned in the reference answer, and does not reference NCCN guidelines for radiotherapy decision-making."
  },
  "1037": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, but it overstates the necessity of preoperative breast MRI (建议行乳腺MRI检查), whereas the reference answer states MRI is optional and not mandatory in this case. Otherwise, the systemic and laboratory assessments are well covered."
  },
  "1038": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, imaging recommendations, and the indications for brain MRI and FDG-PET/CT, with no major omissions or errors."
  },
  "1039": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, standard surgical treatment, the role of lymph node dissection, the lack of need for adjuvant therapy in the absence of high-risk features, and follow-up. No major omissions or errors."
  },
  "1040": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed staging (even referencing AJCC 8th edition), appropriate treatment recommendations, and additional considerations such as molecular testing and MDT discussion. However, it slightly over-specifies the stage as IIIC (AJCC 8th), while the reference answer uses IIIB, and includes more detail than required, but no major clinical errors or omissions are present."
  },
  "1041": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, rationale, surgical recommendation, preoperative assessment, and postoperative considerations, with no major omissions or errors."
  },
  "1042": {
    "score": 4.0,
    "explanation": "4: The model answer covers most key points, including cardiac function, laboratory tests, imaging, and patient assessment, but omits specific mention of placing marker clips in the tumor and lymph nodes, and does not detail the need for image-guided biopsy of suspicious lymph nodes. Minor details such as the exact imaging modalities and rationale for each are less explicit."
  },
  "1043": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including the recommendation for adjuvant chemoradiotherapy, details on sequencing, drug choice, and follow-up, and even adds relevant updates on immunotherapy, with no major omissions or errors."
  },
  "1044": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly recommends dabrafenib plus trametinib as the next-line therapy, referencing guidelines and providing rationale. However, it omits mentioning encorafenib plus binimetinib as an alternative, which is included in the reference answer."
  },
  "1045": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、手术方案、辅助治疗指征及随访，无重大遗漏或错误。"
  },
  "1046": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, lack of actionable mutations, PD-L1 status, and the recommendation for platinum-based chemotherapy combined with immunotherapy as first-line treatment, with alternatives and rationale clearly stated."
  },
  "1047": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient background, rationale, recommended immunotherapy agents, and relevant guidelines, with no major omissions or errors."
  },
  "1048": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, treatment recommendations (synchronous chemoradiotherapy as first choice, consolidation immunotherapy with durvalumab), and the rationale for not recommending surgery. No major omissions or errors are present."
  },
  "1049": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the priority of re-resection, the role of adjuvant radiotherapy if reoperation is not feasible, and the individualized consideration of systemic therapy in the context of high-risk features such as positive margins. No major omissions or errors are present."
  },
  "1050": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly prioritizing EGFR-TKI therapy (especially second-generation agents) and de-emphasizing immunotherapy despite PD-L1 positivity. However, it slightly underplays the potential use of osimertinib (which is also considered in guidelines) and overstates the limited activity of third-generation TKIs for G719X, which is a minor omission."
  },
  "1051": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, further assessment, and treatment planning. However, it omits specific recommendations for脑MRI和纵隔病理分期（如EBUS/纵隔镜），并对分期有轻微不准确（IIIB而非IIIa），因此扣一分。"
  },
  "1052": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, with no major omissions or errors. It even adds relevant details such as cardiac function assessment and genetic counseling, which are appropriate and do not detract from the core answer."
  },
  "1053": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects current guidelines, clearly recommending dabrafenib plus trametinib as first-line therapy and appropriately discussing alternatives. However, it omits mentioning encorafenib plus binimetinib as another guideline-endorsed option, which is included in the reference answer."
  },
  "1054": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging (chest CT), avoidance of routine PET-CT/brain MRI unless symptomatic, and additional considerations such as smoking cessation and survivorship care. No major omissions or errors are present."
  },
  "1055": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers the rationale for EGFR-TKI selection, prioritizes afatinib, mentions osimertinib, and addresses practical considerations, with no major omissions or errors compared to the reference answer."
  },
  "1056": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed reasoning and appropriate treatment recommendations. However, it assigns the stage as IA3 (cT1cN0M0), while the reference answer gives IIB, which is a minor discrepancy likely due to different interpretations of staging criteria, but the rest of the content is correct and thorough."
  },
  "1057": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including accurate staging, consideration of differential diagnosis, detailed treatment strategies (systemic therapy, molecular testing, MDT/local therapy), and aligns closely with the reference answer without major omissions or errors."
  },
  "1058": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including accurate staging, detailed rationale, appropriate first-line systemic therapy, and necessary molecular testing, with no major omissions or errors. The answer is comprehensive and aligns closely with the reference answer."
  },
  "1059": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including the rationale for further surgery, chemoradiotherapy, and the importance of MDT discussion, and even expands on targeted and immunotherapy options. There are no major omissions or errors."
  },
  "1060": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach to staging and treatment, but it contains inaccuracies regarding the T stage (T3 vs. T4) for same-side, different-lobe nodules and omits the need for纵隔淋巴结病理学评估. It also does not fully address the multidisciplinary discussion or the specifics of neoadjuvant/concurrent therapy options."
  },
  "1061": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the clinical scenario, including risk stratification and management options. However, it introduces the >5mm solid component threshold (rather than the ≥6mm in the reference) and emphasizes surgical intervention more than the reference, which prioritizes imaging follow-up unless there is growth or a solid component ≥6mm. Minor guideline threshold discrepancies prevent a perfect score."
  },
  "1062": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、IIIB期、不可手术、同步放化疗及后续免疫治疗，无明显遗漏或错误。"
  },
  "1063": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, molecular findings, PD-L1 status, and the rationale for chemo-immunotherapy as first-line treatment, with correct mention of KRAS G12C inhibitors as later-line options. No major omissions or errors."
  },
  "1064": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major aspects of the reference answer, including骨科评估、放疗、分子检测、全身治疗、骨改良药物等，但在生活方式干预（如戒烟）和姑息治疗的整合方面略有遗漏。"
  },
  "1065": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and treatment, including surgical options, sentinel lymph node biopsy, and adjuvant therapy considerations. However, it omits the recommendation for preoperative breast MRI (if imaging is unclear or multifocality suspected) and does not mention axillary ultrasound or the use of clip placement for suspicious nodes, which are present in the reference answer."
  },
  "1066": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the standard adjuvant therapy and follow-up recommendations, including chemotherapy, consideration of targeted/immunotherapy, detailed follow-up intervals, and supportive care, with no major omissions or errors."
  },
  "1067": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, recommended regimens, and guideline references, with no major omissions or errors."
  },
  "1068": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately recommending chemo-immunotherapy as first-line and correctly noting the limited evidence for HER2-targeted therapy in squamous cell carcinoma, but it adds some extra detail and minor clarifications not present in the reference answer. There are no major omissions, but the answer could be more concise."
  },
  "1069": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including tumor size, HER2 status, lymph node status, guideline recommendations, and rationale for adjuvant chemotherapy plus trastuzumab, with no major omissions or errors."
  },
  "1070": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗方案、手术及辅助治疗均有详细阐述，无明显遗漏或错误。"
  },
  "1071": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of endocrine therapy with CDK4/6 inhibitors, assessment of menopausal status, and monitoring. However, it omits the recommendation for biopsy of metastatic lesions to reassess receptor status and gene testing, which are present in the reference answer."
  },
  "1072": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including staging, surgical recommendation, and adjuvant therapy options. However, it assigns stage IIB (cT3N0M0) rather than stage IIIA, which is a minor but notable discrepancy given the reference answer's interpretation. Otherwise, the clinical content is thorough and accurate."
  },
  "1073": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including timing, content, and special considerations for R2 resection. However, it suggests a slightly more frequent follow-up interval (every 3–6 months in the first 2 years) than the reference answer (every 6 months), and includes additional details not specified in the reference, which, while not incorrect, are minor deviations."
  },
  "1074": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为完整，详细阐述了术后放疗、辅助化疗及免疫治疗的适应证，并强调了多学科讨论，但未将“再次手术以获得阴性切缘”作为首选，略有次序和重点上的偏差。"
  },
  "1075": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including synchronous chemoradiotherapy, pre-treatment assessment, molecular and PD-L1 testing, and consolidation immunotherapy with durvalumab, with no major omissions or errors."
  },
  "1076": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendation, lymph node dissection, and adjuvant therapy, with no major omissions or errors."
  },
  "1077": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and even provides additional context and rationale without introducing errors or omissions."
  },
  "1078": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers the recommended follow-up intervals, necessary examinations, and the indications for PET/CT and brain MRI, with no significant omissions or errors compared to the reference answer."
  },
  "1079": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indication for neoadjuvant therapy, clinical staging, and a comprehensive preoperative assessment plan, with no major omissions or errors."
  },
  "1080": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of staging and preoperative assessment as in the reference answer, including PET-CT, brain MRI, mediastinal lymph node evaluation, pulmonary function tests, and additional relevant preoperative workup, with no major omissions or errors."
  },
  "1081": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of actionable mutations, PD-L1 status, first-line platinum-based chemotherapy, the role and rationale for immunotherapy, and considerations for patient-specific factors. No major omissions or errors are present."
  },
  "1082": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细列举了推荐药物及其代际优势，无明显遗漏或错误。"
  },
  "1083": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional guideline-based rationale without any major omissions or errors."
  },
  "1084": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访时间表、内容、影像学检查、生活方式管理等要点，但对第4年起低剂量CT的具体推荐、PET-CT和脑MRI常规不推荐的表述略有不够明确，存在轻微细节遗漏。"
  },
  "1085": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and imaging modalities. However, it slightly differs in the recommended intervals (e.g., 2 vs. 3 years for the most frequent follow-up), and does not explicitly mention the non-recommendation of routine PET/CT or brain MRI unless symptomatic, which is a minor omission."
  },
  "1086": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prioritization of NTRK inhibitors, rationale, alternative options, and the need for ongoing assessment and supportive care, with no major omissions or errors."
  },
  "1087": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (cT1cN0M0, IA3), appropriate surgical management, and alternative options, with no major omissions or errors."
  },
  "1088": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of MET抑制剂、骨保护治疗、免疫治疗和化疗的排序，并无重大遗漏或错误。"
  },
  "1089": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including first-line NTRK inhibitor therapy, alternative options, and rationale, with no major omissions or errors."
  },
  "1090": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of local and adjuvant systemic therapy, including surgical options, radiotherapy, chemotherapy, and anti-HER2 therapy. However, it introduces some additional details (e.g., mastectomy as an option, mention of pertuzumab) and nuances not present in the reference answer, which, while accurate, slightly diverge from the concise focus of the reference. No major omissions or errors are present."
  },
  "1091": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management steps (re-resection if feasible, adjuvant radiotherapy if not, and adjuvant chemotherapy), and even provides clear rationale and guideline references. No major omissions or errors are present."
  },
  "1092": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear understanding of the staging and treatment approach, but it incorrectly assigns the stage as IIIB instead of IIIA and omits mention of consolidation immunotherapy (Durvalumab) and targeted therapy for EGFR mutations, which are important details in the reference answer."
  },
  "1093": {
    "score": 3.0,
    "explanation": "3: The model answer covers the main points of clinical staging and the role of bronchoscopy, but it incorrectly classifies the T stage as T1c (should be T1b for 2.1cm per AJCC 8th edition), and overstates the necessity of preoperative bronchoscopy, missing the nuance that it is not mandatory for peripheral lesions without central involvement."
  },
  "1094": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, molecular findings, PD-L1 status, and the recommended first-line systemic therapy, with no significant omissions or errors."
  },
  "1095": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and includes appropriate follow-up intervals, imaging recommendations, and supportive care advice, with no major omissions or errors."
  },
  "1096": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it provides a slightly broader follow-up interval (every 3–6 months vs. every 6 months) and extends the follow-up schedule to 5 years before annual visits, which is a minor deviation. All key clinical points are covered, with no major omissions."
  },
  "1097": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging and treatment, but there is a minor inaccuracy in the TNM staging (should be Stage IB, not IA2/IIA for a 4.0 cm tumor per AJCC 8th edition). Otherwise, the management plan is appropriate and matches the reference answer."
  },
  "1098": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including MDT评估、同步放化疗、免疫巩固治疗和手术的严格筛选，但对新辅助治疗后手术的适应证描述略显保守，未充分强调新辅助治疗后手术作为可选方案的地位，且对“新辅助免疫治疗”提及不够。"
  },
  "1099": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including detailed TNM分期、完善评估项目和分子检测的必要性，但分期为ⅢC期（应为ⅢB期），且部分细节如分子检测基因列表略有简化，存在轻微分歧。"
  },
  "1100": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate staging, details the rationale for IA3 (T1cN0M0), and outlines appropriate surgical, adjuvant, and alternative treatments, as well as follow-up, with no major omissions or errors compared to the reference answer."
  },
  "1101": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points, and includes appropriate rationale for chemoradiotherapy, molecular, and PD-L1 testing, with no major omissions or errors."
  },
  "1102": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major points, including纵隔淋巴结分期、远处转移评估、肺功能和心脏功能评估等，但对胸壁受累的进一步影像学评估（如胸壁MRI）和支气管镜术前复查的强调略有不足。"
  },
  "1103": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendation of HER2-targeted ADC therapy (trastuzumab deruxtecan) as first choice, and mentions alternatives and supportive care. However, it omits ado-trastuzumab emtansine as a recommended alternative, which is specifically mentioned in the reference answer."
  },
  "1104": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately identifies afatinib as the first-line treatment for EGFR G719X mutation, and correctly discusses the roles of immunotherapy and chemotherapy, matching the reference answer with no major omissions or errors."
  },
  "1105": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of postoperative management and follow-up, including the lack of routine adjuvant therapy, follow-up intervals, and lifestyle advice. However, it omits the specific recommendation against routine PET/CT or brain MRI in the absence of symptoms and is slightly less concise regarding follow-up imaging modalities."
  },
  "1106": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies dabrafenib plus trametinib as the first-line treatment, referencing guidelines and providing rationale. However, it omits the alternative option of encorafenib plus binimetinib, which is included in the reference answer."
  },
  "1107": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and matches the reference answer in all key aspects, including分期,分子检测,治疗决策,骨转移处理,和支持治疗, with no major omissions or errors."
  },
  "1108": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗方案及替代方案均有详细说明，无重大遗漏或错误。"
  },
  "1109": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including re-resection as first choice, PORT as an alternative, and the possibility of adjuvant chemotherapy. The follow-up schedule is detailed and appropriate, but it omits explicit mention of smoking cessation counseling and the use of PET/CT and brain MRI specifically for suspected recurrence, which are present in the reference answer."
  },
  "1110": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant radiotherapy for R1 resection, consideration of adjuvant chemotherapy, and appropriate follow-up. However, it omits the option of re-operation to achieve negative margins, which is mentioned as the first choice in the reference answer."
  },
  "1111": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes second-generation ALK-TKIs over first-generation, correctly de-emphasizes immunotherapy and chemotherapy, and provides up-to-date guideline references. No major omissions or errors are present."
  },
  "1112": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including EGFR-TKI as first-line therapy, bone-targeted agents, orthopedic/radiation interventions, pain and supportive care, and regular monitoring, with no major omissions or errors."
  },
  "1113": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including the need for pathological mediastinal lymph node assessment, specific methods (EBUS-TBNA, mediastinoscopy), MDT discussion, treatment options based on N2 status, and the need for molecular/PD-L1 testing. There are no major omissions or errors."
  },
  "1114": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the indication for adjuvant therapy, high-risk factors, and a detailed, guideline-based follow-up schedule, with no major omissions or errors."
  },
  "1115": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging, detailed rationale, and a comprehensive discussion of treatment options, including MDT evaluation, chemoradiotherapy, and immunotherapy, with no major omissions or errors."
  },
  "1116": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including broad molecular testing, PD-L1 assessment, and treatment decisions based on results. It provides more detail on testing methods and specific regimens, but omits explicit mention of smoking cessation and palliative care, which are present in the reference answer."
  },
  "1117": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, the use of chest CT, and recommendations against routine brain MRI or PET/CT. However, it slightly differs in the timing of follow-up intervals and omits the explicit mention of low-dose non-contrast CT after 3 years, as well as the specific recommendation for annual physical exams after 5 years."
  },
  "1118": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of assessment and treatment, including MDT discussion, preoperative evaluation, surgical approach, adjuvant therapy, and alternatives if surgery is not feasible, with no major omissions or errors. It also incorporates up-to-date recommendations on molecular testing and adjuvant targeted/immunotherapy, which are appropriate additions."
  },
  "1119": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up intervals, content of follow-up, and lifestyle advice. However, it omits the specific recommendation that after 2–3 years, only low-dose non-contrast chest CT is needed, and it does not explicitly state that routine FDG-PET/CT or brain MRI are not recommended unless indicated."
  },
  "1120": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including the need for adjuvant chemotherapy and radiotherapy, and correctly excludes endocrine and HER2-targeted therapy. It adds minor extra details (e.g., BRCA testing and clinical trials), but does not explicitly mention the need for standardized follow-up, which is a minor omission."
  },
  "1121": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps in staging and treatment, including PET-CT, bronchoscopy, surgical options, and post-op management. However, it introduces some extra details (e.g., wedge resection, segmentectomy, and post-op management) and slightly overemphasizes preoperative biopsy, which are not strictly necessary per the reference answer, but does not omit any major clinical content."
  },
  "1122": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main recommendations, but it suggests a 6–12 month interval for CT in years 3–5, whereas the reference answer recommends annual (every 12 months) CT from year 3 onward. This is a minor deviation from the reference standard."
  },
  "1123": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including随访时间表,内容,健康管理, and复发监测, but it introduces some minor deviations (如实验室检查、靶向/免疫治疗讨论)且随访时间安排与参考答案略有不同，未明确强调不推荐常规PET/CT或脑MRI。整体内容较为全面，只有细节上的小遗漏。"
  },
  "1124": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding staging, the rationale for IIIB/IIIC classification, and the recommended comprehensive molecular and PD-L1 testing, with no major omissions or errors."
  },
  "1125": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer and adds appropriate guideline-based discussion about the adequacy of wedge resection versus lobectomy, which is relevant and accurate. There are no major omissions or errors."
  },
  "1126": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of adjuvant therapy and follow-up, including chemotherapy regimens, timing, consideration of targeted and immunotherapy based on molecular markers, and detailed follow-up schedules. It also references current guidelines and includes additional relevant details, with no major omissions or errors."
  },
  "1127": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of lymph node assessment, systemic workup, and treatment planning, with appropriate detail. However, it omits some minor details such as the need for tumor marker placement before neoadjuvant therapy and does not mention breast MRI for further lesion assessment, which are present in the reference answer."
  },
  "1128": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, but it extends annual follow-up to 5 years (rather than switching to low-dose CT after 2–3 years) and does not explicitly mention low-dose non-contrast CT as an option. Minor differences in timing and imaging modality are present, but overall clinical content is accurate."
  },
  "1129": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately recommending osimertinib as first-line therapy and providing appropriate rationale and guideline references, with no major omissions or errors."
  },
  "1130": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points including the specific targeted therapy, rationale, and supporting evidence, with no major omissions or errors."
  },
  "1131": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable management plan and references guidelines, but it incorrectly recommends routine follow-up CT for a <6mm pure ground-glass nodule, whereas current guidelines generally do not recommend routine follow-up in such low-risk cases. This represents a significant omission and inaccuracy compared to the reference answer."
  },
  "1132": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed reasoning and correct staging (cT3N0M0, IIb期) and appropriate treatment recommendations. However, it does not explicitly mention the possibility of N1 disease in the initial staging (only assumes N0), and does not discuss the scenario of IIIA期（T3N1）如参考答案所述，略有细微遗漏。"
  },
  "1133": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses both ALK靶向治疗 and骨相关药物, and includes appropriate rationale for not using immunotherapy as first-line. It covers all key points from the reference answer with no major omissions or errors."
  },
  "1134": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately references guidelines, explains the rationale, and provides a recommended regimen, with no major omissions or errors."
  },
  "1135": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, molecular testing, and treatment recommendations in detail, with no major omissions or errors."
  },
  "1136": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering RET抑制剂为首选、化疗/免疫治疗为备选、骨保护及对症支持治疗，无重大遗漏或错误。"
  },
  "1137": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the diagnosis of multiple primary lung cancers, appropriate staging, preoperative assessment, surgical options, and postoperative management, with no major omissions or errors."
  },
  "1138": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, alternatives for high-risk or inoperable patients, and the lack of need for further mediastinal evaluation or adjuvant therapy. No major omissions or errors."
  },
  "1139": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上完全一致，涵盖了R1切缘后推荐的再次手术、辅助放疗及完成化疗等要点，无重大遗漏或错误，并补充了指南依据。"
  },
  "1140": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately lists all recommended molecular tests (including PD-L1, EGFR, ALK, ROS1, BRAF, METex14, RET, NTRK, HER2), and clearly explains their significance for systemic therapy selection, with no major omissions or errors."
  },
  "1141": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including follow-up intervals, imaging modality, clinical assessment, and the indications for PET-CT and brain MRI, with no major omissions or errors."
  },
  "1142": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the stage and provides a comprehensive treatment plan, but it overemphasizes systemic therapy as the standard, whereas the reference answer highlights the possibility of treating as synchronous primary tumors with curative local therapy if feasible. Minor omissions regarding the guideline-based approach to dual primaries account for the deduction."
  },
  "1143": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient selection for SRS, indications for WBRT, and guideline recommendations, with no major omissions or errors."
  },
  "1144": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations of adjuvant chemotherapy and postoperative radiotherapy for R1 resection in stage IIB NSCLC. However, it omits the option of concurrent chemoradiotherapy (synchronous), which is preferred if the patient is fit, and does not mention the recommended follow-up strategy. The inclusion of immunotherapy is a minor addition but not a major error."
  },
  "1145": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the non-routine use of FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1146": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the standard follow-up for post-resection NSCLC, including frequency, imaging, and supportive care. However, it slightly overcomplicates the follow-up intervals and adds details (e.g., lab tests, broader imaging) not emphasized in the reference, and does not specify the exact transition to annual follow-up after 3 years as clearly as the reference answer."
  },
  "1147": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, and the lack of indication for routine brain MRI or PET/CT, with no major omissions or errors."
  },
  "1148": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it allows for a 6–12 month interval (rather than strictly every 6 months) in years 3–5 and does not explicitly mention the use of non-contrast CT after 3 years. Minor details such as the explicit exclusion of brain MRI are also omitted."
  },
  "1149": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers both bone metastasis management and systemic therapy, including bone-modifying agents, local treatments, and appropriate systemic options. However, it contains minor omissions, such as not explicitly mentioning early integration of palliative care and smoking cessation interventions."
  },
  "1150": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, imaging modality, avoidance of unnecessary tests, and survivorship care, with no major omissions or errors."
  },
  "1151": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses surgical, adjuvant, and follow-up management, and includes all key recommendations from the reference answer without major omissions or errors."
  },
  "1152": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, content, and smoking cessation advice. However, it slightly deviates from the reference answer regarding the timing and frequency of chest CT (suggesting every 6–12 months rather than strictly every 3–6 months in the first 3 years), and includes optional tumor markers and additional management points not emphasized in the reference, which are minor differences."
  },
  "1153": {
    "score": 4.0,
    "explanation": "4: 模型答案内容非常全面，涵盖了辅助治疗和随访计划，并补充了靶向和免疫治疗的最新进展，但对“可选择仅观察”的选项强调不足，且随访时间表与参考答案略有差异。整体为小的细节性遗漏。"
  },
  "1154": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it differs from the reference answer by classifying the N stage as N3 based on imaging rather than the negative biopsy, leading to a IIIB rather than IIIA stage. This is a minor but important difference in clinical staging and subsequent management."
  },
  "1155": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, EGFR-TKI selection (including both afatinib and osimertinib), bone-targeted therapy, and symptom management, with no major omissions or errors."
  },
  "1156": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the option of adjuvant chemotherapy and detailed follow-up recommendations. However, it overemphasizes recommending adjuvant chemotherapy as a standard rather than an option, and includes some minor deviations (e.g., more frequent follow-up intervals, mention of tumor markers and abdominal imaging not in the reference answer), but overall clinical content is accurate."
  },
  "1157": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging (IVB/M1b) and local treatment options (SRS or surgery), with appropriate rationale and no significant omissions or errors."
  },
  "1158": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the recommended treatment options, including adjuvant chemoradiotherapy, details on PORT, chemotherapy regimens, consideration of immunotherapy, and MDT evaluation, fully aligning with the reference answer and current guidelines."
  },
  "1159": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and clinical assessment. However, it slightly differs in the timing of follow-up intervals (first 2 years vs. first 3 years), and does not explicitly state that routine FDG-PET/CT or brain MRI are not recommended unless clinically indicated, which is a minor omission."
  },
  "1160": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key points from the reference answer, and adds appropriate detail on imaging, surgical options, and adjuvant therapy, with no major omissions or errors."
  },
  "1161": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of actionable mutations, low PD-L1, ECOG status, and the recommendation for platinum-based chemotherapy plus immunotherapy, with appropriate regimen examples and guideline references. No major omissions or errors."
  },
  "1162": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the need to distinguish between multiple primary lung cancers and metastasis, the importance of left lung biopsy, and the possible staging scenarios. However, it omits a direct statement that, per AJCC 8th edition, the default clinical stage is IVa (cT1bN0M1a) if the left nodule is considered metastasis, and lacks explicit mention of NCCN recommendations regarding potentially curative treatment for both lesions."
  },
  "1163": {
    "score": 4.0,
    "explanation": "4: The model answer is very thorough and accurate, but incorrectly assigns the stage as IA2 instead of IB (for T2aN0M0, which is IB per AJCC 8th edition). Otherwise, it covers all key points and provides detailed rationale and alternatives."
  },
  "1164": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential clinical content, including staging, rationale, and standard treatment. However, it omits the specific mention of molecular testing and the option of osimertinib for EGFR mutations, which is a minor but relevant detail."
  },
  "1165": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including correct staging, the need for pulmonary and cardiac function assessment, and MDT discussion. However, it omits the specific recommendation for纵隔淋巴结病理学评估 (e.g., EBUS-TBNA or mediastinoscopy) to rule out occult nodal metastasis, which is a minor but important omission."
  },
  "1166": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、手术方式、术后处理及随访建议均无遗漏或错误，且分期更精确地注明为IA2期，内容详实。"
  },
  "1167": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including standard concurrent chemoradiotherapy, the role of durvalumab consolidation, consideration of EGFR mutations for targeted therapy, and appropriate follow-up. There are no major omissions or errors."
  },
  "1168": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps of axillary assessment and surgical planning, including the use of SLNB and criteria for further management. However, it omits the specific recommendation for preoperative axillary ultrasound and the detailed management if 1–2 sentinel nodes are positive, as highlighted in the reference answer."
  },
  "1169": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of current guidelines, but it overemphasizes标准治疗为免疫联合化疗而对HER2靶向治疗的可选性描述略显保守，未充分体现参考答案中“可及时优先考虑HER2靶向药物”的建议，属于细微差异。骨转移处理和综合管理均有覆盖。"
  },
  "1170": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up intervals, imaging, and lifestyle advice, but it slightly overstates the frequency of imaging (every visit) and omits the explicit recommendation against routine PET/CT or brain MRI, which is present in the reference answer."
  },
  "1171": {
    "score": 5.0,
    "explanation": "5: The model answer covers all the required molecular tests listed in the reference answer, includes additional relevant details (such as KRAS), and provides appropriate clinical context without any major omissions or errors."
  },
  "1172": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main treatment options, including breast-conserving surgery, mastectomy, and adjuvant radiotherapy. However, it omits the recommendation for sentinel lymph node biopsy, which is advised in the reference answer, and slightly overstates that axillary management is generally unnecessary."
  },
  "1173": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately describes the staging and appropriate treatment recommendations, including the role of chemoradiotherapy and immunotherapy. However, it omits the recommendation for further staging with brain MRI and pulmonary function tests, which are important minor details included in the reference answer."
  },
  "1174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including pathology review, comprehensive imaging, laboratory tests, and detailed molecular testing recommendations, with no major omissions or errors."
  },
  "1175": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including accurate staging, detailed rationale for neoadjuvant therapy, specific chemotherapy and HER2-targeted regimens, surgical considerations, and postoperative management, with no major omissions or errors."
  },
  "1176": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including follow-up intervals, recommended examinations, and the lack of need for routine additional imaging or tumor markers. No major omissions or errors are present."
  },
  "1177": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including mediastinal lymph node pathological assessment, brain MRI, and additional preoperative evaluations, with no major omissions or errors. It even provides further clinical reasoning and detail, fully aligning with the reference content."
  },
  "1178": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, providing detailed follow-up intervals, imaging recommendations, and clear statements against routine PET/CT or brain MRI. However, it introduces more granular follow-up intervals and additional details (e.g., lab tests, X-ray), which, while accurate, slightly diverge from the reference's more concise recommendations. No major omissions or errors are present."
  },
  "1179": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the clinical content, matching the reference answer in all key aspects, including indications, rationale, and recommended radiotherapy fields, with no major omissions or errors."
  },
  "1180": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、分期结论、首选同步放化疗及免疫巩固治疗，无遗漏或错误。"
  },
  "1181": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding selective use of preoperative brain MRI and individualized consideration of adjuvant therapy in Stage IB NSCLC, with no major omissions or errors."
  },
  "1182": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy and follow-up, with additional details on targeted and immunotherapy, but slightly overextends beyond the reference answer and omits the specific follow-up interval adjustment if new imaging abnormalities are found."
  },
  "1183": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, and supportive care. However, it slightly differs in the timing of interval changes (splitting 2 vs. 3 years for 3–6 month intervals) and omits the specific recommendation for annual low-dose non-contrast CT after 5 years, as well as not explicitly mentioning the need for more frequent follow-up based on imaging changes or symptoms."
  },
  "1184": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including second-line endocrine plus targeted therapy options, the rationale for gene testing (PIK3CA, BRCA, ESR1), and the indications for chemotherapy. There are no major omissions or errors."
  },
  "1185": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，涵盖了随访频率、检查方式及PET/CT和脑MRI的适应症，无明显遗漏或错误。"
  },
  "1186": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of follow-up frequency, imaging modality, and indications for further imaging, but it slightly overstates the frequency of follow-up and imaging compared to the reference answer and does not specify the use of enhanced CT in the first 2–3 years. Minor details such as explicit mention of cancer survivorship care are also less emphasized."
  },
  "1187": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging, physical exams, and smoking cessation. However, it slightly overemphasizes laboratory tests (which are not routinely recommended) and does not explicitly mention that routine PET/CT or brain MRI are not recommended unless symptoms arise, which is a minor omission."
  },
  "1188": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including staging, multidisciplinary evaluation, neoadjuvant therapy, surgical considerations, and postoperative management, with no major omissions or errors."
  },
  "1189": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the recommendation of MET inhibitors (capmatinib, tepotinib, and savolitinib), and references relevant guidelines. However, it omits crizotinib as an alternative when preferred drugs are unavailable and does not explicitly mention ongoing palliative care and regular assessment of efficacy and side effects."
  },
  "1190": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale for unresectability, recommended concurrent chemoradiation, and the option of consolidation immunotherapy, with no significant omissions or errors."
  },
  "1191": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including the recommendation for palliative systemic chemotherapy, consideration of local palliative radiotherapy for symptoms, and the option of close observation if appropriate. It further expands on targeted and immunotherapy options, which are relevant and accurate, with no major omissions or errors."
  },
  "1192": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis but incorrectly classifies the staging as M1a/IVa, whereas the reference answer correctly identifies it as T4 (due to same-side, different-lobe nodule), stage IIIa. The model answer also omits the recommendation for mediastinal lymph node pathological assessment and preoperative systemic therapy, which are key management steps."
  },
  "1193": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately recommends first-line TRK inhibitor therapy based on NTRK fusion, referencing guidelines and rationale. However, it omits mention of palliative radiotherapy and multidisciplinary palliative care for symptom management, which are included in the reference answer."
  },
  "1194": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging modalities, and the importance of MDT discussion for R1 margin. However, it slightly overemphasizes abdominal imaging and does not clearly state that routine PET/CT and brain MRI are not recommended for surveillance, which are minor omissions compared to the reference answer."
  },
  "1195": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of postoperative chemoradiation for R1 resection in stage IIIA NSCLC, but it introduces immunotherapy, which is not standard in this setting and may cause confusion. It also separates chemo and radiotherapy rather than emphasizing concurrent chemoradiation as the preferred approach, as in the reference answer. Minor omissions include lack of emphasis on concurrent over sequential chemoradiation and routine follow-up/smoking cessation advice."
  },
  "1196": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including follow-up frequency, imaging modality, indications for PET/CT and brain MRI, and smoking cessation advice is the only minor omission. No major errors or omissions are present."
  },
  "1197": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical content, including further assessment, heart function evaluation, and appropriate neoadjuvant therapy. However, it omits the specific mention of placing a localization clip in the tumor and marking suspicious axillary nodes, and does not detail post-operative consolidation with T-DM1 for residual disease."
  },
  "1198": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including优先再次切除、不能手术时辅助放疗、系统治疗的适应证、随访建议及多学科决策，无重大遗漏或错误。"
  },
  "1199": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging, the need for mediastinal lymph node biopsy, treatment options based on resectability, and appropriate molecular testing. However, it omits NTRK1/2/3 from the list of recommended molecular tests and does not explicitly mention early integration of palliative care or smoking cessation, which are included in the reference answer."
  },
  "1200": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of preoperative and staging assessments, including pulmonary and cardiac function, PET-CT, and mediastinal evaluation. However, it includes some additional details (e.g., tumor markers, general labs) not emphasized in the reference and could be more concise, but there are no major omissions."
  },
  "1201": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the indications for FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "1202": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including neoadjuvant chemotherapy with dual HER2-targeted therapy, surgical planning post-treatment, and postoperative management, with no major omissions or errors."
  },
  "1203": {
    "score": 3.0,
    "explanation": "3: The model answer provides a structured and mostly accurate approach but incorrectly stages the tumor as T3N0M0 (Stage IIB) instead of T4N0 (Stage IIIB), which is a significant error. It also omits the need for pathological mediastinal lymph node assessment before definitive treatment."
  },
  "1204": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, structured approach, but it incorrectly assigns the stage as IIA instead of IB according to the AJCC 8th edition for a 4.2 cm, N0, M0 tumor. Otherwise, the treatment recommendations are appropriate and comprehensive."
  },
  "1205": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期分析,强调了T3、N0-1、M0的分期，并详细说明了需进一步明确N分期。也提及了纵隔淋巴结活检、术前评估和分子检测。但未明确建议脑部MRI排除脑转移，也未特别强调上沟瘤相关的特殊影像检查，略有细节遗漏。"
  },
  "1206": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including further axillary assessment, BRCA testing, neoadjuvant chemotherapy, and surgical planning. However, it omits the recommendation for preoperative breast MRI to assess tumor extent/multifocality and does not explicitly mention the need for repeat axillary ultrasound with biopsy of suspicious nodes, which are important for standardized staging."
  },
  "1207": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, with detailed discussion on adjuvant chemotherapy indications, follow-up intervals, and patient counseling. However, it slightly overcomplicates the follow-up schedule compared to the reference and includes some minor details (如肿瘤标志物、腹部影像等) not emphasized in the reference, while not explicitly stating that routine PET/CT或脑MRI is not recommended for surveillance."
  },
  "1208": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive and accurately covers all key points from the reference answer, including prioritization of NTRK抑制剂、免疫治疗、化疗，并引用了权威指南，无明显遗漏或错误。"
  },
  "1209": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of follow-up frequency, content, and rationale, with appropriate references. However, it introduces some minor variations (e.g., mention of 5-year follow-up and low-dose CT as first choice) and slight ambiguity in CT frequency, but these do not significantly detract from the overall accuracy."
  },
  "1210": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including MDT discussion, assessment of resectability, neoadjuvant therapy, and the necessity for comprehensive molecular testing. There are no major omissions or errors."
  },
  "1211": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key steps (neoadjuvant chemo + dual anti-HER2, assessment, surgery, adjuvant therapy, radiotherapy), and includes rationale and guideline reference. No major omissions or errors."
  },
  "1212": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, including staging, rationale for adjuvant chemoradiotherapy, and specific recommendations for both chemotherapy and radiotherapy. There are no major omissions or errors."
  },
  "1213": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1214": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including follow-up intervals, imaging recommendations, and the role of FDG-PET/CT and brain MRI. However, it omits the specific mention of smoking cessation intervention and comprehensive rehabilitation management, which are included in the reference answer."
  },
  "1215": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly recommends NTRK抑制剂（如larotrectinib或entrectinib） as the next step, with appropriate rationale. However, it omits mention of repotrectinib as an alternative NTRK inhibitor, which is included in the reference answer."
  },
  "1216": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including first-line immunochemotherapy, the role of KRAS G12C inhibitors as second-line, and the rationale based on PD-L1 status, with no major omissions or errors."
  },
  "1217": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including systemic platinum-based chemotherapy, the limited role of immunotherapy, and considerations for local and supportive treatment. However, it is slightly more detailed than the reference and introduces immunotherapy plus chemotherapy as an option, which, while evidence-based, is not explicitly mentioned in the reference answer, and the answer is cut off before fully summarizing. Minor omissions and slight overemphasis on immunotherapy prevent a perfect score."
  },
  "1218": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and special considerations for R2 resection. However, it slightly overstates the frequency (every 3–6 months vs. every 6 months) and includes some less emphasized elements (tumor markers, additional imaging), which are not standard unless clinically indicated. Minor omissions include not specifying the transition to low-dose non-contrast CT after 3 years."
  },
  "1219": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the clinical content well, but it incorrectly assigns the stage as IIIC instead of IIIB, which is a minor but important detail. The treatment recommendations are otherwise accurate and comprehensive."
  },
  "1220": {
    "score": 5.0,
    "explanation": "5: The model answer is nearly identical to the reference answer, covering分期、必要的纵隔淋巴结病理学确诊、分子检测、脑部评估、肺功能评估（虽未单独列出但内容完整）、治疗策略（新辅助、同步放化疗、免疫治疗等），无明显遗漏或错误。"
  },
  "1221": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the limited efficacy of EGFR TKIs for exon 20 insertions, the role of immunotherapy plus chemotherapy, the potential but limited use of new EGFR inhibitors, and supportive care for bone metastases. No major omissions or errors are present."
  },
  "1222": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations, including re-resection as first choice, PORT if re-resection is not feasible, and a nuanced discussion of adjuvant chemotherapy. However, it slightly overstates the role of adjuvant chemotherapy in IB期（T2aN0）NSCLC with R1 resection, where evidence is limited and most guidelines do not routinely recommend it. The answer also omits the follow-up surveillance recommendations present in the reference answer."
  },
  "1223": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging, the need for pathological confirmation of nodal status, and further management steps. However, it omits the specific recommendation for brain MRI to rule out intracranial metastasis and does not mention the need for spine or thoracic inlet MRI if chest wall involvement is suspected, which are present in the reference answer."
  },
  "1224": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, standard treatment (concurrent chemoradiotherapy), and consolidation immunotherapy. However, it omits the recommendation for pre-treatment brain MRI to rule out occult metastasis and does not mention sequential chemoradiotherapy as an alternative for patients unable to tolerate concurrent therapy."
  },
  "1225": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM分期、分期分型、治疗建议，并补充了指南依据和多学科讨论等细节，无重大遗漏或错误。"
  },
  "1226": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the clinical stage as cT3N0M0 (IIb期), and lists appropriate preoperative assessments. However, it omits the specific recommendation for脑MRI增强（brain MRI with contrast）to rule out brain metastasis and does not mention targeted MRI for local invasion assessment, which are important details in the reference answer."
  },
  "1227": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, listing all主要分子检测（EGFR、ALK、ROS1、BRAF、KRAS、MET、RET、HER2、PD-L1），并说明了检测的意义和指南依据，但未明确提及NTRK1/2/3，且部分内容以“可根据条件”表述，略有不够全面。"
  },
  "1228": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including follow-up intervals, imaging modality, lifestyle advice, and indications for further investigation. However, it omits the recommendation to continue annual follow-up beyond 5 years and does not explicitly mention that routine follow-up should continue for life, as per some guidelines. Minor differences in the duration of follow-up and slight over-specification of the 5-year cutoff account for the deduction."
  },
  "1229": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including indications for adjuvant therapy, high-risk factors, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "1230": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes emergency management of massive hemoptysis, details local control options, and appropriately addresses the timing and scope of molecular testing, fully matching the reference answer with no major omissions or errors."
  },
  "1231": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical approach, lymph node dissection, rationale, and postoperative considerations, with no major omissions or errors."
  },
  "1232": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main management steps, including surgery, lymph node dissection, and consideration of adjuvant therapy. However, it incorrectly labels the stage as IIB instead of IB, and does not specifically mention preoperative mediastinal lymph node assessment, which is a minor but relevant omission."
  },
  "1233": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the limited efficacy of first/second-generation EGFR-TKIs, the role of amivantamab, and the use of platinum-based chemotherapy. However, it does not explicitly recommend the combination of amivantamab with chemotherapy as the preferred regimen per the latest NCCN guidelines, and it lacks mention of palliative care and smoking cessation."
  },
  "1234": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and recommended treatment, with no significant omissions or errors. It even adds appropriate details about molecular testing, which is relevant and does not detract from the core answer."
  },
  "1235": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including staging, molecular typing, necessary preoperative assessments, and the rationale and choice of neoadjuvant therapy, with no major omissions or errors."
  },
  "1236": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including staging, further imaging, MDT discussion, and the recommendation for neoadjuvant chemo + anti-HER2 therapy. However, it omits specific mention of placing a marker at the tumor bed and axillary node during biopsy, and does not detail the exact laboratory tests as in the reference answer."
  },
  "1237": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, content, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1238": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging (IVB, M1b), the rationale for RET inhibitor selection, and the deprioritization of immunotherapy despite high PD-L1, with no significant omissions or errors."
  },
  "1239": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, molecular subtype, endocrine resistance, treatment options (CDK4/6 inhibitors, chemotherapy for visceral crisis), bone-modifying agents, and supportive care. No major omissions or errors are present."
  },
  "1240": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points covered and no major omissions or errors. It even adds appropriate detail regarding immunotherapy and patient assessment."
  },
  "1241": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modalities, and indications for advanced imaging, with no major omissions or errors."
  },
  "1242": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了肺功能、心脏功能、影像学分期、纵隔淋巴结评估及实验室检查，无重大遗漏或错误，仅在细节和表述顺序上略有扩展。"
  },
  "1243": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging (cT?N2M0, IIIA) and treatment options, including MDT evaluation, neoadjuvant therapy, and the role of surgery and immunotherapy. However, it lacks a clear, concise summary of the recommended stepwise approach and omits the explicit mention of continuing chemoradiotherapy if unresectable, as well as the need for post-operative adjuvant therapy based on pathology."
  },
  "1244": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the staging and first-line treatment, including specific RET inhibitors and guideline recommendations. However, it omits the precise AJCC 8th edition substage (Stage IVA, M1b) and does not mention smoking cessation or palliative care, which are minor but relevant details."
  },
  "1245": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for ALK-TKI monotherapy, specifying drug choices and dosages, and correctly de-emphasizing immunotherapy and chemotherapy. No major omissions or errors are present."
  },
  "1246": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies NTRK抑制剂（拉罗替尼或恩曲替尼）为首选，但未提及瑞波曲替尼（Repotrectinib），且未强调所有可用NTRK抑制剂均可作为一线选择，略有细微遗漏。"
  },
  "1247": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the recommendation against adjuvant therapy, appropriate follow-up intervals, and lifestyle advice. However, it introduces some minor additional details (e.g., optional tumor markers, abdominal ultrasound) and slightly differs in follow-up frequency, which are not strictly necessary per the reference answer."
  },
  "1248": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key molecular tests, including PD-L1, EGFR, ALK, ROS1, and mentions other rare mutations. However, it omits explicit mention of NTRK、METex14、RET、ERBB2（HER2）等具体基因，且对KRAS等的推荐程度表述略有保留，存在轻微遗漏。"
  },
  "1249": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indications for multigene testing, criteria for 21-gene RT-PCR, and detailed recommendations for adjuvant therapy based on risk assessment, with no major omissions or errors."
  },
  "1250": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including随访频率、胸部CT为主、PET-CT和脑MRI不常规推荐、戒烟及幸存者管理，无明显遗漏或错误。"
  },
  "1251": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including molecular subtype, tumor size/stage, guideline recommendations, and rationale for adjuvant chemotherapy, with no significant omissions or errors."
  },
  "1252": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including precise TNM staging, the need for pathological confirmation of nodal status, multidisciplinary evaluation, and appropriate treatment recommendations, with no major omissions or errors."
  },
  "1253": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the recommendation for re-resection to achieve negative margins, alternative of radiotherapy if surgery is not feasible, and even expands with guideline references and MDT discussion. No major omissions or errors are present."
  },
  "1254": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate TNM分期、分期判断、治疗流程和注意事项，且无重要遗漏或错误。"
  },
  "1255": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging, treatment strategy, and rationale included without omissions or errors."
  },
  "1256": {
    "score": 3.0,
    "explanation": "3: The model answer provides a structured and partially correct response but contains a significant staging error (IIb instead of IIIB) and underemphasizes the current guideline recommendations for routine molecular and PD-L1 testing in all NSCLC, including squamous cell carcinoma. These omissions and inaccuracies lower the score."
  },
  "1257": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality choice, and the non-recommendation of routine PET/CT or brain MRI, with no major omissions or errors."
  },
  "1258": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including indications for 21-gene testing, rationale, and recommended adjuvant therapy for intermediate risk, with no major omissions or errors."
  },
  "1259": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers clinical staging, necessary further assessments, and detailed treatment options, with no major omissions or errors compared to the reference answer."
  },
  "1260": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects guideline-based recommendations, prioritizes trastuzumab deruxtecan as second-line therapy, and appropriately discusses alternatives and supportive care, with no major omissions or errors."
  },
  "1261": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including EGFR-TKI as first-line therapy (with preference for osimertinib), bone protection, symptomatic management, and appropriate exclusion of chemotherapy/immunotherapy unless contraindicated. No major omissions or errors."
  },
  "1262": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of routine need for adjuvant therapy, consideration of high-risk features, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "1263": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of history, physical exam, chest CT schedule, and smoking cessation. However, it includes optional tumor marker monitoring (not routinely recommended) and does not specify that PET/CT is not routinely advised, which are minor deviations from the reference answer."
  },
  "1264": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up and management, including surveillance intervals, imaging, lifestyle advice, and management of complications. However, it slightly overemphasizes laboratory and other imaging tests not routinely recommended, and the follow-up intervals are somewhat more detailed than the reference, but overall content is accurate with only minor omissions."
  },
  "1265": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including diagnosis, lack of targetable mutations, recommended platinum-based doublet chemotherapy plus immunotherapy, management of pleural effusion, and supportive care, with no major omissions or errors."
  },
  "1266": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides accurate, guideline-based recommendations, including specific MET inhibitors and dosing. However, it omits mention of crizotinib as a potential option and does not address smoking cessation or palliative care considerations, which are included in the reference answer."
  },
  "1267": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including surgical assessment, chemoradiotherapy as standard, multidisciplinary discussion, and individualized treatment, with additional up-to-date details (e.g., immunotherapy consolidation) and guideline references. No major omissions or errors."
  },
  "1268": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and recommended treatment, with no major omissions or errors."
  },
  "1269": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemoradiation and MDT evaluation, but it introduces additional content (molecular testing and targeted/immunotherapy) not emphasized in the reference answer, and does not specifically recommend concurrent chemoradiation as the first choice, which is a minor omission."
  },
  "1270": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including systemic and local therapy, the role of PD-L1 testing, and a nuanced discussion of molecular profiling. However, it underemphasizes the need for broad molecular testing (beyond EGFR/ALK/ROS1) as recommended in the reference, and does not explicitly mention supportive/palliative care and smoking cessation."
  },
  "1271": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including surgical options, the role of radiotherapy, and the lack of indication for adjuvant systemic therapy in node-negative, triple-negative adenoid cystic carcinoma. There are no major omissions or errors."
  },
  "1272": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including评估、治疗和随访建议, but the CT随访频率略低于参考答案（每6个月 vs. 每3-6个月），且首次术后影像随访时间未明确为3-6个月，属于细节性小遗漏。"
  },
  "1273": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-reasoned, referencing major guidelines and providing a nuanced discussion. However, it omits that most guidelines still“consider” or“recommend” chest wall ± RNI radiotherapy for pT3N0 after mastectomy due to the tumor size, even in the absence of nodal involvement, to reduce local recurrence, as stated in the reference answer. The model answer leans more toward not recommending radiotherapy, which is a minor but important deviation."
  },
  "1274": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging modality, and rationale for stricter surveillance due to R2 resection. However, it slightly overstates the frequency (every 3–6 months vs. every 6 months in the reference) and does not explicitly mention smoking cessation counseling or the routine non-recommendation of PET/CT or brain MRI, which are minor omissions."
  },
  "1275": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it underemphasizes the current guideline trend toward broad molecular profiling in all NSCLC (including squamous), which the reference answer highlights. Otherwise, the staging, rationale, and treatment recommendations are well covered."
  },
  "1276": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the stage (IIIA, T2-3N2M0), and providing a comprehensive, guideline-based discussion of treatment options, including MDT evaluation, chemoradiotherapy, and consideration of surgery and immunotherapy, with no major omissions or errors."
  },
  "1277": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of concurrent chemoradiotherapy followed by durvalumab maintenance, with appropriate detail and rationale. However, it omits the mention of osimertinib maintenance for patients with EGFR 19del/L858R mutations, which is a minor but relevant omission."
  },
  "1278": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of systemic therapy as the primary treatment and the indications for SVC stenting. However, it omits the mention of palliative radiotherapy as an option, does not explicitly recommend further staging investigations (e.g., enhanced CT, brain MRI, PET/CT), and lacks a brief note on multidisciplinary assessment for final decision-making."
  },
  "1279": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately applies the AJCC 8th edition TNM staging, and correctly concludes IIIB stage, with no major omissions or errors."
  },
  "1280": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up frequency, content, and imaging. However, it omits the specific recommendation against routine PET-CT and brain MRI, and does not emphasize smoking cessation counseling as a regular intervention. Minor differences in follow-up intervals are also present."
  },
  "1281": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and management, but it slightly misstates the stage as IIA instead of IB and does not mention adjuvant osimertinib for EGFR mutation, which is included in the reference answer."
  },
  "1282": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the clinical scenario, including the need to clarify the nature of the contralateral nodule and the implications for staging and treatment. However, it omits a clear, direct statement that—based on current information—the most likely clinical stage is Stage IVA (M1a, N0) per AJCC 8th edition, as in the reference answer, and does not explicitly recommend MDT discussion or preoperative mediastinal evaluation."
  },
  "1283": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1284": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps including neoadjuvant therapy, surgical planning, adjuvant therapy, and radiotherapy, with no major omissions or errors. It even adds appropriate detail and guideline references, enhancing completeness."
  },
  "1285": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive and covers all key points from the reference answer, including biopsy of metastatic lesions, reassessment of ER/PR/HER2, relevant molecular testing (PIK3CA, ESR1, BRCA1/2), and the rationale for each. There are no major omissions or errors."
  },
  "1286": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了随访频率、影像学检查、生活方式管理及指南依据，无重大遗漏或错误。"
  },
  "1287": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, surgical approach, perioperative considerations, and postoperative management, with no major omissions or errors."
  },
  "1288": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of systemic therapy options, including the role of KRAS G12C inhibitors, immunotherapy, and chemotherapy, as well as detailed bone-related management. However, it omits explicit mention of orthopedic evaluation for bone stabilization and palliative radiotherapy, which are present in the reference answer."
  },
  "1289": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging, further assessment, molecular testing, and treatment recommendations, but it omits some details such as the full list of recommended gene tests (e.g., KRAS, BRAF, MET, RET, NTRK, HER2) and the explicit mention of palliative orthopedic intervention for bone metastasis risk."
  },
  "1290": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses staging, details the need for further nodal assessment, outlines standard treatment options including MDT discussion, and incorporates current guidelines and immunotherapy, with no major omissions or errors."
  },
  "1291": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, rationale for inoperability, standard treatment (concurrent chemoradiotherapy), the role of durvalumab, and the need for molecular testing. No major omissions or errors are present."
  },
  "1292": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of follow-up timing, content, and additional management, but it slightly overstates the frequency (every 3–6 months vs. every 6 months) and includes some extra, less essential details not emphasized in the reference answer. Minor differences in recommended intervals and additional tests are present, but no major omissions."
  },
  "1293": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key management steps, and includes appropriate details on surgical, adjuvant, and non-surgical options, with no major omissions or errors."
  },
  "1294": {
    "score": 4.0,
    "explanation": "4: 模型答案内容基本完整，涵盖了辅助化疗和术后放疗的推荐，并提及MDT讨论和指南依据，但未明确强调“如可行优先再次手术切除”这一首选方案，属于轻微遗漏。"
  },
  "1295": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including postoperative chemoradiotherapy, follow-up, smoking cessation, and survivor management, and even adds appropriate details such as MDT discussion and molecular testing, without any major omissions or errors."
  },
  "1296": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based recommendations for adjuvant chemotherapy and follow-up. However, it differs from the reference answer by more strongly recommending adjuvant chemotherapy rather than presenting it as optional after shared decision-making, which is a minor but important nuance."
  },
  "1297": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, content, and lifestyle advice. However, it slightly overstates the frequency of follow-up in years 3–5 (every 6 months instead of annually after year 3), and does not explicitly mention that routine PET/CT or brain MRI is not recommended unless symptomatic, which are minor omissions."
  },
  "1298": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering both adjuvant chemoradiotherapy and necessary imaging (PET-CT, brain MRI), with additional appropriate details on molecular testing and patient assessment, without any major omissions or errors."
  },
  "1299": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging, symptom monitoring, and lifestyle advice. However, it slightly overstates the need for some tests (e.g., head MRI, bone scan) without clear indications, and the follow-up intervals differ somewhat from the reference, which recommends annual CT after 3 years rather than after 5 years. Minor omissions and slight deviations from guideline specifics prevent a perfect score."
  },
  "1300": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including detailed TNM staging, treatment recommendations, and MDT involvement. However, it incorrectly assigns stage IIIC instead of the correct stage IIIB for cT1cN3M0 NSCLC, which is a minor but notable staging error."
  },
  "1301": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including cardiac assessment, lab tests, imaging, and metastatic workup. However, it omits the specific mention of影像引导下粗针穿刺活检及腋窝淋巴结穿刺和标记（如未完成）, which are important for guiding neoadjuvant therapy, and places less emphasis on the need for marker placement."
  },
  "1302": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including imaging, clinical assessment, and lifestyle advice. However, it omits the explicit recommendation against routine PET/CT or brain MRI and does not specify the 2–3 year interval before switching to annual follow-up, instead suggesting 2 years. Minor differences in timing and detail prevent a perfect score."
  },
  "1303": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including continued ovarian suppression, switching endocrine agents, addition of CDK4/6 inhibitors, consideration of chemotherapy if needed, and bone-targeted therapy, with no major omissions or errors."
  },
  "1304": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, including MDT discussion and the possibility of neoadjuvant therapy plus surgery for select N2 cases. However, it places more emphasis on surgical options than current guidelines, which generally recommend chemoradiotherapy as the standard for stage IIIB (N2) disease, making surgery less favored. Minor deviation from the reference answer's prioritization."
  },
  "1305": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, accurately identifies the stage as IVA (M1a), and details appropriate first-line treatment options, including rationale for chemo-immunotherapy and supportive care, with no major omissions or errors."
  },
  "1306": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and closely matches the reference answer, covering diagnosis, treatment strategies (including HER2-targeted therapy, chemotherapy, endocrine therapy, and bone support), and necessary further assessments (biopsy, receptor status, organ function). No major omissions or errors are present."
  },
  "1307": {
    "score": 3.0,
    "explanation": "3: The model answer provides accurate staging and a reasonable treatment plan, but it incorrectly stages the disease as IVB (M1c) instead of IVA (M1b) and recommends chemo-immunotherapy as first-line, whereas the reference answer recommends chemotherapy alone due to PD-L1 <1%. These are significant deviations from the reference answer."
  },
  "1308": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the rationale for adjuvant chemoradiotherapy, details on regimen and sequencing, and the importance of follow-up and molecular testing, with no major omissions or errors."
  },
  "1309": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of all key aspects in the reference answer, including adjuvant chemotherapy, immunotherapy, targeted therapy, and follow-up, with no major omissions or errors. It even expands on the rationale and evidence, fully aligning with current guidelines."
  },
  "1310": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering HER2靶向治疗为首选、化疗为备选、骨保护治疗、免疫治疗的适用性及指南依据，无明显遗漏或错误。"
  },
  "1311": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, indications for 21基因RS检测, and the rationale for omitting chemotherapy, but it slightly overemphasizes the role of Ki-67 and age, and does not明确 state that21基因RS检测 is recommended to guide chemotherapy decision as directly as the reference answer."
  },
  "1312": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and guideline-based management without omissions or errors."
  },
  "1313": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the TNM stage and recommending appropriate surgical management. However, it differs from the reference answer in the specific T and stage classification (T1cN0M0, IA3 vs. T2aN0M0, IB), which may reflect a minor discrepancy in tumor size categorization, but overall clinical recommendations are appropriate."
  },
  "1314": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including accurate staging, mediastinal lymph node pathological confirmation, molecular and PD-L1 testing, and additional relevant pre-treatment assessments. No major omissions or errors."
  },
  "1315": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive and matches the reference answer in all key aspects, including accurate staging, detailed preoperative assessment, and appropriate neoadjuvant treatment recommendations, with no major omissions or errors."
  },
  "1316": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly identifying the stage as IVB (M1c) and recommending BRAF/MEK inhibitor therapy as first-line. However, it omits mentioning encorafenib + binimetinib as an alternative regimen, which is included in the reference answer."
  },
  "1317": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1318": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers the key points of staging (M1a vs. second primary), diagnostic approach, and treatment strategy, and aligns closely with the reference answer with no major omissions or errors."
  },
  "1319": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and adds relevant guideline-based details without introducing errors or omissions."
  },
  "1320": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including concurrent chemoradiation, consolidation with Durvalumab, and consideration of EGFR mutation status, with no major omissions or errors."
  },
  "1321": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all required genes, PD-L1, testing methods, and rationale, with no major omissions or errors."
  },
  "1322": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers clinical staging, preoperative assessment, and treatment planning with appropriate detail. However, it omits the specific recommendation for postoperative T-DM1 consolidation therapy in patients with residual disease, which is a key point in the reference answer."
  },
  "1323": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for re-resection, the role of adjuvant radiotherapy if re-resection is not feasible, and the lack of recommendation for adjuvant chemotherapy, with no major omissions or errors."
  },
  "1324": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good clinical reasoning, but it places more emphasis on chemotherapy as first-line due to drug availability, rather than prioritizing exon 20-targeted agents as in the reference answer. It also discusses local drug accessibility, which is a minor but relevant omission from the reference."
  },
  "1325": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including the need for re-resection, adjuvant chemoradiotherapy, follow-up, and supportive care, with no major omissions or errors. The clinical content is comprehensive and accurate."
  },
  "1326": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for MET inhibitor monotherapy as first-line treatment, and correctly deprioritizing immunotherapy and chemotherapy. No major omissions or errors are present."
  },
  "1327": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including systemic therapy (chemotherapy, immunotherapy, targeted therapy if indicated) and symptomatic/palliative local treatments. However, it omits some specific local palliative options (e.g., external beam radiotherapy, bronchoscopic laser/photodynamic therapy) and the prioritization of acute bleeding management, which are mentioned in the reference answer."
  },
  "1328": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it incorrectly assigns the stage as IB (cT2aN0M0) instead of IIB (T2bN0M0) as per the reference answer; otherwise, the treatment recommendations are appropriate and detailed."
  },
  "1329": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including the timing and modality of imaging follow-up. However, it slightly overemphasizes additional imaging (e.g., neck/abdomen CT, bone scan) and genetic considerations, which are not standard unless clinically indicated, and does not explicitly mention that routine PET/CT and brain MRI are not recommended unless symptomatic."
  },
  "1330": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, including the use of multigene assays, risk stratification, and endocrine therapy options. However, it does not explicitly recommend 21-gene expression profiling as the first step, and the endocrine therapy section is slightly less specific about the duration and indications for ovarian suppression compared to the reference answer."
  },
  "1331": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the use of KRAS G12C抑制剂为首选，并补充了免疫治疗和二线化疗的选择，但对免疫治疗的适应证和优先级描述略显冗余，且未完全强调KRAS G12C抑制剂为首选的简明性。"
  },
  "1332": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, the role of chest CT, and the non-routine use of FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1333": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，无重大遗漏或错误，详细说明了放疗的必要性及放射范围选择，符合指南推荐。"
  },
  "1334": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of treatment options and multidisciplinary evaluation, but it incorrectly stages the patient as stage IIIA (T3N2M0) instead of the correct stage IIIB per AJCC 8th edition for T3N2M0. This is a significant inaccuracy in clinical staging, though the treatment recommendations are otherwise appropriate."
  },
  "1335": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including first-line use of NTRK inhibitors (larotrectinib or entrectinib), guideline recommendations, and monitoring considerations, with no major omissions or errors."
  },
  "1336": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including the frequency and type of imaging, clinical follow-up, and not recommending routine PET-CT or brain MRI. However, it omits the specific mention of smoking cessation counseling and related pharmacotherapy, which is a minor but relevant detail."
  },
  "1337": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing NTRK抑制剂（larotrectinib或entrectinib）为一线治疗，并说明了化疗和免疫治疗为后续选择，无重大遗漏或错误。"
  },
  "1338": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, including staging, surgical recommendation, MDT discussion, and the rationale for molecular testing. However, it omits specific mention of preoperative pulmonary function testing and mediastinal lymph node assessment (e.g., EBUS or mediastinoscopy), which are important steps highlighted in the reference answer."
  },
  "1339": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate staging, detailed rationale, and appropriate treatment recommendations, including the option of consolidation immunotherapy. No major omissions or errors are present."
  },
  "1340": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including SRS for brain metastasis, platinum-based chemotherapy plus immunotherapy, treatment sequencing, and regular imaging follow-up, with no major omissions or errors."
  },
  "1341": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately recommends dabrafenib plus trametinib as first-line therapy, addresses supportive and symptom control measures, and discusses alternatives if targeted therapy is not feasible, matching the reference answer in all key aspects."
  },
  "1342": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including imaging, pathology, systemic staging, and laboratory tests. It adds appropriate details (e.g., cardiac function assessment for anti-HER2 therapy), but omits mention of tumor bed marker placement and is slightly less structured regarding the rationale for each test."
  },
  "1343": {
    "score": 3.0,
    "explanation": "3: The model answer provides a generally accurate and structured approach, including adjuvant radiotherapy and chemotherapy, and covers follow-up, but omits the preferred option of re-operation for R1 resection and overemphasizes molecular testing/targeted therapy, which is not standard in this context. There are also minor deviations in follow-up intervals and imaging recommendations."
  },
  "1344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including diagnosis, surgical options (mastectomy vs. breast-conserving surgery with nipple-areola excision), axillary management, and adjuvant therapy considerations, with no major omissions or errors."
  },
  "1345": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the indication for neoadjuvant therapy and a comprehensive list of preoperative assessments, with no major omissions or errors. Minor differences in wording and order do not affect the clinical content."
  },
  "1346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including re-resection as first choice, PORT if not operable, individualized consideration of adjuvant therapy, and a detailed, guideline-consistent follow-up plan. No major omissions or errors are present."
  },
  "1347": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, but it slightly overemphasizes enhanced CT for routine follow-up (whereas low-dose non-contrast CT is preferred after 2–3 years) and does not explicitly mention smoking cessation intervention. Otherwise, the clinical content and management steps are accurate."
  },
  "1348": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it differs from the reference answer in分期（分期为IVB/M1c而非IVA/M1b）; otherwise, it covers all key points including分子检测, 支持治疗, and靶向治疗的适应证. Minor differences in staging terminology account for the deduction."
  },
  "1349": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the decision against adjuvant therapy, criteria for high-risk features, and a detailed, guideline-consistent follow-up schedule. No major omissions or errors are present."
  },
  "1350": {
    "score": 4.0,
    "explanation": "4: 模型答案与参考答案内容基本一致，分期准确，处理措施全面，补充了病理学诊断和替代治疗选择，略超出参考答案，但未将术前支气管镜检查作为术前评估的一部分强调，存在细微差异。"
  },
  "1351": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging, the need for pathological confirmation, and the standard of care (concurrent chemoradiotherapy). However, it incorrectly assigns stage IIIC instead of IIIB, and does not explicitly mention the need for pathological confirmation of N3 status before finalizing treatment, which are minor but important omissions."
  },
  "1352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including detailed recommendations for adjuvant chemotherapy, immunotherapy, and follow-up intervals, with no major omissions or errors. It even provides additional evidence and rationale, fully aligning with current standards."
  },
  "1353": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including staging, treatment recommendations, and evaluation process. However, it adds a step of preoperative histological confirmation (biopsy), which, while reasonable, is not always mandatory for peripheral, operable nodules and is not explicitly mentioned in the reference answer. Otherwise, there are no major omissions or errors."
  },
  "1354": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the significance of R1 margin, preference for reoperation, alternative of radiotherapy, non-recommendation of simple surveillance, and a detailed follow-up plan if further treatment is declined. No major omissions or errors are present."
  },
  "1355": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, imaging recommendations, and the lack of indication for routine PET-CT or brain MRI, with no major omissions or errors."
  },
  "1356": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including standard chemotherapy, immunotherapy, other HER2-targeted agents, clinical trials, and supportive care. However, it omits specific mention of Ado-trastuzumab emtansine as a preferred HER2 ADC option, which is highlighted in the reference answer."
  },
  "1357": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including detailed TNM staging, imaging, lymph node assessment, and preoperative evaluation. However, it slightly overstates the T分期（T4 vs T3）和分期（IIIB vs IIB），并未明确强调脊柱MRI重点部位，且未提及脑MRI，存在小的分期和评估细节偏差。"
  },
  "1358": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, surgical recommendation, and considerations for adjuvant therapy, with no major omissions or errors."
  },
  "1359": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendation of fam-trastuzumab deruxtecan (DS-8201) as first choice, mentions alternatives, and discusses immunotherapy and clinical trials. However, it omits ado-trastuzumab emtansine (Kadcyla) as a specific alternative and does not explicitly mention palliative care and side effect management, which are present in the reference answer."
  },
  "1360": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, surgical options, and rationale for not recommending neoadjuvant therapy, with appropriate detail on adjuvant therapy considerations. No major omissions or errors are present."
  },
  "1361": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, guideline recommendations, the role and interpretation of Oncotype DX 21-gene testing, and the decision-making process for adjuvant chemotherapy. No major omissions or errors are present."
  },
  "1362": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including follow-up intervals, imaging recommendations, and the rationale for not routinely performing PET/CT or brain MRI. It also adds appropriate detail about R1 status and multidisciplinary considerations without introducing errors or omissions."
  },
  "1363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including mediastinal lymph node assessment, pulmonary function evaluation, surgical indications, and adjuvant therapy considerations, with additional relevant details and no major omissions or errors."
  },
  "1364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including further molecular testing, functional assessments, and a detailed, guideline-based treatment strategy. There are no major omissions or errors, and the answer is comprehensive and clinically accurate."
  },
  "1365": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the need for postoperative radiotherapy and chemotherapy, and the role of further staging. However, it omits the preferred option of reoperation for R1 resection, which is emphasized in the reference answer as the first-line recommendation."
  },
  "1366": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, core investigations, and supportive care. However, it slightly differs in the recommended CT frequency (suggesting every 6–12 months rather than every 3–6 months in the first 2–3 years) and does not explicitly mention that routine PET/CT or brain MRI is not recommended for asymptomatic patients, which are minor omissions."
  },
  "1367": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for EGFR-TKI monotherapy (specifically afatinib), and correctly de-emphasizing immunotherapy and chemotherapy, with no major omissions or errors."
  },
  "1368": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps, including axillary ultrasound, biopsy of suspicious nodes, and marking positive nodes. However, it adds extra details (e.g., MRI/CT, guideline references) and slightly overstates the role of routine biopsy in cN0 cases, which is not standard, making it a minor deviation from the reference."
  },
  "1369": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key aspects of adjuvant therapy and follow-up, and even expands on targeted and immunotherapy options, with no major omissions or errors compared to the reference answer."
  },
  "1370": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of adjuvant chemotherapy, timing, and follow-up, and also discusses adjuvant radiotherapy and immunotherapy, which are reasonable to mention. However, it omits the specific mention of EGFR mutation and adjuvant targeted therapy, which is a minor but important omission."
  },
  "1371": {
    "score": 4.0,
    "explanation": "4: 模型答案内容基本完整，涵盖了辅助化疗的推荐、依据、方案及随访计划，但未强调辅助化疗可“考虑”或“个体化决策”，而是直接推荐，略缺对患者意愿和整体状况的讨论。随访计划略详细于参考答案，但核心内容一致。"
  },
  "1372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key points from the reference answer, including the recommendation for adjuvant chemotherapy, consideration of targeted/immune therapy, and a detailed, guideline-consistent follow-up plan. There are no major omissions or errors."
  },
  "1373": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM staging, appropriate surgical recommendations, and mentioning SBRT as an alternative for inoperable patients, with no major omissions or errors."
  },
  "1374": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, rationale, and recommended treatment (concurrent chemoradiation and consolidation immunotherapy), with no major omissions or errors."
  },
  "1375": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately details the staging, rationale, and stepwise treatment plan, including chemoradiotherapy and consolidation immunotherapy, and even provides additional relevant specifics."
  },
  "1376": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the stage as IIb (T3N0M0) and providing appropriate, detailed next-step treatment recommendations without major omissions or errors."
  },
  "1377": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including cardiac function assessment, HER2 confirmation, baseline labs, MRI, and fertility counseling. However, it omits the specific mention of影像引导下肿瘤标记和腋窝超声及穿刺活检等操作, which are important for surgical planning and staging."
  },
  "1378": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of staging and preoperative assessment, with detailed explanations. However, it slightly overemphasizes some workups (e.g., tumor markers, detailed lab tests) that are not strictly necessary per guidelines, and the staging could be more precise regarding Stage IB. Minor omissions include perioperative smoking cessation and rehabilitation advice."
  },
  "1379": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it assigns stage IIIC (cT2N3M0) instead of stage IIIB, which is the correct stage for T2N3M0 per the 8th AJCC edition; this is a minor but notable staging error. Otherwise, the clinical content and management plan are correct."
  },
  "1380": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately prioritizes NTRK抑制剂靶向治疗，with appropriate drug recommendations and rationale. However, it omits the important aspect of局部处理（如胸膜固定术、引流）和姑息治疗 for symptomatic malignant pleural effusion, which is mentioned in the reference answer."
  },
  "1381": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including HER2靶向治疗（trastuzumab deruxtecan为首选）、二线化疗、免疫维持、临床试验和支持治疗，但内容略显冗长，且对免疫维持的推荐不够明确，未强调“继续现有免疫治疗”作为维持的优先顺序。"
  },
  "1382": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable overview but overstates the necessity of adjuvant chemotherapy, omitting the guideline-based option of observation for some patients and lacking discussion of individualized risk-benefit assessment. The follow-up plan is generally correct but includes minor inaccuracies and unnecessary details (e.g., routine tumor markers), and misses the emphasis on smoking cessation and health management."
  },
  "1383": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering all key aspects of the reference answer and adding some extra details (如随访目的、生活方式指导等). However, it slightly overstates随访频率 (3-6个月 vs. 6个月) and suggests肿瘤标志物和其他影像学检查 as optional, which are not routinely recommended, making it a minor deviation."
  },
  "1384": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging (T2N3M0, IIIB), rationale, and standard treatment (concurrent chemoradiotherapy, consolidation immunotherapy), with no major omissions or errors."
  },
  "1385": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, molecular findings, and first-line treatment recommendations, with additional detail but no major omissions or errors."
  },
  "1386": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good clinical reasoning, but it incorrectly stages the tumor as IIA (T2N0M0) instead of IB (T2aN0M0) per the reference answer and AJCC 8th edition. Otherwise, the treatment recommendations are appropriate and comprehensive."
  },
  "1387": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it suggests a slightly more frequent follow-up schedule in the first two years and does not explicitly mention smoking cessation counseling, which is a minor omission. Otherwise, the clinical content and recommendations are accurate."
  },
  "1388": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, with detailed staging and appropriate management recommendations. However, it slightly overstates the stage as IB (AJCC 8th edition classifies 3–4 cm as T2a, which is IB, while the reference answer uses IA, possibly reflecting a minor staging nuance), and adds extra detail about high-risk factors for adjuvant therapy, which is not in the reference answer but is not incorrect. Minor differences prevent a perfect score."
  },
  "1389": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including further workup, treatment principles, and MDT discussion. However, it omits the recommendation for brain MRI to rule out brain metastases and does not mention the possibility of broad molecular profiling, even if rare in squamous cell carcinoma."
  },
  "1390": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need to switch from chemotherapy to ROS1-targeted therapy, recommended drugs, and the rationale for prioritizing entrectinib in cases with brain metastases. No major omissions or errors are present."
  },
  "1391": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the lack of routine recommendation for adjuvant therapy in stage IB NSCLC without high-risk features, detailed follow-up intervals, and patient counseling. There are no major omissions or errors."
  },
  "1392": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed staging (T1bN0M0, IA2) and appropriate treatment recommendations. The only minor omission is not explicitly mentioning segmentectomy as an alternative to lobectomy for small, peripheral tumors, which the reference answer includes."
  },
  "1393": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key steps, including PET-CT, surgical options, and lymph node dissection, but adds extra detail about biopsy and alternative treatments, which, while accurate, are not strictly required for this scenario and slightly dilute the focus on the reference answer’s main points."
  },
  "1394": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including indications for 21-gene testing, interpretation of Recurrence Score, and detailed recommendations for adjuvant chemotherapy and endocrine therapy, with no major omissions or errors."
  },
  "1395": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, the lack of need for preoperative mediastinal lymph node pathological assessment, and appropriate surgical recommendations, with no major omissions or errors."
  },
  "1396": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including stage, standard of care (concurrent chemoradiotherapy), durvalumab consolidation, and MDT discussion. However, it omits the mention of osimertinib as consolidation for EGFR-mutant cases, which is a minor but relevant detail."
  },
  "1397": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, symptom assessment, and smoking cessation. However, it suggests a slightly more frequent follow-up schedule in the first two years and includes additional optional tests not emphasized in the reference, which are minor deviations."
  },
  "1398": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale for non-surgical management, standard concurrent chemoradiotherapy, and the option of consolidation immunotherapy, with no significant omissions or errors."
  },
  "1399": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging and treatment, but it equivocates between stage IIIA and IIIB rather than definitively stating IIIB (T4N2M0) as in the reference. It also omits mention of EGFR mutation testing and the potential use of osimertinib for EGFR-positive cases."
  },
  "1400": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and options for neoadjuvant therapy, with no significant omissions or errors."
  },
  "1401": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management options (re-resection, radiotherapy, and surveillance) and providing appropriate rationale and follow-up recommendations without omissions or errors."
  },
  "1402": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, covers all key management points including adjuvant radiotherapy, MDT discussion, follow-up, and system therapy considerations, and references relevant guidelines. There are no major omissions or errors compared to the reference answer."
  },
  "1403": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and guideline-based discussion, but it overstates the need for routine regional nodal irradiation (RNI) in all such patients, whereas the reference answer correctly states that RNI should be individualized and is not universally required. This is a significant deviation from the reference, resulting in partial accuracy."
  },
  "1404": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it incorrectly assigns stage IA2 instead of IB (the correct stage for a 3.1 cm tumor per AJCC 8th edition is IB, not IA2). Otherwise, it covers all key steps and management recommendations."
  },
  "1405": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the rationale for best supportive care as the first choice and the cautious consideration of single-agent immunotherapy in select cases. However, it provides more detail than required and slightly overemphasizes the option of immunotherapy, which is not the standard recommendation per guidelines for PS 3 patients."
  },
  "1406": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical details, pathological findings, guideline recommendations, and the need for further systemic therapy assessment. No major omissions or errors are present."
  },
  "1407": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for best supportive care, referencing guidelines, and discussing exceptions and symptom management, with no major omissions or errors."
  },
  "1408": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it slightly differs in the follow-up intervals after 2 years (6–12 months vs. reference's 6 months for 2 years, then annually), and it adds extra detail about high-risk patients for brain MRI, which is not in the reference. No major errors, but minor deviations in timing and additional content."
  },
  "1409": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main management options (re-resection, radiotherapy, follow-up), and correctly excludes adjuvant chemotherapy. However, it omits some details about the recommended follow-up schedule, smoking cessation, survivorship care, and the non-recommendation of routine PET-CT/brain MRI, which are present in the reference answer."
  },
  "1410": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale for CDK4/6 inhibitor plus fulvestrant, and consideration of chemotherapy if visceral crisis develops. No major omissions or errors are present."
  },
  "1411": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including surgical options, adjuvant therapy, and the rationale for BRCA genetic testing, with no major omissions or errors. The content is comprehensive and accurate."
  },
  "1412": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including cardiac assessment, lab tests, imaging, and MDT discussion. However, it omits the placement of tumor and lymph node markers, and does not explicitly mention the need for further metastatic workup (e.g., PET/CT or bone scan) or detailed imaging for staging, which are present in the reference answer."
  },
  "1413": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including优先再次手术、放疗选择、辅助化疗的适应证、随访时机与频率，并引用权威指南，无明显遗漏或错误。"
  },
  "1414": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed TNM breakdown and appropriate management steps, but incorrectly assigns the clinical stage as IA2 instead of IB, which is a significant inaccuracy. It also omits the recommendation for invasive mediastinal lymph node assessment to rule out occult metastasis before surgery."
  },
  "1415": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, closely matching the reference answer with no major omissions or errors. It correctly summarizes the patient’s situation, details the recommended treatment options, and appropriately references current guidelines."
  },
  "1416": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding adjuvant therapy indications, high-risk factors, and detailed follow-up recommendations, with no major omissions or errors."
  },
  "1417": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly prioritizing ALK-TKI therapy for ALK重排阳性肺鳞癌，并指出阿来替尼为首选，但未提及吸烟戒断和姑息治疗等综合管理措施，且未强调克唑替尼作为一线选择的地位，略有细节差异。"
  },
  "1418": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive and covers all key aspects from the reference answer, including MDT评估,分子检测,同步放化疗,免疫巩固,症状管理,随访,以及个体化和靶向治疗的补充说明，无明显遗漏或错误。"
  },
  "1419": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including TNM分期、治疗方案（同步放化疗）、巩固免疫治疗及个体化建议，但分期为IIIc而非IIIB（根据第8版AJCC，N3通常为IIIB），存在轻微分期不准确的瑕疵。"
  },
  "1420": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of staging, multidisciplinary evaluation, and treatment options, including recent advances like consolidation immunotherapy. However, it differs from the reference answer in分期（IIIB vs IIIA），并未完全按照参考答案的分期标准，且对新辅助治疗的讨论略有不同。"
  },
  "1421": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including imaging schedule, the role of chest CT, avoidance of unnecessary advanced imaging, emphasis on smoking cessation, and additional relevant management considerations, with no major omissions or errors."
  },
  "1422": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for immunotherapy plus chemotherapy, the role of KRAS G12C inhibitors, and guideline recommendations, with no major omissions or errors."
  },
  "1423": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it assigns stage IIIA (cT1cN2M0) instead of IIIB, which is a minor staging discrepancy given current AJCC 8th edition criteria. Otherwise, the diagnostic and therapeutic recommendations are comprehensive and appropriate."
  },
  "1424": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately describes the surgical approach, addresses special situations, discusses the role of adjuvant therapy, and covers non-surgical options, matching the reference answer in all key aspects without major omissions or errors."
  },
  "1425": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of current guidelines, but it omits the specific mention of amivantamab联合卡铂/培美曲塞这一首选方案，并对培美曲塞在鳞癌中的应用未作充分说明。"
  },
  "1426": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for immunotherapy plus chemotherapy, bone protection, and supportive care, with no major omissions or errors."
  },
  "1427": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the use of NTRK inhibitors as first-line therapy, management of pleural effusion, alternative options if NTRK inhibitors are not available or tolerated, and supportive care. There are no major omissions or errors."
  },
  "1428": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of routine recommendation for adjuvant chemotherapy in T2aN0 NSCLC post-R0 resection, the role of high-risk factors, and detailed, guideline-based follow-up recommendations. No major omissions or errors are present."
  },
  "1429": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including reoperation, adjuvant radiotherapy, and follow-up. It adds detail on chemotherapy and targeted/immune therapy, which, while not incorrect, are not emphasized in the reference answer. The follow-up intervals are slightly more detailed but generally consistent. Minor omissions include not explicitly mentioning smoking cessation and survivorship care."
  },
  "1430": {
    "score": 4.0,
    "explanation": "4: The model answer与参考答案在分期和治疗原则上基本一致，内容全面，涵盖了分期、MDT评估、手术与放化疗选择及辅助治疗，但对“术前同步放化疗”作为标准首选的强调略有不足，且对术后辅助治疗的细节略多于参考答案，存在轻微偏差。"
  },
  "1431": {
    "score": 0.0,
    "explanation": "0: The model answer does not address the clinical scenario or provide any relevant medical content; it is a generic response to a formatting error."
  },
  "1432": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but recommends routine CT follow-up for a 6mm subsolid nodule in a low-risk patient, which is more aggressive than current guidelines that generally do not recommend routine follow-up for nodules <6mm without high-risk features. There are some inaccuracies and over-management compared to the reference answer."
  },
  "1433": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including endocrine therapy as the mainstay, the limited role of chemotherapy, indications for radiotherapy, and HER2-targeted therapy not being recommended. There are no major omissions or errors."
  },
  "1434": {
    "score": 4.0,
    "explanation": "4: 模型答案内容较为完整，涵盖了再次手术、放疗和辅助化疗等主要治疗选择，但未强调同步放化疗为优选方案，也未提及多学科团队决策和随访建议，存在轻微遗漏。"
  },
  "1435": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including staging, the need to confirm the nature of the renal lesion, and the general treatment strategy (systemic therapy, MDT discussion, local treatment if oligometastatic). However, it omits some details about post-operative systemic therapy and regular imaging follow-up, and the treatment steps are not as clearly structured as in the reference answer."
  },
  "1436": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期（cT1cN0M0, IA3期),手术为首选, 术式与辅助治疗原则，且无重要遗漏或错误。"
  },
  "1437": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering the recommended annual follow-up frequency, specific examination content, and the indications for additional imaging, with no major omissions or errors."
  },
  "1438": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the need for R0切除、放疗、辅助化疗的个体化考虑，但对PET/CT和脑MRI的推荐较参考答案更积极，略有超出常规建议，且随访方案未详细提及。"
  },
  "1439": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it diverges from the reference answer by倾向于双原发肺癌的分期和处理，而未直接采用M1a分期。虽然临床上确实需鉴别双原发与转移，但参考答案更强调按M1a处理。整体内容详实，只有分期判断上有细微差异。"
  },
  "1440": {
    "score": 4.0,
    "explanation": "4: The model answer covers the main points of standard treatment—postoperative radiotherapy and adjuvant chemotherapy—and also discusses possible immunotherapy and targeted therapy, which are reasonable extensions. However, it omits the option of re-operation (补救性切除) as the first-line recommendation for R1 resection, which is a key point in the reference answer."
  },
  "1441": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including follow-up intervals, imaging, and additional considerations such as smoking cessation and late toxicity monitoring. However, it slightly differs in the timing of follow-up intervals (front-loading the first 2 years instead of 3) and adds some details not explicitly mentioned in the reference, such as laboratory tests and psychological assessment, which are useful but not essential. Minor discrepancies prevent a perfect score."
  },
  "1442": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately discusses the rationale for best supportive care, and appropriately addresses the rare scenario of considering immunotherapy if PS is tumor-related, with correct risk assessment. No major omissions or errors."
  },
  "1443": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical options, indications for radiotherapy, endocrine therapy, and the lack of need for chemotherapy or HER2-targeted therapy. No major omissions or errors are present."
  },
  "1444": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the case, correctly identifying T3N0M0 staging and providing detailed treatment principles. However, it incorrectly assigns the stage as IIIa instead of IIb, which is a minor but notable error. Otherwise, the clinical content closely matches the reference answer."
  },
  "1445": {
    "score": 4.0,
    "explanation": "4: 模型答案内容基本完整，涵盖了切缘阳性后的主要治疗选择（放疗、辅助化疗），并有详细说明和指南依据，但遗漏了“若可耐受，优先考虑再次手术切除以获得阴性切缘”这一首选方案。"
  },
  "1446": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, with detailed staging, appropriate recommendations for further pathological confirmation, and a nuanced discussion of treatment options. However, it slightly overemphasizes concurrent chemoradiotherapy as the standard, whereas the reference answer prioritizes neoadjuvant therapy plus surgery, and it adds molecular testing, which, while relevant, is not central to the reference answer. Minor differences in staging terminology (T2b vs T3) are present but do not significantly affect the overall clinical content."
  },
  "1447": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps, including new adjuvant chemoradiotherapy, surgical evaluation, and postoperative management, with appropriate references to guidelines. However, it slightly overemphasizes同步放化疗 as首选，而参考答案更强调新辅助化疗±放疗，且对R1切除后处理未详细说明，存在细微差异。"
  },
  "1448": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including detailed TNM staging, rationale for IIIB/IIIC classification, and appropriate treatment recommendations with additional up-to-date details (e.g., maintenance immunotherapy), without any major omissions or errors."
  },
  "1449": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the priority of reoperation, the alternative of radiotherapy if surgery is not feasible, and the non-recommendation of surveillance alone. There are no major omissions or errors."
  },
  "1450": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, logical approach, but it incorrectly assigns the stage as IIA (T2bN0M0) instead of IIB (T3N0M0) per the reference answer, due to a misinterpretation of the T descriptor for a 6.0 cm tumor. Otherwise, the treatment recommendations and rationale are appropriate."
  },
  "1451": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, adjuvant therapy, and alternative options, with no significant omissions or errors."
  },
  "1452": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of second/third-generation ALK inhibitors, specific drug recommendations, and rationale for not choosing chemotherapy or immunotherapy as first-line. No major omissions or errors."
  },
  "1453": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale for non-surgical management, and the recommended sequence of chemoradiation followed by consolidation immunotherapy, with no major omissions or errors."
  },
  "1454": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including first-line endocrine therapy with CDK4/6 inhibitors, consideration of menopausal status, need for metastatic biopsy to reassess receptor status, and relevant molecular/genetic testing. There are no major omissions or errors."
  },
  "1455": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了再切除、辅助放疗、辅助化疗、MDT讨论及详细随访计划，无重大遗漏或错误，仅随访频率略更细致，内容更为详尽。"
  },
  "1456": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of need for adjuvant therapy and providing detailed, guideline-consistent follow-up recommendations without omissions or errors."
  },
  "1457": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately recommends TRK inhibitors as first-line therapy, specifying larotrectinib and entrectinib with dosing. However, it omits repotrectinib as an option and lacks mention of follow-up and management upon progression, which are included in the reference answer."
  },
  "1458": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies the clinical stage and most necessary preoperative assessments, but it omits the specific mention of纵隔镜或EUS/EBUS取样进行病理性纵隔淋巴结评估, which is an important detail in the reference answer."
  },
  "1459": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including全身性评估（PET-CT、脑MRI）、新辅助治疗评估、多学科会诊等，但对纵隔淋巴结的病理性评估和支气管镜检查的具体补充不够详细。"
  },
  "1460": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up and risk management, including surveillance intervals, imaging, risk of recurrence, and health management. However, it includes some minor additional recommendations (e.g., routine lab tests, tumor markers, and imaging beyond chest CT) that are not standard per the reference, and it does not explicitly state that routine FDG-PET/CT or brain MRI are unnecessary."
  },
  "1461": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major clinical points, including staging, need for biopsy, imaging, and appropriate systemic and supportive therapies. It adds detail about spinal cord compression management, but omits explicit mention of bone-modifying agents (如双膦酸盐或地诺单抗) and regular efficacy/toxicity monitoring, which are present in the reference answer."
  },
  "1462": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and recommended treatment, with no significant omissions or errors."
  },
  "1463": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including pathological confirmation, comprehensive staging, laboratory and symptom assessment, appropriate endocrine and targeted therapy, bone-modifying agents, supportive care, and regular evaluation, with no major omissions or errors."
  },
  "1464": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including re-resection, chemoradiation, and follow-up, and even adds up-to-date guideline-based details and rationale. There are no major omissions or errors."
  },
  "1465": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including follow-up intervals, imaging modality, and lack of need for adjuvant therapy. However, it omits specific mention of not recommending routine PET/CT or brain MRI unless clinically indicated, and does not explicitly mention smoking cessation counseling, which are minor but relevant omissions."
  },
  "1466": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately identifies the stage (IIIA, T4N0M0), and details both surgical and non-surgical management, including the role of EGFR-TKI (osimertinib) as adjuvant therapy, consistent with current guidelines and the reference answer. No major omissions or errors are present."
  },
  "1467": {
    "score": 5.0,
    "explanation": "5: The model answer provides identical clinical content to the reference answer, correctly identifying dabrafenib plus trametinib as the first-line treatment, referencing guidelines, and including appropriate considerations and alternatives. No major omissions or errors are present."
  },
  "1468": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the use of NTRK抑制剂（larotrectinib、entrectinib）为标准治疗，但未提及repotrectinib作为进展后可选药物，也未说明TRK抑制剂耐药或用尽后的其他系统治疗选择，存在轻微遗漏。"
  },
  "1469": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the staging, and provides a nuanced, guideline-consistent discussion of treatment options, including MDT, neoadjuvant therapy, and individualized considerations, with no major omissions or errors."
  },
  "1470": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including follow-up intervals, recommended imaging (chest CT), and clinical assessment. However, it slightly overstates the need for annual CT beyond 5 years (guidelines often individualize this), and the reference answer more clearly states that routine PET/CT or brain MRI are not recommended unless symptomatic. Minor differences in detail, but no major omissions."
  },
  "1471": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of post-operative management and follow-up for Stage IIIA (N2) NSCLC, and even expands on targeted and immunotherapy options based on molecular profiling, with no major omissions or errors."
  },
  "1472": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including diagnosis, mutation type, rationale for osimertinib as first-line therapy, alternative options, and guideline references, with no major omissions or errors."
  },
  "1473": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points: neoadjuvant chemotherapy plus dual HER2-targeted therapy, and adjuvant T-DM1 for ypN1. However, it omits the recommendation for adjuvant radiotherapy and does not mention the alternative of completing trastuzumab±pertuzumab for 1 year if T-DM1 cannot be tolerated."
  },
  "1474": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication, drug options, duration, rationale, and considerations for drug selection, with no major omissions or errors."
  },
  "1475": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including recommending re-resection as first choice and adjuvant radiotherapy if reoperation is not feasible. It provides more detail on chemotherapy, noting it is not routinely indicated for Stage IB without high-risk features, which is a minor deviation from the reference answer but not a major omission."
  },
  "1476": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期、手术方案、术后辅助治疗及随访等要点，无明显遗漏或错误。"
  },
  "1477": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, with detailed staging, comprehensive molecular testing recommendations, and appropriate first-line therapy selection. However, it incorrectly assigns stage IVB instead of IVA (per AJCC 8th edition, single organ, multiple lesions = M1b = IVA), and omits mention of smoking cessation and early palliative care, which are included in the reference answer."
  },
  "1478": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical content, including the need for pathological confirmation, MDT discussion, and preference for surgery or radiotherapy. However, it adds an extra step of biopsy (not explicitly required if imaging and history are clear for recurrence) and omits the recommendation for molecular testing and PD-L1 assessment to guide further therapy, which is present in the reference answer."
  },
  "1479": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it differs from the reference answer in分期（IA3 vs IB），并未提及分化差、脉管侵犯等高危因素对辅助治疗决策的影响，且对辅助治疗的讨论略显简化。"
  },
  "1480": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed explanation of staging and treatment. However, it incorrectly assigns stage IIIC instead of IIIB for T2N3M0 per AJCC 8th edition, which is a minor but notable error; otherwise, the treatment recommendations are appropriate and comprehensive."
  },
  "1481": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemoradiotherapy for R1 resection in NSCLC, including the rationale, guideline references, and consideration of re-resection. However, it omits explicit mention of the recommended follow-up schedule and smoking cessation advice, which are present in the reference answer."
  },
  "1482": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points addressed and no significant omissions or errors."
  },
  "1483": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，详细说明了适应证、药物选择及疗程，并补充了部分细节。"
  },
  "1484": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the recommendation of afatinib as first-line therapy for EGFR L861Q mutation, and correctly advises against immunotherapy or chemotherapy. However, it introduces osimertinib as an alternative, which, while supported by some evidence, is not the primary guideline-recommended option for this specific mutation, making this a minor deviation from the reference answer."
  },
  "1485": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering both the assessment and management of hemoptysis and the recommended molecular testing, with good detail. However, it omits the suggestion for brain MRI to rule out brain metastasis and does not mention smoking cessation or palliative care integration, which are present in the reference answer."
  },
  "1486": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key recommendations, specific drug regimens, and additional considerations without any major omissions or errors."
  },
  "1487": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key points from the reference answer, with additional up-to-date details on immunotherapy and targeted therapy, and no major omissions or errors."
  },
  "1488": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendation of switching to osimertinib for EGFR 19del mutation, with appropriate rationale and guideline references. However, it omits the option of completing current chemotherapy/maintenance in some cases and does not mention amivantamab-lazertinib as an alternative, nor does it address smoking cessation and palliative care integration."
  },
  "1489": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including history, physical exam, chest CT, and timing intervals. However, it slightly overemphasizes laboratory and tumor marker testing (which is not routinely recommended) and suggests a more frequent follow-up interval (every 3–6 months) than the reference answer (every 6 months), which is a minor deviation from standard guidelines."
  },
  "1490": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for 21-gene RT-PCR testing, the rationale, and detailed guidance for adjuvant therapy based on test results, with no major omissions or errors."
  },
  "1491": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need for pre-treatment axillary lymph node marking, the approach to sentinel lymph node biopsy post-neoadjuvant therapy, and the criteria for omitting axillary dissection. No major omissions or errors are present."
  },
  "1492": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including surgical treatment, detailed preoperative assessments, and specific imaging and functional tests. However, it omits explicit mention of brain MRI for metastasis screening and is less specific about the need for mediastinal lymph node pathological evaluation in all cases, not just when nodes are suspicious."
  },
  "1493": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the need for postoperative radiotherapy, consideration of adjuvant chemotherapy, and appropriate follow-up. However, it omits the preferred recommendation of re-resection to achieve negative margins as the first choice, which is emphasized in the reference answer. Minor differences in follow-up intervals and additional mention of targeted therapy are present but do not detract significantly from the overall accuracy."
  },
  "1494": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical steps, including staging, neoadjuvant therapy, and subsequent management. However, it omits specific recommendations about tumor and lymph node marking before neoadjuvant therapy and lacks detail on high-risk postoperative adjuvant therapy options (e.g., olaparib or abemaciclib for certain patients)."
  },
  "1495": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it differs from the reference answer in分期（IA3期 vs IB期）—this is due to a difference inT分期判定（T1c vs T2a），但整体内容、治疗建议和分期依据都很全面，仅有细微分歧。"
  },
  "1496": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, preoperative assessment, surgical recommendations, and adjuvant therapy, with no major omissions or errors. It even adds appropriate details about MDT评估 and molecular testing, which are relevant and do not detract from the core content."
  },
  "1497": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale, recommended regimen (aromatase inhibitor plus CDK4/6 inhibitor), and the addition of bone-modifying agents, with no major omissions or errors."
  },
  "1498": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including first-line chemo-immunotherapy, the role and timing of KRAS G12C inhibitors, and supportive care, with no major omissions or errors."
  },
  "1499": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals and imaging modalities. However, it omits the specific recommendation for low-dose non-contrast CT after 5 years and does not clearly state that PET/CT or brain MRI are only recommended when recurrence or metastasis is highly suspected, rather than as routine."
  },
  "1500": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, including all key recommendations from the reference answer, and adds relevant details about alternative agents, dosing, and rationale, with no major omissions or errors."
  },
  "1501": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major aspects, including staging, necessary pre-treatment evaluations, and detailed neoadjuvant therapy recommendations. However, it omits the suggestion to place a marker clip in the suspicious axillary lymph node and does not mention the post-operative use of T-DM1 if pCR is not achieved, which are present in the reference answer."
  },
  "1502": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering initial staging, necessary preoperative assessments, and appropriate neoadjuvant treatment strategy for HER2-positive, hormone receptor-negative breast cancer, with no major omissions or errors."
  },
  "1503": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM分期、AJCC分期、手术为首选、术后辅助化疗，并无重要遗漏或错误。"
  },
  "1504": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, and recommendations against routine brain MRI or PET/CT in asymptomatic patients, with no major omissions or errors."
  },
  "1505": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and stepwise management, including surgical and non-surgical options, with no significant omissions or errors."
  },
  "1506": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including frequency, content, and additional considerations. However, it slightly overstates the frequency of follow-up in the first 2 years (every 3–6 months vs. every 6 months in the reference) and includes optional tumor markers and imaging not routinely recommended, which are minor deviations."
  },
  "1507": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, indications, and options for neoadjuvant therapy, but it places slightly more emphasis on direct surgery as the default and does not explicitly recommend neoadjuvant therapy as a reasonable option as clearly as the reference answer. Minor omissions in guideline-based rationale prevent a perfect score."
  },
  "1508": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and standard treatment strategy, with no major omissions or errors. Minor expansions (e.g., molecular testing) are appropriate and do not detract from completeness."
  },
  "1509": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all recommended molecular and biomarker tests and providing appropriate, guideline-based treatment strategies according to the results, with no major omissions or errors."
  },
  "1510": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key molecular tests and their clinical significance, but it omits some less common genes (e.g., ERBB2/HER2, METex14 skipping) and does not explicitly mention the option of plasma ctDNA testing. Otherwise, it aligns well with the reference answer."
  },
  "1511": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including recommended molecular and PD-L1 testing, and how results guide therapy. However, it omits NTRK and ERBB2 (HER2) in the initial gene list, and the last line is incomplete, missing the full recommendation for PD-L1 TPS <1%."
  },
  "1512": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including risk stratification, follow-up intervals, and the rationale against immediate PET/CT or biopsy, with no major omissions or errors."
  },
  "1513": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points on staging (cT2aN2M0, IIIA) and comprehensive molecular pathology testing, including all relevant genes and PD-L1, with no significant omissions or errors."
  },
  "1514": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including the need for pathological diagnosis, molecular testing, and systemic therapy. However, it omits explicit mention of palliative intent, the option of close observation for indolent disease, and the importance of considering the patient's overall status and wishes, which are present in the reference answer."
  },
  "1515": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging, assessment, and treatment recommendations. However, it incorrectly assigns stage IIIC (should be IIIB per current AJCC 8th edition for T2aN3M0), which is a minor but notable staging error. Otherwise, the clinical content is thorough."
  },
  "1516": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, covers guideline recommendations, high-risk factors, and follow-up, with no major omissions or errors."
  },
  "1517": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including local treatment options, the limited role of systemic therapy, and the rationale based on the tumor’s biology and prognosis, with no major omissions or errors."
  },
  "1518": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including pulmonary function, mediastinal lymph node assessment, and additional relevant tests. However, it introduces heart function and tumor marker/molecular testing, which, while useful, are not strictly required per the reference answer, and it does not explicitly mention the selective use of bronchoscopy for tumor localization."
  },
  "1519": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key aspects of follow-up, includes appropriate intervals, imaging modalities, and additional considerations such as MDT discussion for R2 resection, and aligns closely with the reference answer without major omissions or errors."
  },
  "1520": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides detailed rationale and guideline support without any major omissions or errors."
  },
  "1521": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (cT1bN0M0/IA期) and standard treatment (lobectomy with lymph node dissection, SBRT if inoperable), with no major omissions or errors."
  },
  "1522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including initial systemic therapy, subsequent local radical treatment to both primary and metastatic sites, and the importance of MDT discussion, with no major omissions or errors."
  },
  "1523": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of NTRK inhibitors as first-line therapy, rationale for prioritizing targeted therapy over immunotherapy or chemotherapy, and relevant guideline references, with no major omissions or errors."
  },
  "1524": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, chest CT, and lifestyle advice. However, it omits the specific recommendation for low-dose non-contrast CT after 5 years and does not explicitly state that routine brain MRI or PET/CT is unnecessary in asymptomatic patients."
  },
  "1525": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendation of using NTRK inhibitors as first-line therapy, referencing guidelines and providing rationale. However, it omits mention of repotrectinib as an option and does not discuss the scenario where NTRK fusion is discovered after starting systemic therapy or the need for multidisciplinary, individualized treatment planning."
  },
  "1526": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of the reference answer, and even expands on guideline details without introducing errors or omissions."
  },
  "1527": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, indications for PET/CT and brain MRI, and health management, with no major omissions or errors."
  },
  "1528": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, with clear recommendations on follow-up intervals, imaging, and the non-routine use of PET/CT or brain MRI. However, it slightly differs in the timing of follow-up intervals and omits explicit mention of smoking cessation counseling and survivorship care, which are included in the reference answer."
  },
  "1529": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, the role of chest CT, and the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "1530": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical steps, including MDT评估,手术切除,术前评估,辅助化疗,分子检测,以及不能手术时的放化疗选择，内容与参考答案一致且更为详细，无重大遗漏或错误。"
  },
  "1531": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including switching to ALK-TKI therapy, specific drug recommendations, rationale for stopping current treatment, and monitoring, with no major omissions or errors."
  },
  "1532": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering MDT评估、局部与全身治疗选择，并详细说明了再次放疗、化疗、免疫和靶向治疗的适应证，但对“优先系统治疗”原则表述不够突出，且未完整写出靶向治疗内容，存在轻微遗漏。"
  },
  "1533": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, molecular status, PD-L1 expression, recommended immunochemotherapy regimens, and rationale, with no major omissions or errors."
  },
  "1534": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, need for pathological confirmation, and standard treatment strategy, but it adds extra detail on molecular testing and supportive care while not explicitly emphasizing the need for pathological confirmation of N3 status (e.g., via EBUS/EUS/biopsy) before finalizing stage and treatment, which is a minor omission."
  },
  "1535": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of staging, rationale, and treatment strategy, including MDT discussion, chemoradiotherapy, consolidation immunotherapy, and molecular testing. However, it incorrectly assigns stage IIIA (cT2N2M0) instead of the more appropriate stage IIIB (as per the reference answer, given \"多发\"纵隔淋巴结和右上肺占位，且未排除T4可能性)，which is a minor but relevant omission."
  },
  "1536": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, rationale, targeted therapy, alternative options, and supportive care, with no major omissions or errors."
  },
  "1537": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key points, including staging, further necessary investigations, and management of bone metastasis, with only minor differences in T分期（T3 vs T4）和分期分组（IVB vs IV），但整体内容与参考答案高度一致，未有重大遗漏。"
  },
  "1538": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant chemotherapy, immunotherapy, and follow-up, with additional detail on targeted therapy and immunotherapy options. However, it is slightly more elaborate than required and introduces some recommendations (e.g., immunotherapy, targeted therapy) that, while evidence-based, are not explicitly mentioned in the reference answer, making it a minor deviation."
  },
  "1539": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of BRAF/MEK inhibitor therapy, rationale, alternative options, and guideline references, with no major omissions or errors."
  },
  "1540": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key aspects of the reference answer, including adjuvant radiotherapy, chemotherapy, individualized treatment, and follow-up, with no major omissions or errors. It even provides additional guideline references and detailed regimen options, fully aligning with current clinical recommendations."
  },
  "1541": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, rationale for neoadjuvant therapy, specific regimens, surgical considerations, and adjuvant therapy, with no major omissions or errors."
  },
  "1542": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, including correct staging (cT4dN1-2M0, stage IIIb/IIIc), recognition of inflammatory breast cancer, and outlines the standard treatment sequence (neoadjuvant chemo + anti-HER2, surgery, adjuvant therapy, radiotherapy, follow-up) with no major omissions or errors."
  },
  "1543": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, accurately summarizes the case, references relevant guidelines, and clearly explains the role and interpretation of 21基因RT-PCR检测 in guiding adjuvant chemotherapy decisions, with no major omissions or errors."
  },
  "1544": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the N3 status, M0, and recommending concurrent chemoradiotherapy as the first-line treatment. However, it assigns stage IIIC instead of IIIB (the reference answer uses IIIB, which is more commonly accepted for T1-2N3M0), and includes additional details about consolidation immunotherapy, which, while current, is not explicitly required by the reference answer. Minor staging discrepancy prevents a perfect score."
  },
  "1545": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of approved KRAS G12C-targeted therapy for squamous cell carcinoma, the role of PD-L1 expression, and the recommendation for immunotherapy combined with platinum-based chemotherapy. No major omissions or errors are present."
  },
  "1546": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable overview of treatment options and correctly notes the limited efficacy of first- and second-generation EGFR-TKIs, but it omits the most up-to-date first-line recommendation (amivantamab-vmjw combined with platinum and pemetrexed) and instead defaults to chemotherapy as first-line, which is no longer the preferred approach per current guidelines."
  },
  "1547": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant therapy, follow-up intervals, imaging, and supportive care. However, it adds details about adjuvant therapy and molecular testing not specified in the reference answer, and the follow-up imaging frequency is slightly more frequent than guideline recommendations, representing minor deviations."
  },
  "1548": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including adjuvant chemotherapy, follow-up intervals, and smoking cessation. However, it introduces additional details (e.g., targeted/immune therapy, specific trial names) and minor deviations in follow-up timing, and does not fully finish the follow-up content, leading to minor omissions."
  },
  "1549": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up frequency, imaging modality, and additional considerations. However, it omits the specific recommendation for low-dose non-contrast CT after 5 years and does not explicitly mention smoking cessation and health management advice, which are present in the reference answer."
  },
  "1550": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the indications for brain MRI and FDG-PET/CT, with no major omissions or errors."
  },
  "1551": {
    "score": 4.0,
    "explanation": "4: 模型答案内容非常全面，涵盖了系统性治疗、骨相关治疗、对症支持、基因检测及疗效评估等核心要点，但对全身状况评分、骨活检复核激素受体/HER2状态、心理支持等细节略有遗漏。"
  },
  "1552": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, treatment recommendations, and even adds the current standard of care regarding maintenance immunotherapy, with no major omissions or errors."
  },
  "1553": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了随访频率、影像学选择及不推荐常规PET-CT/脑MRI等要点，无明显遗漏或错误。"
  },
  "1554": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including staging, pathology review, systemic therapy options, and consideration of molecular changes. However, it omits explicit mention of regular efficacy and toxicity assessment, supportive/palliative care for refractory cases, and comprehensive genetic testing beyond BRCA, which are present in the reference answer."
  },
  "1555": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prioritization of RET inhibitors, specific drug names, timing, and additional considerations, with no major omissions or errors."
  },
  "1556": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of adjuvant chemotherapy and the consideration of radiotherapy, but it overemphasizes the lack of recommendation for adjuvant radiotherapy in N2 disease, which is still considered in selected cases per guidelines. It also adds immunotherapy, which is a recent update but not universally standard yet, making the answer slightly divergent from the reference."
  },
  "1557": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the stage (IIIB), recommending further functional assessment, and outlining standard treatment. However, it adds molecular testing and immunotherapy consolidation, which, while relevant, are not strictly required at this stage per the reference answer, and it omits the explicit recommendation for pathological confirmation of N3 disease before definitive chemoradiotherapy."
  },
  "1558": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including RET inhibitor monotherapy as first-line, specific drug names, rationale, and the role of PD-L1/other therapies. No major omissions or errors."
  },
  "1559": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key steps, including axillary biopsy, baseline evaluation, MDT discussion, and neoadjuvant therapy planning. However, it omits some specific details from the reference answer, such as the placement of marker clips in the tumor and lymph node, the use of advanced imaging (e.g., PET-CT, bone scan, breast MRI), and BRCA1/2 genetic testing."
  },
  "1560": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately restates the diagnosis, and details all key steps for pathological and molecular testing, including rationale and guideline-based recommendations. No major omissions or errors are present."
  },
  "1561": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要治疗选择（放疗和化疗）、随访建议和戒烟等内容，但未将“再次切除”作为首选方案，且随访频率略有不同，部分细节（如不常规推荐脑MRI和PET/CT）未明确提及。"
  },
  "1562": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the key points of staging and surgical considerations, but it incorrectly classifies T4N0M0 as stage IIIA instead of the more accurate IIIB (per the reference answer and latest staging), and does not explicitly mention neoadjuvant therapy as the preferred initial approach."
  },
  "1563": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and specific regimen details, with no major omissions or errors."
  },
  "1564": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects current guidelines, covers both neoadjuvant and adjuvant therapy considerations, and provides appropriate next-step recommendations without major omissions or errors."
  },
  "1565": {
    "score": 4.0,
    "explanation": "4: The model answer covers almost all key clinical steps, including the need for ultrasound-guided biopsy and subsequent management based on results. However, it omits the important detail of placing a marker in the biopsied positive node for targeted removal after neoadjuvant therapy, which is emphasized in the reference answer."
  },
  "1566": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the case, but it incorrectly assigns stage IIIC instead of IIIB for cT2aN3M0 NSCLC per AJCC 8th edition. All other clinical content and treatment recommendations are accurate and thorough."
  },
  "1567": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers staging, pathology, and all appropriate next-step management options, including surgical and adjuvant therapies, and even discusses neoadjuvant therapy considerations. No major omissions or errors are present."
  },
  "1568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including surgical approach, lymph node dissection, perioperative assessment, adjuvant therapy considerations, and follow-up, with no major omissions or errors."
  },
  "1569": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key points, recommending postoperative chemoradiation as standard, and provides additional context on chemotherapy, immunotherapy, and surgical considerations. However, it introduces some minor details (e.g., immunotherapy) that are less emphasized in the reference answer and could be considered supplementary rather than core to the standard of care."
  },
  "1570": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the case, correctly identifying T4N2M0 staging and recommending concurrent chemoradiotherapy with consolidation immunotherapy. However, it incorrectly assigns the stage as IIIB instead of IIIA (per the reference answer and current AJCC 8th edition), which is a minor but notable error."
  },
  "1571": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed TNM staging and appropriate treatment recommendations. However, it assigns stage IIIC (T1cN3M0) instead of stage IIIB (T1-2N3M0) as in the reference, which may reflect a difference in staging edition or interpretation, and omits mention of the need to assess pulmonary function and general condition before therapy."
  },
  "1572": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, content, and lifestyle advice. However, it omits the specific recommendation for low-dose non-contrast CT after 2–3 years, does not explicitly state that routine PET/CT or brain MRI are not recommended unless clinically indicated, and the follow-up intervals are slightly broader than the reference."
  },
  "1573": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations, including alternatives if surgery is not feasible. However, it slightly overstates the T stage (T1c vs. T1b) and stage (IA3 vs. IA2) based on the 2.2 cm size, which is a minor inaccuracy."
  },
  "1574": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding surgical treatment, the role of adjuvant therapy, and the lack of necessity for preoperative genetic testing, with no major omissions or errors."
  },
  "1575": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of adjuvant therapy and follow-up, and even provides additional detail on molecular testing and individualized treatment, with no major omissions or errors."
  },
  "1576": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of mediastinal lymph node pathological assessment and pulmonary function testing. However, it omits the recommendation for brain MRI to rule out intracranial metastasis and does not mention possible MRI for superior sulcus involvement, which are included in the reference answer."
  },
  "1577": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly stating that adjuvant chemotherapy is not recommended for IA stage and providing a detailed follow-up plan. However, it omits the option of discussing adjuvant chemotherapy for IIA stage (as in the reference), and does not mention smoking cessation or cancer survivorship management, which are minor but relevant omissions."
  },
  "1578": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional guideline-based details and logical sequencing. There are no major omissions or errors."
  },
  "1579": {
    "score": 3.0,
    "explanation": "3: The model answer provides a generally accurate TNM staging process and appropriate surgical recommendations, but incorrectly assigns the stage as IIA instead of IIB, and underestimates the importance of broad molecular and PD-L1 testing in squamous cell carcinoma, which are recommended in the reference answer. These omissions and inaccuracies lower the score."
  },
  "1580": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, providing detailed recommendations for adjuvant chemotherapy and follow-up. However, it slightly overemphasizes the recommendation for adjuvant chemotherapy (using \"推荐\" rather than \"可选择\") and does not mention smoking cessation or survivorship care, which are included in the reference answer."
  },
  "1581": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, rationale for switching to ROS1 inhibitors, specific drug options, and consideration of patient status. No major omissions or errors are present."
  },
  "1582": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential steps of performing a pathological assessment of the suspicious axillary lymph node using FNA or core needle biopsy. However, it omits the important detail of placing a marker clip in the biopsied node for future surgical identification, which is present in the reference answer."
  },
  "1583": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, drug options, and sequencing of therapy, with no major omissions or errors."
  },
  "1584": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of follow-up timing, content, and management, but it slightly differs in CT frequency recommendations (mentions 6–12 months rather than strictly every 3–6 months initially, and does not specify non-contrast CT after 5 years). It also adds some extra but relevant details, such as lifestyle advice and tumor markers, but omits the explicit recommendation against routine PET/CT and brain MRI in asymptomatic patients."
  },
  "1585": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, includes all key investigations (mediastinal biopsy, brain MRI), accurately describes the staging, and provides detailed, guideline-concordant treatment recommendations with no major omissions or errors."
  },
  "1586": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale for non-surgical management, and detailing both standard and subsequent recommended therapies without omissions or errors."
  },
  "1587": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points including the use of crizotinib as first-line therapy, the rationale for targeted therapy over chemotherapy, and mentioning alternative ROS1 inhibitors. No major omissions or errors are present."
  },
  "1588": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including reoperation, radiotherapy, and adjuvant chemotherapy. However, it omits specific follow-up recommendations and the option for individualized treatment if the patient cannot tolerate chemoradiotherapy."
  },
  "1589": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key clinical points from the reference answer, and adds appropriate detail without introducing errors or omissions."
  },
  "1590": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including staging, surgical recommendation, and follow-up. However, it incorrectly assigns the stage as IA3 (cT1cN0M0) instead of IB (T2aN0M0), which is a minor but important detail. Otherwise, the clinical content is accurate."
  },
  "1591": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps including pathological biopsy of the nipple/areolar lesion, confirmation of diagnosis, and subsequent surgical management options based on pathology and extent, with no major omissions or errors."
  },
  "1592": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and all key steps of standard treatment without omissions or errors."
  },
  "1593": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key management steps, including re-resection, radiotherapy, and adjuvant chemotherapy, as well as detailed follow-up. However, it introduces additional content (e.g., targeted/immunotherapy) not specified in the reference and slightly differs in follow-up intervals, which are minor deviations."
  },
  "1594": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including detailed preoperative assessments (lung function, mediastinal lymph node evaluation, cardiac and other routine assessments) and a thorough approach to pathological staging, with no major omissions or errors."
  },
  "1595": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，详细阐述了首选MET抑制剂靶向治疗，并补充了局部治疗和其他方案的考虑，无重大遗漏或错误。"
  },
  "1596": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for MET抑制剂作为首选，并明确指出免疫治疗和化疗仅为后续选择，无重大遗漏或错误。"
  },
  "1597": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including maintenance therapy, immunotherapy, and HER2-targeted therapy, as well as supportive care. However, it places more emphasis on immunotherapy as maintenance rather than prioritizing HER2-targeted therapy as the first choice after chemotherapy, which is the main recommendation in the reference answer. Minor omissions and a slight difference in prioritization prevent a perfect score."
  },
  "1598": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including indications and rationale for adjuvant chemotherapy, anti-HER2 therapy, endocrine therapy, and radiotherapy, with appropriate detail and no major omissions or errors."
  },
  "1599": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects including systemic chemotherapy, the role of immunotherapy, bone-targeted therapy, pain management, and supportive care, with no major omissions or errors."
  },
  "1600": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, mutation status, rationale for osimertinib as first-line therapy, and reasons for not choosing immunotherapy or chemotherapy. There are no major omissions or errors."
  },
  "1601": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a systematic approach to clinical staging and preoperative assessment. However, it assigns T2bN0M0 (stage IIA) rather than T3N0M0 (stage IIB) as in the reference, which is a minor but notable discrepancy in T staging. Otherwise, the preoperative evaluation is thorough and appropriate."
  },
  "1602": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, but it incorrectly assigns the clinical stage as IIIa instead of IIB, which is a significant but single error; otherwise, the treatment recommendations and reasoning are appropriate and thorough."
  },
  "1603": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including re-resection, radiotherapy, and follow-up, with additional details on chemotherapy and MDT discussion. However, it slightly overemphasizes adjuvant chemotherapy (which is not standard for IB without high-risk features) and follow-up intervals differ somewhat from the reference, making minor omissions and deviations."
  },
  "1604": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, and considerations for adjuvant therapy, with no major omissions or errors."
  },
  "1605": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of indication for adjuvant therapy in stage IB without high-risk features, the role of molecular testing, and the recommendation for regular follow-up. No major omissions or errors are present."
  },
  "1606": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing BRAF/MEK inhibitor therapy and mentioning alternative options only if targeted therapy is unavailable, with no major omissions or errors."
  },
  "1607": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it slightly differs in the recommended frequency and duration of follow-up visits and chest CT scans, and adds extra detail about laboratory tests and guidelines. These are minor omissions and variations, but the core clinical content is accurate."
  },
  "1608": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including frequency, recommended tests, and when to consider additional imaging. However, it slightly overstates the duration and frequency of CT scans (suggesting up to 5 years every 6–12 months, rather than transitioning to annual scans after 5 years), and includes some extra details not strictly required by the reference answer. Minor deviations prevent a perfect score."
  },
  "1609": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the tumor staging (cT1cN2M0, IIIA), MDT discussion, neoadjuvant therapy, surgical considerations, and alternative treatments, with no major omissions or errors."
  },
  "1610": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, including schedule, content, imaging, and additional considerations like smoking cessation. However, it slightly over-specifies the frequency (every 3–6 months vs. every 6 months) and adds some details (e.g., lab tests, comorbidity management) not emphasized in the reference, but these do not detract from the core clinical content."
  },
  "1611": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate TNM staging, appropriate next steps for mediastinal lymph node confirmation, multidisciplinary discussion, treatment options, and additional relevant recommendations such as molecular testing, with no major omissions or errors."
  },
  "1612": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly identical to the reference answer, thoroughly covering staging and systemic therapy selection, including rationale and drug options. However, it omits explicit mention of bone protection agents and palliative/supportive care, which are minor but relevant details."
  },
  "1613": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of molecular testing and treatment decision-making for stage IIIB NSCLC, including comprehensive gene testing, PD-L1 assessment, the rationale for testing, standard concurrent chemoradiotherapy, consolidation immunotherapy, and the role of targeted therapy upon progression. There are no major omissions or errors."
  },
  "1614": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including indications for neoadjuvant therapy and detailed preoperative assessments. However, it introduces some ambiguity about the necessity of neoadjuvant therapy (suggesting direct surgery is also reasonable), and omits mention of lesion marker clip placement, which is a minor but relevant detail."
  },
  "1615": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, but it incorrectly分期s the case as IIB期 instead of IB期, which is a significant but single error; otherwise, the clinical reasoning and recommendations closely match the reference answer."
  },
  "1616": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale for immunotherapy plus chemotherapy, specific drug regimens, and the reasoning against monotherapy. No major omissions or errors are present."
  },
  "1617": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, interpretation of the 21-gene score, guideline recommendations, and specific endocrine therapy options, with no major omissions or errors."
  },
  "1618": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging, symptom assessment, and lifestyle advice. However, it slightly deviates from the reference in the recommended frequency and type of CT (suggesting low-dose CT for all years), and includes some additional but less emphasized points (e.g., tumor markers, second primary screening), while not explicitly stating the non-recommendation of routine PET/CT or brain MRI unless symptomatic."
  },
  "1619": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, correctly recommending osimertinib monotherapy and providing rationale. However, it omits mentioning the possible consideration of combination therapy with chemotherapy in special circumstances and does not address supportive care or smoking cessation."
  },
  "1620": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including staging, treatment options (synchronous chemoradiotherapy, durvalumab maintenance), and the role of molecular testing. However, it slightly underemphasizes the guideline recommendation to perform molecular testing for common driver genes even in squamous cell carcinoma, as stated in the reference answer."
  },
  "1621": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately discusses the indications for adjuvant chemotherapy, provides appropriate regimen recommendations, addresses the option of observation, and details a suitable follow-up schedule, matching the reference answer in all key aspects."
  },
  "1622": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical approach, sentinel lymph node biopsy, the necessity of adjuvant radiotherapy, and consideration of adjuvant systemic therapy. No major omissions or errors are present."
  },
  "1623": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed TNM分期（T1cN0M0, IA3期）和治疗建议（手术优选、SBRT备选），但与参考答案相比，分期细分略有不同（T1b vs T1c, IA vs IA3），且对术前进一步病理明确的建议略超出题干要求，属于细节性差异。整体内容无重大遗漏或错误。"
  },
  "1624": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗推荐及术后管理均无遗漏或错误，仅在术式选择上补充了亚肺叶切除的可选性，属于合理扩展。"
  },
  "1625": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, clearly recommending ROS1靶向治疗（如克唑替尼、恩曲替尼）为一线首选，并排除了免疫和化疗作为首选。唯一小的遗漏是未提及瑞普替尼（Repotrectinib）作为可选药物。"
  },
  "1626": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, exclusion of targeted therapy, choice of platinum-based doublet chemotherapy plus immunotherapy, rationale, and guideline references, with no major omissions or errors."
  },
  "1627": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of clinical staging and preoperative assessment, including detailed imaging, laboratory, and functional evaluations, and even adds appropriate MDT discussion and cardiac assessment for HER2-targeted therapy. There are no major omissions or errors compared to the reference answer."
  },
  "1628": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging rationale, N3 definition, treatment recommendations, and the role of consolidation immunotherapy, with no major omissions or errors."
  },
  "1629": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference, thoroughly covering the rationale for ALK-TKI as first-line therapy, addressing the irrelevance of PD-L1 status in this context, and correctly deprioritizing immunotherapy and chemotherapy. No major omissions or errors are present."
  },
  "1630": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but overemphasizes同步放化疗 (concurrent chemoradiotherapy), which is not the standard for multifocal, unresectable, N1-stage lung cancer without significant symptoms; systemic (palliative) chemotherapy is preferred per the reference. There are some omissions regarding the role of systemic therapy as the mainstay and the option of observation in asymptomatic patients."
  },
  "1631": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key steps—neoadjuvant chemoradiotherapy, reassessment, surgery, and postoperative management—without omissions or errors. It even provides additional detail and guideline references, fully aligning with current standards."
  },
  "1632": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM and stage, and providing appropriate surgical recommendations with no significant omissions or errors."
  },
  "1633": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points, including the distinction between multiple primary lung cancers, separate TNM staging, and appropriate treatment strategies, with no major omissions or errors."
  },
  "1634": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including no need for adjuvant therapy, appropriate follow-up intervals, and recommended tests. However, it slightly overemphasizes physical examination (not specifically required in the reference), extends annual CT to 5 years (reference suggests after 2-3 years), and adds some extra details not present in the reference answer. Minor deviations prevent a perfect score."
  },
  "1635": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with current guidelines, emphasizing concurrent chemoradiotherapy followed by consolidation immunotherapy. However, it omits the importance of invasive mediastinal staging (e.g., EBUS or mediastinoscopy) to confirm N2 disease and does not mention the potential for surgical evaluation after neoadjuvant therapy, which are key steps in the reference answer."
  },
  "1636": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately describes the staging, treatment strategy, and even adds appropriate detail regarding molecular testing, which does not detract from the core answer."
  },
  "1637": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including RET抑制剂为首选、脑部姑息放疗、免疫治疗非首选、支持治疗及多学科管理，无明显遗漏或错误。"
  },
  "1638": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging, adjuvant therapy options, and follow-up, with appropriate references to guidelines and clinical trials. However, it omits some minor details such as the explicit recommendation against routine PET/CT or brain MRI in asymptomatic patients and the emphasis on smoking cessation and survivorship care."
  },
  "1639": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers the need for pathological confirmation of N2 disease, details the staging, and outlines both surgical and non-surgical treatment pathways in line with the reference answer, with no major omissions or errors."
  },
  "1640": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of follow-up frequency and imaging recommendations, including not routinely performing brain MRI or FDG-PET/CT in asymptomatic patients. However, it adds some extra details (e.g., abdominal imaging, lab tests) and slightly differs in the timing for follow-up intervals, but these are minor and do not detract from the core clinical content."
  },
  "1641": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including RET抑制剂为首选、免疫治疗疗效有限、化疗为备选，并补充了指南依据，无重大遗漏或错误。"
  },
  "1642": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it omits“再次手术切除以争取R0切除”为首选的建议，直接将辅助放疗作为首选，且对戒烟指导和肿瘤生存管理等随访内容未提及。"
  },
  "1643": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed TNM staging and appropriate treatment recommendations. However, it assigns stage IIIC (AJCC 8th edition), while the reference answer uses stage IIIB, reflecting a minor discrepancy in staging conventions. Otherwise, the clinical content and management plan are correct."
  },
  "1644": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up intervals, imaging modalities, and the lack of indication for routine brain MRI or PET/CT, with no major omissions or errors."
  },
  "1645": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the staging and treatment, but it introduces ambiguity regarding T2b vs. T3 due to the lack of explicit chest wall invasion, whereas the reference answer assumes T3 based on \"邻近胸壁\" per guidelines. The model answer also adds details about molecular testing and alternative treatments, which, while accurate, are not strictly required for this scenario. Minor omissions and slight over-qualification prevent a perfect score."
  },
  "1646": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for MET inhibitor targeted therapy, specific drug examples, the rationale for not prioritizing immunotherapy or chemotherapy, and appropriate references. No major omissions or errors are present."
  },
  "1647": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including synchronous chemoradiotherapy, consolidation immunotherapy, molecular testing, and supportive care, with no major omissions or errors."
  },
  "1648": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the case, but it incorrectly assigns the T stage as T3 instead of T4 for同侧不同肺叶的多发病灶 per the reference answer, and does not clearly state the overall stage as IIIB. Otherwise, the management plan and reasoning are appropriate."
  },
  "1649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including diagnosis, preferred targeted therapies (Amivantamab, Mobocertinib), the limited efficacy of standard EGFR-TKIs and immunotherapy, and the importance of clinical trials and supportive care, with no major omissions or errors."
  },
  "1650": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for re-resection, the alternative of postoperative radiotherapy if surgery is not feasible, and the lack of indication for adjuvant chemotherapy. It also references relevant guidelines and emphasizes multidisciplinary discussion, with no major omissions or errors."
  },
  "1651": {
    "score": 5.0,
    "explanation": "5: 临床分期和首选治疗方案与参考答案完全一致，涵盖所有关键信息，无明显遗漏或错误。"
  },
  "1652": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up frequency, imaging, and lifestyle management. However, it slightly differs in the recommended duration and frequency of chest CT scans and omits the explicit recommendation against routine use of PET/CT or brain MRI unless clinically indicated."
  },
  "1653": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including adjuvant chemotherapy with HER2-targeted therapy, radiotherapy, and the rationale for omitting endocrine therapy, with no major omissions or errors."
  },
  "1654": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering staging, rationale, and all recommended treatment strategies, including perioperative therapy, chemoradiotherapy, surgical considerations, and consolidation immunotherapy, with no major omissions or errors."
  },
  "1655": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including prioritizing re-excision for negative margins, considering radiotherapy if re-excision is not feasible, and addresses subsequent adjuvant therapy. There are no major omissions or errors."
  },
  "1656": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including imaging modality, frequency, and additional follow-up considerations. However, it slightly differs from the reference answer regarding the frequency in the third year (model answer suggests annual CT from year 3, while the reference allows for continued 6-monthly follow-up in year 3), and it omits explicit mention of low-dose, non-contrast CT after 3 years."
  },
  "1657": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, and the indications for PET/CT and brain MRI, with no major omissions or errors."
  },
  "1658": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, content, and lifestyle advice. However, it suggests a slightly more frequent follow-up schedule than the reference and includes optional tumor marker testing and additional imaging, which are not routinely recommended, representing minor deviations from the reference answer."
  },
  "1659": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging, and supportive care. However, it slightly differs in the recommended frequency and type of chest CT (suggesting every 6-12 months rather than every 3-6 months in the first 3 years, and not specifying contrast use), and does not explicitly mention that routine PET-CT or brain MRI are not recommended unless symptoms arise. Minor omissions prevent a perfect score."
  },
  "1660": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key aspects of clinical staging, necessary preoperative assessments, and treatment recommendations, with no major omissions or errors compared to the reference answer."
  },
  "1661": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and logical reasoning but incorrectly classifies the staging as M1a (IVA) instead of T4 (IIIB) for same-side, different-lobe nodules, which is a significant inaccuracy. It also omits the recommendation for mediastinal lymph node pathological assessment, which is crucial for accurate staging and management."
  },
  "1662": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly stages the patient as IIB instead of IB, which is a significant error. It also recommends adjuvant chemotherapy and targeted/immune therapy as standard, which is not generally indicated for IB without high-risk features, leading to notable inaccuracies in both staging and management."
  },
  "1663": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the staging, rationale, and recommendations regarding mediastinal lymph node assessment, with no significant omissions or errors."
  },
  "1664": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient summary, rationale for omitting chemotherapy, and detailed endocrine therapy recommendations, with no major omissions or errors."
  },
  "1665": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including patient characteristics, guideline references, and individualized decision-making. However, it is somewhat lengthy, does not clearly state that standard treatment is endocrine therapy (tamoxifen ± ovarian suppression), and lacks a concise summary of endocrine therapy options and duration, which are present in the reference answer."
  },
  "1666": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points from the reference answer, including病灶评估、腋窝评估、全身状况、实验室检查等，但对腋窝可疑淋巴结穿刺及标记物置入等细节描述不够具体，且部分内容如常规血常规、肝肾功能等未明确列出为“常规”检查，略有扩展但无重大遗漏。"
  },
  "1667": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1668": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it suggests a slightly more frequent follow-up schedule in the first 2–5 years and adds optional imaging of the upper abdomen, which is not standard for all patients. Minor differences in follow-up intervals and additional details about high-risk factors are present, but no major omissions or errors."
  },
  "1669": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it omits the option和优先级 of“再次手术以获得阴性切缘”作为首选，其次才是放疗；此外，随访方案描述略不详细。其他内容与参考答案一致。"
  },
  "1670": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging (IV期/M1), rationale, recommended systemic therapy (endocrine + CDK4/6 inhibitor), bone-modifying agents, and supportive care, with no major omissions or errors."
  },
  "1671": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and even provides additional relevant details without introducing errors or omissions."
  },
  "1672": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good clinical reasoning, but it omits thatKRAS G12C抑制剂可作为首选（如可及），并将其仅列为二线，未完全反映参考答案中“优选KRAS G12C抑制剂”的最新推荐。此外，免疫联合化疗的适用性解释较为充分，但对药物可及性等决策因素提及较少。"
  },
  "1673": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key points from the reference answer, and adds relevant details such as the rationale for each treatment, specific regimens, and consideration of immunotherapy, without introducing errors or major omissions."
  },
  "1674": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable and structured approach but diverges from the reference answer by recommending neoadjuvant therapy as the first-line strategy, which is not indicated in the reference for this clinical scenario. It covers most treatment modalities but introduces steps (neoadjuvant therapy) not required for this patient, leading to some inaccuracies."
  },
  "1675": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, covering imaging, clinical follow-up, and lifestyle interventions. However, it omits the explicit mention of not routinely recommending brain MRI and does not specify increasing follow-up frequency for new or residual imaging findings."
  },
  "1676": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including staging, the need for further mediastinal lymph node assessment, and preoperative functional evaluation. However, it does not specify the likely T3 stage (as in the reference) and is less definitive about the stage, instead suggesting T1-2, which is a minor omission."
  },
  "1677": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers术前评估和治疗流程的主要内容，包括分期、影像学、手术方式选择及术后辅助治疗思路，但略有遗漏如肿瘤床标记物放置、腋窝可疑淋巴结穿刺及高危患者基因检测和靶向药物评估等细节。"
  },
  "1678": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including follow-up intervals, imaging modality, avoidance of unnecessary tests, smoking cessation, and patient education, with no major omissions or errors. It even adds relevant details on health management and psychosocial support, which are appropriate and do not detract from the core clinical content."
  },
  "1679": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the use of KRAS G12C inhibitors, alternative chemotherapy, and clinical trials, with no major omissions or errors. It also appropriately addresses the non-recommendation of further immunotherapy and considers patient status."
  },
  "1680": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the clinical stage and listing appropriate preoperative assessments. However, it misclassifies the stage as IA3 instead of IB (per AJCC 8th edition, 2.5 cm is T1c, which is IB), and omits mention of brain MRI as an optional assessment, which are minor but relevant omissions."
  },
  "1681": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, rationale, and recommended treatment, including the option of consolidation immunotherapy, with no significant omissions or errors."
  },
  "1682": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key molecular tests (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, PD-L1), with appropriate rationale. However, it omits explicit mention of KRAS and ERBB2 (HER2), which are included in the reference answer, and slightly underemphasizes the recommendation for broad molecular profiling regardless of clinical features."
  },
  "1683": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key management steps, including re-resection, adjuvant radiotherapy, and consideration of chemotherapy. However, it omits details about follow-up recommendations and survivorship care, which are present in the reference answer."
  },
  "1684": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it extends the annual follow-up to 5 years (rather than 3) and adds some guideline references and recommendations about tumor markers and PET-CT, which are not mentioned in the reference. Minor differences in timing and extra details account for the slight deduction."
  },
  "1685": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of adjuvant chemotherapy and postoperative radiotherapy for R1 resection in Stage IIB NSCLC, with additional details on immunotherapy and targeted therapy. However, it omits specific follow-up recommendations and could better emphasize the decision-making process based on patient tolerance and functional status."
  },
  "1686": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding recommended imaging (chest CT), the non-routine use of PET-CT and brain MRI, and provides appropriate justification without omissions or errors."
  },
  "1687": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes MET抑制剂靶向治疗, names appropriate drugs, references guidelines, and covers alternative options and supportive care considerations, with no major omissions or errors."
  },
  "1688": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding axillary assessment, the role of SLNB, and the lack of need for further axillary biopsy, with no major omissions or errors."
  },
  "1689": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the recommendation for postoperative radiotherapy, consideration of adjuvant chemotherapy, and a detailed follow-up plan. However, it omits the preferred option of re-operation for R1 resection, which is emphasized in the reference answer as the first-line approach."
  },
  "1690": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the stage, explaining the rationale, and outlining the standard management, including chemoradiotherapy and consolidation immunotherapy, with no major omissions or errors."
  },
  "1691": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately identifies the stage, and correctly recommends ROS1-targeted therapy as first-line treatment, with appropriate mention of drug options and sequencing. No major omissions or errors are present."
  },
  "1692": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including staging, molecular subtype, standard chemotherapy plus anti-HER2 therapy (with options for dual-targeted therapy), and the rationale for omitting endocrine therapy. It also appropriately mentions radiotherapy, which is relevant for N1 disease post-mastectomy. No major omissions or errors are present."
  },
  "1693": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including reoperation as first choice, postoperative radiotherapy if reoperation is not feasible, consideration of adjuvant chemotherapy, and follow-up recommendations. It also adds MDT discussion and guideline references, with no major omissions or errors."
  },
  "1694": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of the differential between multiple primary lung cancers and intrapulmonary metastasis, but it omits the standard approach of分期为M1a（IV期）并未明确指出NCCN推荐的“treat as two primaries if both curable”原则，且未强调MDT讨论的重要性。整体内容较为完整，但分期和治疗决策的主流观点表达不够清晰。"
  },
  "1695": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including concurrent chemoradiotherapy, platinum-based regimens, durvalumab consolidation, and additional considerations, with no major omissions or errors."
  },
  "1696": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including follow-up intervals, imaging modality, and indications for head MRI/PET-CT. However, it omits the specific recommendation for smoking cessation counseling and support, which is present in the reference answer."
  },
  "1697": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies the stage as T3N0M0 (IIb期), outlines appropriate next steps, and discusses MDT evaluation and neoadjuvant therapy. However, it introduces some confusion regarding the stage (mentioning IIIB and local advanced), and omits specific mention of brain MRI and mediastinal nodal staging, which are important details in the reference answer."
  },
  "1698": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly explains the rationale and references guidelines, matching the reference answer in content and reasoning."
  },
  "1699": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers分期, MDT讨论,治疗策略, and分子检测, but it omits强调病理分期（如纵隔淋巴结活检确认N2）和戒烟干预、姑息医疗评估等细节。整体内容与参考答案高度一致，仅有少量细节遗漏。"
  },
  "1700": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, corresponding stage, and appropriate next steps including surgical evaluation, perioperative assessment, and adjuvant therapy, with no major omissions or errors."
  },
  "1701": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points on staging, rationale, and recommended treatment (including consolidation immunotherapy) clearly and accurately addressed. No major omissions or errors."
  },
  "1702": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including guideline recommendations and the rationale for adjuvant chemotherapy in early TNBC. However, it does not explicitly state that in this specific case (pT1N0, tumor ≤0.5 cm), adjuvant systemic therapy is not needed, which is a minor omission."
  },
  "1703": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including staging, rationale, specific drug regimens, surgical planning, and post-neoadjuvant considerations, with no major omissions or errors. It is comprehensive and aligns closely with the reference answer."
  },
  "1704": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including首选ROS1靶向药物（克唑替尼/恩曲替尼）、骨保护治疗（双膦酸盐或地诺单抗）、疼痛和骨折风险评估、支持治疗及吸烟戒断建议，无重大遗漏或错误。"
  },
  "1705": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging (T1cN3M0, IIIB), rationale, and standard treatment recommendations, including chemoradiotherapy and consolidation immunotherapy, with no significant omissions or errors."
  },
  "1706": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of MET抑制剂, the rationale despite PD-L1 expression, and subsequent options. No major omissions or errors are present."
  },
  "1707": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key elements of follow-up frequency, imaging modality, and supportive care, but it slightly overstates the frequency of follow-up (suggesting every 3–6 months in the first 2 years and every 6 months in years 3–5, rather than every 6 months for 2–3 years then annually). It also includes some extra but non-essential details."
  },
  "1708": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately explains the rationale and guidelines, and reaches the same management conclusion."
  },
  "1709": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访频率、内容和健康管理，但对3年后随访频率的描述与参考答案略有不同（未明确3年后改为每6个月，5年后每年），且影像学随访时间点略有不一致。整体内容准确，只有细节上的小差异。"
  },
  "1710": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy, including chemotherapy, radiotherapy, and newer options like immunotherapy and targeted therapy. However, it goes beyond the reference answer by including immunotherapy and targeted therapy, which, while evidence-based, are not explicitly mentioned in the reference answer and may not be standard for all patients in this scenario. Minor over-detail and slight deviation from the reference answer prevent a perfect score."
  },
  "1711": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including immediate switch to ALK-TKI, preferred agents, rationale, and guideline support, with no major omissions or errors."
  },
  "1712": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including systemic metastasis evaluation, basic labs, breast MRI, and axillary assessment. However, it omits the specific mention of tumor bed marker placement for surgical localization and does not explicitly state axillary ultrasound with possible biopsy and clip placement, which are important details in the reference answer."
  },
  "1713": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，分期、手术为首选、术前评估、术后辅助治疗等要点均有覆盖，并补充了分子靶向治疗的考虑，无明显遗漏或错误。"
  },
  "1714": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical reasoning, indications, and next steps, but it omits some specific details such as the placement of metal markers in the tumor and lymph nodes, and the explicit mention of sentinel lymph node biopsy planning."
  },
  "1715": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of indication for adjuvant therapy, criteria for high-risk features, and the recommendation for close follow-up, with no major omissions or errors."
  },
  "1716": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it suggests annual follow-up for at least 3–5 years rather than specifying 2 and 4 years as in the reference. This is a minor deviation, but otherwise the clinical content is accurate and comprehensive."
  },
  "1717": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, recommended imaging, and the non-recommendation of routine FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "1718": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, surgical recommendation, lymph node management, and adjuvant therapy, with no significant omissions or errors."
  },
  "1719": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly prioritizes NTRK抑制剂为首选，但遗漏了骨转移相关的骨保护治疗（如双膦酸盐或denosumab）及姑息治疗等支持措施。"
  },
  "1720": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including clinical staging, surgical recommendations, and alternative options. However, it stages the tumor as T1c (IA3) rather than T1b (IA2) as in the reference, which is a minor discrepancy given the 2.5cm size (T1b: >1cm–2cm, T1c: >2cm–3cm). Otherwise, the clinical reasoning and recommendations are accurate."
  },
  "1721": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering follow-up frequency, recommended imaging, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including patient characteristics, risk stratification, the role of multigene assays, and guideline-based recommendations for adjuvant therapy. There are no major omissions or errors."
  },
  "1723": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides a thorough rationale, covers all key points (no need for chemotherapy, standard endocrine therapy, and follow-up), and even adds guideline references and details about radiotherapy, which are appropriate and do not detract from the core answer."
  },
  "1724": {
    "score": 3.0,
    "explanation": "3: The model answer covers the TNM分期和处理建议的主要内容，但分期错误（应为IIA期而非IA2期），且未提及完善脑MRI和EBUS等进一步分期检查，存在一定遗漏和不准确之处。"
  },
  "1725": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies the clinical stage and main treatment recommendation, but it omits the need for系统性病理纵隔淋巴结评估（如EBUS-TBNA或纵隔镜活检）来排除隐匿性纵隔转移, which is an important step before surgery."
  },
  "1726": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including patient characteristics, tumor biology, and rationale for endocrine therapy. However, it does not clearly state the duration of endocrine therapy (5–10 years) and does not mention regular follow-up, which are present in the reference answer."
  },
  "1727": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including PET/CT, lung function assessment, and treatment pathways. It adds brain MRI and routine labs, which are reasonable but not strictly required at this stage, and otherwise closely matches the reference answer with only minor additional details."
  },
  "1728": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging modality, and supportive care. However, it omits the specific recommendation to avoid PET/CT or brain MRI in asymptomatic patients and does not explicitly mention that routine over-testing is not advised, which are minor but relevant omissions."
  },
  "1729": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly recommending EGFR-TKI monotherapy and not recommending immunotherapy or chemotherapy. However, it differs from the reference answer by prioritizing afatinib (a second-generation TKI) over osimertinib (a third-generation TKI), which is currently preferred per guidelines for rare EGFR mutations when feasible. This constitutes a minor omission rather than a major error."
  },
  "1730": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the key points, including follow-up frequency, content, and the non-routine use of PET-CT/brain MRI. However, it omits the specific recommendation for enhanced CT in the first 2–3 years and does not mention ongoing smoking cessation counseling or tumor health management."
  },
  "1731": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly recommending switching to ROS1-targeted therapy and naming appropriate agents. However, it omits mention of repotrectinib and ceritinib as options, and does not explicitly discuss the possibility of completing the current systemic therapy or maintenance as in the reference answer."
  },
  "1732": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, surgical approach, postoperative adjuvant therapy, and consideration of targeted therapy. There are no major omissions or errors."
  },
  "1733": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including RET抑制剂为首选、免疫治疗和化疗的备选地位，并详细分析了各治疗选择的依据，无重大遗漏或错误。"
  },
  "1734": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key aspects of the reference answer, and adds appropriate detail regarding molecular testing, systemic therapy options, and the role of local therapy in oligometastatic disease, with no major omissions or errors."
  },
  "1735": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it incorrectly分期为IIA期（应为IB期），且随访时间表略有不同（参考答案建议2-3年每6个月，3年后每年，模型答案为2年内每3-6个月，2-5年每6个月，5年后每年），但总体内容和要点基本一致。"
  },
  "1736": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of follow-up, imaging modalities, and frequency, with some additional detail. However, it slightly differs from the reference answer in the first 2–3 years' frequency breakdown and includes more on tumor markers and other tests, which, while useful, are not emphasized in the reference. Minor deviations prevent a perfect score."
  },
  "1737": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, including rationale, drug choices, and guideline references. However, it introduces osimertinib as a first-line option, which is less established for G719X compared to afatinib, and omits erlotinib/gefitinib, which are mentioned in the reference answer. Minor differences in drug prioritization and omission of some recommended agents prevent a perfect score."
  },
  "1738": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical recommendation, the lack of indication for neoadjuvant therapy, and consideration of adjuvant chemotherapy postoperatively. No major omissions or errors are present."
  },
  "1739": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1740": {
    "score": 3.0,
    "explanation": "3: The model answer covers the clinical staging accurately and provides a reasonable treatment plan, but it omits the current标准推荐的新辅助化疗为首选（尤其是三阴性、>2cm），未提及含铂方案、免疫治疗、术前标记等关键细节，且将手术作为首选与指南不符。"
  },
  "1741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including RET抑制剂为首选、化疗/免疫治疗备选、支持治疗、吸烟干预、分子检测、指南依据等，无明显遗漏或错误，内容详实且规范。"
  },
  "1742": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately details the staging, and outlines the standard treatment per guidelines, including concurrent chemoradiation and consolidation immunotherapy, with appropriate mention of molecular testing. No major omissions or errors are present."
  },
  "1743": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommended platinum-based chemotherapy plus pemetrexed, the role of immunotherapy, and alternatives if immunotherapy is contraindicated. No major omissions or errors are present."
  },
  "1744": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the correct staging, standard treatment options, and next steps, with detailed explanations. However, it is slightly more verbose and includes some additional details not strictly required, and the last section is incomplete, missing a clear summary of follow-up and surveillance."
  },
  "1745": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including the need for lung function testing, brain MRI, clinical staging, and the standard of care (concurrent or sequential chemoradiotherapy, consideration of immunotherapy, and that surgery is not recommended). It also adds appropriate detail without introducing errors or omissions."
  },
  "1746": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of osimertinib as first-line therapy, rationale, dosing, and additional considerations; there are no major omissions or errors."
  },
  "1747": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including tumor size, subtype, guideline recommendations, and the need for shared decision-making regarding adjuvant chemotherapy. No major omissions or errors are present."
  },
  "1748": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key molecular and immunological tests, specifies relevant genes, discusses sample adequacy and alternative testing, and matches the reference answer in clinical content without major omissions or errors."
  },
  "1749": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including EGFR-TKI (osimertinib) as first-line therapy, symptom control (pain management, bone protection), and the non-recommendation of chemo/immunotherapy, with no major omissions or errors."
  },
  "1750": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing accurate staging (cT1bN0M0, IA2), and comprehensively listing all relevant preoperative assessments, including those mentioned in the reference and some additional reasonable details. No major omissions or errors are present."
  },
  "1751": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including bone risk assessment, local and systemic therapy, use of bone-modifying agents, and the rationale for EGFR-TKI selection. It provides additional detail without omitting any major clinical content."
  },
  "1752": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach with chemotherapy and immunotherapy options, but it omits the guideline-recommended use of Ado-trastuzumab emtansine (T-DM1) as the preferred next-line HER2-targeted therapy after T-DXd failure, which is a significant omission."
  },
  "1753": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, correctly identifying advanced stage (IV) NSCLC with ALK rearrangement and recommending ALK TKI as first-line therapy. However, it misclassifies the M stage as IVB (M1c) rather than IVA (M1b), as only bone (a single organ) is involved, and slightly overemphasizes the distinction between IVB and IVA, which is a minor but notable detail."
  },
  "1754": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and adds relevant guideline references and considerations for molecular testing, with no major omissions or errors."
  },
  "1755": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the role of observation, indications for adjuvant therapy, high-risk features, and shared decision-making, with no major omissions or errors."
  },
  "1756": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with all key points addressed, including precise TNM staging, further assessments, and recommended treatment. Minor additions (e.g., brain MRI, molecular testing) are appropriate and do not detract from the core content."
  },
  "1757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including imaging frequency, clinical follow-up, lifestyle advice, and escalation if abnormalities are found, with no major omissions or errors."
  },
  "1758": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key aspects (chemotherapy, endocrine therapy, radiotherapy, and HER2-targeted therapy), and provides appropriate rationale and regimen details, with no major omissions or errors compared to the reference answer."
  },
  "1759": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the clinical staging (cT1bN0M0, IA2), the rationale for brain MRI, and preoperative assessments. However, it omits the specific recommendation for系统性纵隔淋巴结清扫或取样 to rule out occult N2 disease, which is a minor but important detail."
  },
  "1760": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, with clear recommendations on follow-up intervals and imaging. However, it introduces some minor variations in the frequency of follow-up and adds details about laboratory tests and molecular subtypes for brain MRI, which, while accurate, are not strictly necessary per the reference answer."
  },
  "1761": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the need (or lack thereof) for adjuvant therapy, discusses high-risk factors, and provides a detailed, guideline-consistent follow-up plan. No major omissions or errors are present."
  },
  "1762": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it differs from the reference answer by分期为IIIB（cT4N2M0）而非IIIA（参考答案为T3/4, N1/2, M0，倾向IIIA），且在进一步评估部分虽内容丰富，但未强调术前可切除性评估和与重要结构关系的影像学检查。整体内容详实，仅有细微分歧和小部分遗漏。"
  },
  "1763": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including precise TNM staging, the need for pathological confirmation of N2, MDT discussion, treatment options (synchronous chemoradiotherapy, possible surgery, consolidation immunotherapy), and molecular testing, with no major omissions or errors."
  },
  "1764": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points, including the importance of R1切缘阳性、二次手术、辅助化疗和放疗的选择，与参考答案内容一致，无明显遗漏或错误。"
  },
  "1765": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key management options, including re-resection, postoperative radiotherapy, and adjuvant chemotherapy, with appropriate rationale. However, it omits the recommendation for concurrent chemoradiotherapy (preferred over sequential or single modality in this context) and does not mention regular follow-up or smoking cessation advice, which are included in the reference answer."
  },
  "1766": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured response but contains a significant inaccuracy in TNM staging, labeling cT2aN0M0 as IA2 instead of the correct IB stage. It also overstates the indication for brain MRI in this context, whereas the reference answer correctly states it is optional for stage IB without neurological symptoms."
  },
  "1767": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, structured approach, but it incorrectly分期s the tumor as IIA期 instead of IB期, which is a minor but important detail. Otherwise, the diagnostic and therapeutic steps are accurate and comprehensive."
  },
  "1768": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately identifies the clinical stage and main management steps, but it omits the important recommendation for preoperative pathological mediastinal lymph node assessment to rule out occult N2 disease before proceeding to surgery."
  },
  "1769": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including the need for systemic therapy and chemoradiation, but it adds the option of re-operation, which, while reasonable, is not emphasized in the reference answer. Minor additional details are included, but the core clinical content aligns closely."
  },
  "1770": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need to switch to ROS1-targeted therapy, specific drug recommendations, rationale, and practical steps, with no major omissions or errors."
  },
  "1771": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred BRAF/MEK inhibitor combination, alternative options, and guideline support, with no major omissions or errors."
  },
  "1772": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including TNM分期、IIb期、术前评估、手术为首选、辅助治疗及不可手术时的替代方案，无明显遗漏或错误。"
  },
  "1773": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed analysis and appropriate treatment recommendations, but it incorrectly assigns the stage as IIIC instead of IIIB, which is a significant inaccuracy. It also omits the recommendation for comprehensive molecular testing and supportive care, both of which are present in the reference answer."
  },
  "1774": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately interprets the staging, and details the next steps in management, including MDT evaluation, surgical and non-surgical options, and adjuvant therapies, with no significant omissions or errors."
  },
  "1775": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the significance of R1 resection, the role of adjuvant radiotherapy and chemotherapy, and the need for MDT discussion. However, it omits the option of reoperation for R0 resection, which is the first recommendation in the reference answer."
  },
  "1776": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging as IB (T2aN0M0) and correctly stating that brain MRI is not routinely required in asymptomatic early-stage NSCLC patients, with no major omissions or errors."
  },
  "1777": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, surgical recommendation, and postoperative considerations, with only minor elaborations that do not detract from correctness."
  },
  "1778": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the staging, surgical recommendation, and additional considerations without any major omissions or errors."
  },
  "1779": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，明确指出NTRK抑制剂为首选，解释了靶向治疗优先于免疫治疗，并提及后续治疗选择，无重大遗漏或错误。"
  },
  "1780": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including re-resection as first choice, PORT if re-resection is not feasible, and that adjuvant chemotherapy is generally not recommended unless other high-risk features exist. No major omissions or errors."
  },
  "1781": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately discussing the limitations of KRAS G12C inhibitors in squamous cell carcinoma, and correctly prioritizing immunotherapy plus chemotherapy. It provides more detail than the reference but omits explicit mention of supportive care and smoking cessation, which are minor omissions."
  },
  "1782": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main recommendations of postoperative chemoradiation for R1 resection in stage IIIA NSCLC, but it introduces additional details about sequencing (sequential vs. concurrent), targeted/immune therapy, and guideline references, which, while accurate, slightly diverge from the reference answer's emphasis on concurrent chemoradiation as the standard. Minor omission is the lack of clear prioritization of concurrent chemoradiation as the first-line recommendation."
  },
  "1783": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering分期、纵隔淋巴结病理学评估、全面分子检测（包括主要基因和PD-L1），并补充了全身状况评估，无重大遗漏或错误。"
  },
  "1784": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, up-to-date approach, including diagnostic steps and individualized systemic therapy options. However, it introduces additional details (如分子分型、靶向/免疫治疗) not explicitly mentioned in the reference answer, and does not emphasize“姑息化疗为主”或“密切观察”作为首选，略有偏离参考答案的核心要点。"
  },
  "1785": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, covering all key aspects of the reference answer, including first-line treatment options, the role of KRAS G12C inhibitors, management of bone metastases, and guideline references, with no major omissions or errors."
  },
  "1786": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of postoperative follow-up, including frequency, recommended imaging, and supportive care. However, it provides a slightly broader range for follow-up intervals and includes optional tests (e.g., tumor markers) not emphasized in the reference, and does not explicitly state that routine PET/CT or brain MRI are not recommended unless symptomatic, which is a minor omission."
  },
  "1787": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key management options, including salvage radiotherapy, consideration of adjuvant chemotherapy, MDT discussion, and detailed follow-up recommendations. However, it places more emphasis on radiotherapy as first-line rather than re-resection, which is the preferred initial approach per the reference answer, and the follow-up intervals are slightly broader than specified. Minor omissions and differences prevent a perfect score."
  },
  "1788": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a clear, structured approach, but it assigns the stage as IIA (cT2bN0M0) rather than IIB (T3N0M0) as in the reference answer. This is a minor staging discrepancy, but the rest of the clinical reasoning and treatment recommendations are accurate and comprehensive."
  },
  "1789": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering TNM分期、分期分级、支气管镜和纵隔淋巴结处理的适应证与理由，无明显遗漏或错误。"
  },
  "1790": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed TNM staging, rationale, and treatment strategy. The only minor issue is the use of \"IIIC期\" instead of \"IIIB期\"—according to the AJCC 8th edition, T1cN3M0 is IIIB, not IIIC, for non-small cell lung cancer. Otherwise, the answer is thorough and correct."
  },
  "1791": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers所有主要内容，包括适应证、评估目的和具体检查，但对腋窝淋巴结穿刺活检及标记物置入的细节描述不够明确，且部分内容如肿瘤标志物和生育力评估虽有补充，但并非必需。整体内容与参考答案高度一致，仅有细微遗漏。"
  },
  "1792": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with accurate staging, detailed rationale, and appropriate, guideline-based treatment recommendations, including MDT evaluation and options for neoadjuvant therapy, surgery, and chemoradiotherapy. No major omissions or errors are present."
  },
  "1793": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, correctly stating that adjuvant chemotherapy is not routinely recommended and providing a reasonable follow-up plan. However, it slightly overemphasizes the IAI/IA3 staging (the reference uses IIA), and the follow-up intervals are somewhat broader and less specific than the reference, missing details like the emphasis on enhanced CT in the first 2–3 years and smoking cessation advice."
  },
  "1794": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of assessment and individualized treatment, including pathology review, systemic evaluation, imaging, and a detailed, guideline-consistent therapeutic plan with supportive care. There are no major omissions or errors compared to the reference answer."
  },
  "1795": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately outlining the rationale for best supportive care as first-line, with appropriate mention of the limited role for single-agent palliative chemotherapy in select cases. No major omissions or errors."
  },
  "1796": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, lack of actionable mutations, low PD-L1, and the recommendation for platinum-based doublet chemotherapy plus immunotherapy, with specific regimen examples and rationale. No major omissions or errors."
  },
  "1797": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including reoperation as first choice, radiotherapy as an alternative, follow-up recommendations, and guideline references, with no major omissions or errors."
  },
  "1798": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including precise clinical staging (cT2N1M0), rationale for neoadjuvant systemic therapy (chemotherapy plus dual HER2-targeted therapy), and subsequent management steps. No major omissions or errors are present."
  },
  "1799": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach to staging and management, but incorrectly stages the tumor as IIb (T2bN1M0) instead of IIIA (T3N1M0), missing the correct T descriptor for a 5cm mass. This is a significant inaccuracy, though the treatment recommendations are otherwise appropriate."
  },
  "1800": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, drug choices, and guideline recommendations, with no major omissions or errors."
  },
  "1801": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including maintenance therapy, HER2-targeted therapy upon progression, and clinical trials. However, it omits mention of ado-trastuzumab emtansine as an alternative HER2-targeted agent and does not emphasize individualized treatment and close monitoring as in the reference answer."
  },
  "1802": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the stage as cT2aN0M0 (IB), and providing a comprehensive, detailed, and correct list of preoperative assessments without major omissions or errors."
  },
  "1803": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including systemic therapy recommendations, the limited evidence for HER2-targeted therapy in squamous cell carcinoma, and the importance of multidisciplinary and supportive care. However, it underemphasizes the potential use of HER2-targeted agents (which the reference answer lists as first-line if available) and places more emphasis on chemo-immunotherapy as the standard, which is a minor but notable omission given the HER2 mutation context."
  },
  "1804": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, and the non-recommendation of routine FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "1805": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "1806": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key steps of pathological staging and molecular marker testing, including the rationale for broad molecular profiling and PD-L1 testing. However, it omits the specific recommendation for介入操作（如EBUS-TBNA、EUS、纵隔镜等）以获得N3区淋巴结的病理证实, which is a critical step in the reference answer."
  },
  "1807": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding follow-up frequency, imaging modality, and the indications for brain MRI and FDG-PET/CT, with no major omissions or errors."
  },
  "1808": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including accurate TNM staging, stage grouping, and appropriate initial treatment recommendations. However, it omits mention of the option of concurrent chemoradiotherapy with subsequent Durvalumab maintenance for patients unsuitable for surgery, which is present in the reference answer."
  },
  "1809": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for re-resection, consideration of adjuvant radiotherapy if reoperation is not feasible, and the lack of recommendation for adjuvant chemotherapy. There are no major omissions or errors."
  },
  "1810": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of adjuvant chemotherapy, specific regimens, and the role of radiotherapy, with additional mention of targeted and immunotherapy options. However, it slightly overstates the role of adjuvant targeted/immune therapy (which is not yet standard for all patients) and omits the detailed follow-up schedule described in the reference answer."
  },
  "1811": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it adds a 5-year follow-up suggestion and omits specifying that CT can be with or without contrast. These are minor deviations, but overall the clinical content is accurate and comprehensive."
  },
  "1812": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, lymph node dissection, and adjuvant therapy considerations, with no major omissions or errors."
  },
  "1813": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects including chemotherapy, anti-HER2 therapy, radiotherapy, and the rationale for omitting endocrine therapy, with no major omissions or errors."
  },
  "1814": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of EGFR G719X突变的治疗选择，详细说明了药物选择、免疫治疗和化疗的地位，并引用了权威指南，无重大遗漏或错误。"
  },
  "1815": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies osimertinib monotherapy as the standard first-line treatment, with appropriate rationale and dosing. However, it omits the alternative option of combining osimertinib with chemotherapy and does not mention smoking cessation or early palliative care, which are included in the reference answer."
  },
  "1816": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including the recommendation for postoperative radiotherapy (PORT) for R1 resection, consideration of adjuvant chemotherapy, and the need for MDT discussion, fully aligning with the reference answer and current guidelines."
  },
  "1817": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly identifying the T and N stage, and recommending concurrent chemoradiotherapy as the standard of care. However, it assigns stage IIIC (rather than IIIB as in the reference, which is more widely accepted for T1–2N3M0 in most guidelines), and adds consolidation immunotherapy, which, while increasingly standard, was not mentioned in the reference answer. Minor staging discrepancy and extra detail account for the one-point deduction."
  },
  "1818": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding of the case, including detailed reasoning about differential diagnosis (多原发 vs. 转移) and appropriate next steps. However, it incorrectly states IIIB期 for T4N0M0 (should be IIIA期 per AJCC 8th edition), and places more emphasis on放化疗而非新辅助治疗+手术，这与参考答案略有出入。"
  },
  "1819": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗建议及术后处理均有详细说明，无明显遗漏或错误。"
  },
  "1820": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale, specific drug options, guideline support, and additional supportive measures, with no major omissions or errors."
  },
  "1821": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of clinical staging, further assessment, and MDT discussion, but it omits some minor but relevant details such as the recommendation for metallic marker placement in the tumor and the possible consideration of neoadjuvant therapy for breast-conserving candidates."
  },
  "1822": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且补充了具体的MET抑制剂名称和后线治疗细节，无重大遗漏或错误。"
  },
  "1823": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, recommended imaging, and the indications for PET-CT/brain MRI, with no major omissions or errors."
  },
  "1824": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of the reference answer, including clinical staging, rationale for neoadjuvant therapy, specific regimens, and post-operative management. However, it omits details about tumor and lymph node marking before neoadjuvant therapy and the use of T-DM1 for patients with high recurrence risk or non-pCR after surgery."
  },
  "1825": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes EGFR-TKI (specifically osimertinib), addresses the role of PD-L1, brain metastases, and provides guideline references. No major omissions or errors are present."
  },
  "1826": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the lack of need for adjuvant therapy, detailed follow-up intervals, and the rationale based on current guidelines, with no significant omissions or errors."
  },
  "1827": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, standard of care (concurrent chemoradiotherapy), consolidation immunotherapy, alternative options, and MDT involvement, with no significant omissions or errors."
  },
  "1828": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of recommending postoperative radiotherapy (PORT) for R1 resection and discussing the selective use of adjuvant chemotherapy based on risk factors. However, it omits the preferred option of reoperation to achieve negative margins, which is emphasized in the reference answer. Regular follow-up recommendations are also not mentioned."
  },
  "1829": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including stage, unresectability, concurrent chemoradiotherapy as standard, consolidation immunotherapy, and considerations for treatment tolerance, with no major omissions or errors."
  },
  "1830": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including no need for adjuvant therapy, no routine brain MRI, and appropriate follow-up with chest CT. However, the follow-up interval is slightly more frequent than the reference (every 3–6 months vs. every 6 months in the first 2 years), and it does not explicitly mention smoking cessation counseling or lifestyle management."
  },
  "1831": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including accurate TNM staging, correct stage grouping (IIIC per AJCC 8th edition), and appropriate treatment recommendations (concurrent chemoradiotherapy followed by durvalumab consolidation), with no major omissions or errors."
  },
  "1832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, including the rarity of ROS1 rearrangement in squamous cell carcinoma, the recommendation of ROS1 inhibitors as first-line therapy, specific drug options, and guideline references, with no major omissions or errors."
  },
  "1833": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，分期、靶向治疗推荐、免疫治疗不作为一线等要点均有覆盖，无明显遗漏或错误。"
  },
  "1834": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key aspects of the reference answer, including影像学评估,腋窝评估,实验室检查,乳腺MRI,以及多学科讨论等。唯一的轻微遗漏是未明确提及肿块定位夹/标记物的放置和腋窝可疑淋巴结的穿刺后标记，这些是术前评估中特别重要的细节。"
  },
  "1835": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访频率、内容及影像学检查等要点，但对随访年限的分段与参考答案略有不同，并未明确3年后改为每年低剂量CT，且未强调无需常规PET/CT或脑MRI，仅在有症状时才建议。整体内容较为全面，仅有细微差异。"
  },
  "1836": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes RET抑制剂 as first-line, details alternatives, and references guidelines and evidence, with no major omissions or errors."
  },
  "1837": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major aspects of the reference answer, including分期、心脏功能、实验室检查、局部评估等，但对腋窝穿刺活检及标记物植入等细节描述略有不足，且部分内容如肿瘤标志物、传染病筛查等为补充项，未完全与参考答案一致。"
  },
  "1838": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including follow-up intervals, recommended imaging, the role of PET/CT and MRI, and health management advice, with no major omissions or errors."
  },
  "1839": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering分期 (cT2N0M0), and detailing the need for adjuvant chemotherapy, anti-HER2 therapy, and endocrine therapy, with no major omissions or errors."
  },
  "1840": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, treatment recommendations, and additional considerations such as molecular testing, with no major omissions or errors."
  },
  "1841": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the staging and first-line systemic therapy, correctly identifying IV stage and recommending MET inhibitors. However, it includes savolitinib (not universally approved for this indication) and omits mention of palliative care and smoking cessation counseling, which are present in the reference answer."
  },
  "1842": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major aspects, including systemic metastasis evaluation, cardiac assessment, laboratory tests, molecular typing, and local imaging. However, it omits the specific mention of core needle biopsy and marker placement for both the breast lesion and suspicious axillary nodes, which are important procedural details in the reference answer."
  },
  "1843": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the recommended follow-up intervals, imaging modality, and the lack of indication for routine brain MRI or PET/CT in asymptomatic IA patients. No major omissions or errors are present."
  },
  "1844": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including术前评估（乳腺MRI、全身分期、常规检查）、手术方式选择、辅助/新辅助治疗等，但对肿瘤床标记物的提及和术前全身影像学的适应证略有不同，且部分细节如术前标记物未明确，略有小幅遗漏。"
  },
  "1845": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including follow-up intervals, imaging modality, and lifestyle management. However, it is less specific about the exact timing and type of CT (enhanced vs. low-dose, with/without contrast) in later years, and does not explicitly mention the avoidance of routine PET/CT or brain MRI unless recurrence is suspected, which are present in the reference answer."
  },
  "1846": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the correct staging and main treatment options, including MDT evaluation, chemoradiotherapy, and consolidation immunotherapy. However, it places more emphasis on同步放化疗 as the primary recommendation and only secondarily mentions新辅助治疗和手术, whereas the reference answer prioritizes新辅助系统治疗±免疫治疗后评估手术机会, which is a subtle but important difference in treatment sequencing."
  },
  "1847": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately identifying the stage as IIIB (T4N2M0) and recommending concurrent chemoradiotherapy as standard, with appropriate mention of consolidation immunotherapy and alternative options, with no major omissions or errors."
  },
  "1848": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering diagnosis, staging, and detailed stepwise treatment recommendations without major omissions or errors."
  },
  "1849": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately discusses guideline recommendations, tumor size, nodal status, and patient age, and correctly concludes that adjuvant chemotherapy is recommended. No major omissions or errors."
  },
  "1850": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately detailing the TNM staging, specifying the need for pathological assessment of mediastinal nodes, and mentioning additional preoperative evaluations. No major omissions or errors are present."
  },
  "1851": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of adjuvant therapy and follow-up, including chemotherapy, immunotherapy, targeted therapy, and individualized radiotherapy, as well as detailed follow-up schedules and supportive care. However, it introduces additional details (e.g., immunotherapy, targeted therapy, tumor markers) not specified in the reference answer and slightly deviates from the recommended imaging modality and frequency, making it more comprehensive but with minor differences from the reference."
  },
  "1852": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical steps, including neoadjuvant chemotherapy, surgical planning, and adjuvant therapy, and mentions BRCA mutation and PARP inhibitors. However, it omits specific details such as the use of pembrolizumab in neoadjuvant therapy and the recommendation for pre-treatment biopsy and marker placement, which are present in the reference answer."
  },
  "1853": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of EGFR-TKI as first-line therapy, rationale, alternatives, and relevant clinical considerations, with no major omissions or errors."
  },
  "1854": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging (IVB, M1c) and comprehensive next steps. However, it omits建议完善脑MRI以排除颅内转移这一重要检查，且对ECOG评分的具体意义未强调，略有细微差别。"
  },
  "1855": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of staging and preoperative assessment, but it includes some additional general preoperative workup (e.g., routine labs, anesthesia evaluation) not specified in the reference, and slightly overemphasizes some imaging (e.g., bone scan) that may overlap with PET-CT. Minor omissions include not explicitly stating the guideline-based indication for brain MRI in stage II and above."
  },
  "1856": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including correct TNM staging, need for brain MRI, and surgical recommendation. However, it omits the suggestion for spinal/chest inlet MRI if the tumor is close to the spine and does not explicitly mention multidisciplinary discussion or neoadjuvant therapy consideration, which are minor omissions."
  },
  "1857": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the need for adjuvant chemotherapy, provides rationale, specifies regimens, and covers follow-up and supportive care, with no major omissions or errors compared to the reference answer."
  },
  "1858": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indication for RET抑制剂（Selpercatinib或Pralsetinib）一线治疗，并补充了指南依据和不推荐其他治疗的理由，无重大遗漏或错误。"
  },
  "1859": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the need for biopsy, reassessment of ER/PR/HER2, and comprehensive molecular/genetic testing. However, it omits explicit mention of genetic counseling for hereditary risk and is slightly less concise in summarizing the need for full-body assessment and specific laboratory tests."
  },
  "1860": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it uses stage IIIC (AJCC 8th edition) instead of IIIB as in the reference, which is a minor discrepancy but does not affect the overall clinical management."
  },
  "1861": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including BRAF/MEK inhibitor therapy, bone-targeted agents, local management for bone metastases, supportive care, and consideration of PD-L1 for future immunotherapy. No major omissions or errors are present."
  },
  "1862": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the significance of EGFR G719X mutation, limited benefit of immunotherapy, and the recommendation to switch to a second-generation EGFR-TKI. No major omissions or errors are present."
  },
  "1863": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the use of EGFR Exon 20插入突变特异性靶向药物（阿米沃替尼、莫博替尼）, the limited role of免疫治疗, and alternative options if targeted therapy is unavailable. No major omissions or errors."
  },
  "1864": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, surgical recommendations, and postoperative management without omissions or errors."
  },
  "1865": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of staging, molecular testing, and treatment recommendations, including supportive care and consideration of targeted therapy if mutations are present. However, it slightly overemphasizes the axillary lymph node (which is not typical for lung cancer staging), and the explanation of N stage could be clearer; also, the answer is cut off at the end."
  },
  "1866": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient eligibility for 21-gene testing, the rationale, and the decision-making process for chemotherapy based on the test result, with no major omissions or errors."
  },
  "1867": {
    "score": 4.0,
    "explanation": "4: 模型答案与参考答案几乎一致，分期准确，处理建议全面，但未特别强调术前应进行纵隔淋巴结的病理性评估（如EBUS-TBNA）和脑部MRI排查脑转移，属于轻微遗漏。"
  },
  "1868": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up frequency, recommended imaging, and the indications for FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1869": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, drug choice, dosing, and clear explanation of why other options are not preferred. No major omissions or errors."
  },
  "1870": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了辅助治疗的适应证、高危因素、随访频率和内容，无明显遗漏或错误。"
  },
  "1871": {
    "score": 5.0,
    "explanation": "5: The model answer matches the reference answer in clinical content, covers all key recommendations, and provides appropriate rationale and references without any major omissions or errors."
  },
  "1872": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and closely matches the reference answer, but it has minor discrepancies in the timing of imaging intervals (e.g., \"每6-12个月\" instead of strictly \"每6个月\") and does not explicitly mention the non-recommendation of脑MRI unless symptomatic. Otherwise, it covers the essential clinical content."
  },
  "1873": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, accurately describing the staging and new adjuvant therapy, including specific regimens and treatment flow. However, it omits the important detail about switching to T-DM1 postoperatively if there is residual disease, which is a key guideline recommendation."
  },
  "1874": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of adjuvant therapy for this patient, including endocrine therapy, anti-HER2 therapy, chemotherapy, and the rationale for omitting radiotherapy. It is comprehensive, guideline-based, and contains no major omissions or errors."
  },
  "1875": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers staging, molecular testing, and treatment, including emergency management of SVCS. However, it incorrectly assigns T3 instead of T4 (应为T4因肿瘤侵犯上腔静脉)，并未完全覆盖所有推荐的分子检测靶点（如NTRK、METex14等），且对同步放化疗后免疫巩固的适应证表述略有简化。"
  },
  "1876": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient characteristics, rationale, recommended regimen, and guideline support, with no major omissions or errors."
  },
  "1877": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all major points, including symptom relief with bronchoscopic intervention, systemic therapy, and supportive care. However, it introduces immunotherapy and targeted therapy, which, while relevant in modern practice, are not explicitly mentioned in the reference answer and may not be first-line in this context; also, the answer could more clearly emphasize the palliative intent and multidisciplinary decision-making."
  },
  "1878": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging rationale, treatment recommendations, and relevant details, with no significant omissions or errors."
  },
  "1879": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging rationale, need for pathological confirmation, non-surgical management, preferred chemoradiotherapy, and consolidation immunotherapy, with no major omissions or errors."
  },
  "1880": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging, rationale, and detailed treatment strategy, including targeted therapy, supportive care, and individualized management, with no major omissions or errors."
  },
  "1881": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good clinical reasoning, but it incorrectly assigns the stage as IA2 instead of IB (since T2aN0M0 is IB per AJCC 8th edition). Otherwise, the treatment recommendations and rationale are appropriate."
  },
  "1882": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main management options, including postoperative radiotherapy, adjuvant chemotherapy, and MDT discussion, as well as detailed follow-up recommendations. However, it omits the first-choice recommendation of re-operation for R1 resection if feasible, which is a key point in the reference answer."
  },
  "1883": {
    "score": 5.0,
    "explanation": "5: The model answer provides a comprehensive and accurate approach to staging and treatment, covering all key clinical points from the reference answer, including the need for pathological confirmation of N2, MDT discussion, treatment options, and additional workup. No major omissions or errors are present."
  },
  "1884": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key management options (re-operation, radiotherapy, and surveillance), with appropriate rationale and guideline references. There are no major omissions or errors."
  },
  "1885": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately covers the tumor staging and main treatment recommendations, including surgery and adjuvant chemotherapy. However, it omits the need for preoperative pulmonary function and comprehensive assessment, and does not mention the consideration of observation or risk stratification for adjuvant therapy, which are minor but relevant details."
  },
  "1886": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including the recommendation for concurrent chemoradiotherapy, rationale, and consideration of surgery after neoadjuvant therapy. However, it slightly overemphasizes concurrent chemoradiotherapy as the \"standard\" without equally presenting the option of neoadjuvant therapy followed by surgery, which is also mentioned in the reference answer. Minor omissions in the balance of options prevent a perfect score."
  },
  "1887": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured response but incorrectly stages the tumor as IIA instead of IB, which is a significant error. While the follow-up and adjuvant therapy recommendations are largely appropriate, the staging inaccuracy is a notable omission."
  },
  "1888": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of the reference answer, including the need for systemic staging, the rationale for systemic therapy, and consideration of palliative local treatment. However, it adds extra detail about molecular testing and immunotherapy options, which, while relevant, are not explicitly mentioned in the reference answer, and it does not emphasize \"palliative chemotherapy\" as the primary recommendation as clearly as the reference. Minor omissions and slight differences in emphasis prevent a perfect score."
  },
  "1889": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage of staging, rationale, standard treatment (concurrent chemoradiotherapy), and additional details such as consolidation immunotherapy and molecular testing, with no major omissions or errors."
  },
  "1890": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including staging, rationale for neoadjuvant therapy, specific regimen suggestions, and the sequence of treatment steps, with no major omissions or errors."
  },
  "1891": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers所有主要术前评估内容，包括肺功能、影像学、实验室及心脏评估，但比参考答案更详细，且增加了部分可选检查（如骨扫描、肿瘤标志物），虽无大错但略有超出常规必要范围，且未明确指出部分检查为可选项。"
  },
  "1892": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred use of trastuzumab deruxtecan, alternative options, and relevant guidelines, with no major omissions or errors."
  },
  "1893": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key recommendations of adjuvant concurrent chemoradiotherapy, rationale, and guideline support. However, it introduces additional options (targeted/immune therapy) that are not standard in this context and omits explicit mention of multidisciplinary discussion and regular follow-up, which are present in the reference answer."
  },
  "1894": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the use of KRAS G12C抑制剂（Sotorasib或Adagrasib）作为二线治疗，并补充了多西他赛等传统方案和临床试验的选择，但比参考答案多了一些背景分析，略显冗长，且未完全强调KRAS G12C抑制剂为首选。"
  },
  "1895": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering RET抑制剂为首选、具体药物、免疫治疗和化疗的次选地位，并补充了指南和文献依据，无明显遗漏或错误。"
  },
  "1896": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了标准一线治疗、KRAS G12C靶向药物的适应证及后续治疗选择，无重大遗漏或错误。"
  },
  "1897": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately details the rationale for afatinib as first-line therapy, discusses alternative options, addresses bone metastasis management, and appropriately excludes immunotherapy, matching the clinical content of the reference answer without major omissions or errors."
  },
  "1898": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the non-recommendation of chemotherapy, rationale, endocrine therapy options, and indications for radiotherapy, with no major omissions or errors."
  },
  "1899": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with additional relevant details and no major omissions or errors. It accurately addresses the indication for adjuvant endocrine therapy and provides appropriate rationale and treatment options."
  },
  "1900": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了分期判断、活检、分子分型、手术、腋窝处理、放疗及全身治疗等要点，无明显遗漏或错误。"
  },
  "1901": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for re-resection, the alternative of radiotherapy if surgery is not feasible, and the lack of indication for adjuvant chemotherapy. There are no major omissions or errors."
  },
  "1902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including adjuvant chemotherapy, postoperative radiotherapy for R1 resection, molecular testing, and follow-up recommendations, with no major omissions or errors."
  },
  "1903": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential aspects of clinical staging, further metastatic workup, and preoperative assessment, including cardiac evaluation and relevant imaging. However, it omits the specific mention of marker clip placement in the breast and axillary lesions, which is an important detail in the reference answer."
  },
  "1904": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key aspects of the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1905": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including first-line immunochemotherapy, the role of KRAS G12C inhibitors as subsequent therapy, and additional management for bone metastases, with no major omissions or errors."
  },
  "1906": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects of staging, pathological subtyping, and molecular marker testing, with appropriate detail. However, it omits NTRK1/2/3 fusion testing and does not mention the need for additional tissue acquisition if sample is insufficient, which are minor but relevant omissions."
  },
  "1907": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the need for further local treatment (radiotherapy), consideration of adjuvant chemotherapy, MDT discussion, and detailed follow-up recommendations. However, it omits the option of reoperation as the first choice if feasible, which is emphasized in the reference answer."
  },
  "1908": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects NCCN guidelines, details first-line and subsequent therapy choices, addresses the role and limitations of KRAS G12C inhibitors, and includes supportive management—matching the reference answer with no major omissions or errors."
  },
  "1909": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies MET抑制剂为首选，但列举了未获批或不推荐的药物（如塞瑞替尼、卡博替尼），未准确点出卡马替尼和替普替尼为首选，存在部分药物选择错误，内容有一定不准确性。"
  },
  "1910": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for reoperation, the alternative of postoperative radiotherapy if surgery is not feasible, and the lack of recommendation for adjuvant chemotherapy. It also references relevant guidelines and provides clear rationale, with no major omissions or errors."
  },
  "1911": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, including surgical resection as first choice, the need for further staging to rule out metastasis, and consideration of adjuvant therapy based on pathology and molecular markers. There are no major omissions or errors."
  },
  "1912": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It provides thorough justification, guideline references, and matches the reference answer’s recommendations."
  },
  "1913": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容基本一致，涵盖了随访、辅助化疗的适应证、免疫治疗、具体随访方案及戒烟等要点，无明显遗漏或错误。"
  },
  "1914": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding of current guidelines, correctly prioritizing platinum-based chemotherapy plus immunotherapy for squamous NSCLC and noting the limited evidence for HER2-targeted therapy in this subtype. However, it omits the option of multidisciplinary discussion, palliative radiotherapy for symptom control, and does not explicitly mention that HER2-targeted therapy can be considered first-line per the latest guidelines if available, which are minor but relevant omissions."
  },
  "1915": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key aspects of staging, further assessment, and treatment recommendations, with no major omissions or errors."
  },
  "1916": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including staging, the limited benefit of adjuvant chemotherapy for T2aN0, individualized decision-making, and detailed follow-up recommendations. However, it introduces some extra detail (e.g., EGFR mutation and targeted therapy) that is not strictly necessary for this case, and the answer is cut off before fully listing chemotherapy regimens. Minor omissions and slight over-elaboration prevent a perfect score."
  },
  "1917": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering both adjuvant chemotherapy and postoperative radiotherapy for R1 resection in Stage IIB NSCLC, with no major omissions or errors."
  },
  "1918": {
    "score": 4.0,
    "explanation": "4: The model answer accurately identifies the clinical stage and provides a detailed rationale, but omits支气管镜检查 and纵隔淋巴结病理学评估 as specifically mentioned in the reference answer. Otherwise, it covers the necessary preoperative assessments comprehensively."
  },
  "1919": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including H&P、胸部CT、随访频率、症状驱动的进一步检查等，但未明确强调首3年可3-6个月随访一次、5年后建议低剂量无增强CT、以及戒烟指导和癌症幸存者健康管理等内容。"
  },
  "1920": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including immunotherapy options, chemotherapy combinations, patient-specific considerations, and guideline references, with no major omissions or errors."
  },
  "1921": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，分期、治疗原则、药物选择、特殊情况处理及多学科管理均有详细阐述，无重大遗漏或错误。"
  },
  "1922": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including适应证、分期、腋窝评估、心脏功能评估、基础实验室检查等，但未明确提及肿瘤区放置标记物这一细节，略有小遗漏。"
  },
  "1923": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including neoadjuvant systemic therapy (chemotherapy ± immunotherapy), surgical resection with lymph node dissection, consideration of adjuvant therapy, and alternative strategies for unresectable disease. It also provides additional detail without omitting any major clinical content."
  },
  "1924": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points of clinical staging (cT2N1M0), molecular subtype, and appropriate next steps including neoadjuvant therapy, surgery, and adjuvant treatment. However, it omits specific mention of pre-chemotherapy tumor and lymph node marking, which is an important operational detail highlighted in the reference answer."
  },
  "1925": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering immunotherapy, chemotherapy, HER2-targeted therapy limitations, and the role of clinical trials, with no major omissions or errors."
  },
  "1926": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and includes appropriate details on targeted therapy, symptomatic management, and subsequent options, with no major omissions or errors."
  },
  "1927": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key aspects of the reference answer, including preoperative assessment, exclusion of metastasis, surgical treatment, and consideration of adjuvant therapy based on risk factors, with no major omissions or errors."
  },
  "1928": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including follow-up intervals, imaging modality, and lifestyle advice. However, it omits the specific recommendation for contrast-enhanced CT in the first 2–3 years and does not explicitly mention the avoidance of routine FDG-PET/CT or brain MRI, which are minor but relevant details."
  },
  "1929": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential elements of the reference answer, including follow-up intervals, recommended imaging, and lifestyle advice. However, it slightly differs in the duration and frequency of CT scans and does not explicitly mention that routine FDG-PET/CT or brain MRI are not recommended unless symptomatic, which is a minor omission."
  },
  "1930": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, covering the main points of the reference answer, including follow-up intervals, content, and special considerations. However, it omits the specific recommendation for enhanced CT in the first 5 years and does not explicitly state that routine FDG-PET/CT or brain MRI are not needed unless clinically indicated."
  },
  "1931": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且对首选药物做了更详细的补充，分子检测项目也无遗漏，无重大错误或遗漏。"
  },
  "1932": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering staging (IVa, M1a), the rationale, and the preferred RET inhibitor therapy, as well as symptomatic management of pleural effusion. No major omissions or errors are present."
  },
  "1933": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately outlines the standard treatment, including ovarian suppression, aromatase inhibitor, and CDK4/6 inhibitor. However, it omits the recommendation for bone-protective agents in the context of bone metastases, which is a minor but important detail present in the reference answer."
  },
  "1934": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points from the reference answer, including分子分型、全身转移评估、基础实验室检查、心脏功能、乳腺及腋窝评估等，但略有遗漏，如未明确提及腋窝可疑淋巴结植入标记物和术前对肿块植入标记物等细节。"
  },
  "1935": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, with detailed staging and appropriate treatment recommendations. However, it uses Stage IIIC (AJCC 8th edition), while the reference uses Stage IIIB, which may reflect a minor discrepancy in staging conventions. Otherwise, clinical content is thorough and correct."
  },
  "1936": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including病理学确认N3期的必要性、具体取材方式、同步放化疗为首选、以及多学科评估和免疫巩固治疗，无明显遗漏或错误。"
  }
}